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ABSTRACT 
Vitamin E is a well known fat soluble chain breaking antioxidant. It is a general 
tenn used to describe a family of eight stereoisomers of tocopherols. Selective retention 
of a-tocopherol in the human circulation system is regulated by the a -Tocopherol 
Transfer Protein (a-TIP). 
Using a fluorescently labelled a-tocopherol (NBD-a-Toc) synthesized in our 
laboratory, a fluorescence resonance energy transfer (FRET) assay was developed to 
monitor the kinetics of ligand transfer by a-hTTP in lipid vesicles. Preliminary results 
implied that NBD-a-Toe simply diffused from 6-His-a-hTTP to acceptor membranes 
since the kinetics of transfer were not responsive to a variety of conditions tested. After 
a series of trouble shooting experiments, we identified a minor contaminant, E coli. outer 
membrane porin F (OmpF) that co-purified with 6-His-a-hTTP from the metal affinity 
column as the source of the problem. 
In order to completely avoid OmpF contamination, a GST -a-hTTP fusion protein 
was purified from a glutathione agarose column followed by an on-column thrombin 
digestion to remove the GST tag. We then demonstrated that a-hTTP utilizes a 
collisional mechanism to deliver its ligand. Furthennore, a higher rate of a-tocopherol 
transfer to small unilamellar vesicles (SUV s) versus large unilamellar vesicles (LUV s) 
indicated that transfer is sensitive to membrane curvature. These findings suggest that a-
hTTP mediated a-Toc transfer is dominated by the hydrophobic nature of a-hTTP and 
the packing density of phospholipid head groups within acceptor membranes. 
Based on the calculated free energy change (dG) when a protein is transferred 
from water to the lipid bilayer, a model was generated to predict the orientation of a-
hTTP when it interacts with lipid membranes. Guided by this model, several 
hydrophobic residues expected to penetrate deeply into the bilayer hydrophobic core, 
were mutated to either aspartate or alanine. Utilizing dual polarization interferometry 
and size exclusion vesicle binding assays, we identified the key residues for membrane 
binding to be F 165, F 169 and 1202. In addition, the rates of ligand transfer of the u-TTP 
mutants were directly correlated to their membrane binding capabilities, indicating that 
membrane binding was likely the rate limiting step in u-TTP mediated transfer of u-Toc. 
The propensity of u-TTP for highly curved membrane provides a connection to its co-
localization with u-Toc in late endosomes. 
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1. INTRODUCTION 
1.1. Overview of Vitamin E 
Vitamin E is a well known fat soluble chain breaking antioxidant, it is a general 
term used to describe a family of eight stereoisomers of tocopherols. Vitamin E is 
synthesized only in plants. It is abundant in green leafy vegetables and various seed oils 
[1-3]. Vitamin E was first identified by Evans and Bishop as substance X that was 
required for reproduction in rats that were being fed rancid fat as an oxidative stress. In 
the absence of substance X, the animals exhibited normal growth but were sterile due to 
defective placental development [4]. Two years later, this anti-sterility dietary factor 
was renamed "vitamin E" in succession to the then recently discovered vitamin D [5] . 
The chemical structure of vitamin E was not elucidated until 1935, when Evans et al. 
finally crystallized an alcohol from wheat germ oil which contain vitamin E activity [3]. 
The term "tocopherol" is constructed from the ancient Greek word tokos, meaning 
childbirth and pherein to bear or to bring. 
The early research effort on the antioxidant properties of vitamin E was pioneered 
by Mattill and his colleagues [6-8]. Initially, the only significant function of vitamin E 
was accredited to its antioxidant activity. However, in recent years, increasing evidence 
suggests that vitamin E may have other important cellular impacts besides its antioxidant 
properties (reviewed in [9, 10]. Whether or not the alternative cellular functions of 
vitamin E are directly linked to its antioxidant properties has become a topic for debate in 
the field of vitamin E research (reviewed in [11, 12]). 
1.2. Biochemical Properties of Vitamin E 
1.2.1. Vitamin E structures 
1 
Vitamin E describes four structurally similar forms (a, ~, "(, 0) of tocopherols and 
tocotrienols (Fig. 1) (reviewed in [13]). The structure of vitamin E is composed of a 6-
hydroxy-chroman head group with a 16-carbon hydrocarbon side chain linked at the C-2 
position, known as a phytyl or isoprenoid tail. As shown in Fig. 1, the isomers are 
differentiated by the degree of methylation at Rl and R2 positions on the 6-chromanol 
ring, where a-tocopherol features a fully methylated chromanol [13]. Unlike tocopherols 
with a fully saturated phytyl side chain, tocotrienols contain an isoprenoid chain with 
three double bonds at the 3', 7' and 11' positions. The naturally occurring a-tocopherol 
tocopherols: 
4' 8' 
R2 tocopherol! R, R2 
CHa tocotrienol 
tocotrienols: a- CH3 CH3 
~- CH3 H 
R2 .r.:; .r.:; y- H CH3 7' 11' 
CH3 6- H H 
Figure 1: Structure of tocopherols and tocotrienols 
has the 2R,4'R,8'R configuration, designated as RRR a-tocopherol [2,5,7,8-tetramethyl-
2R-( 4'R,8 'R, 12-trimethyltridecyl)-6-chromanol]. Synthetic a-tocopherol, however, 
consists of an equimolar racemic mixture of eight stereoisomers due to the chiral carbon 
centers at positions 2', 4', and 8', designated as all-rac-a-tocopherol. Therefore, dietary 
vitamin E supplements contain only 12.5% RRR-a-Toe, the most bioactive tocopherol 
isoform. Despite a similar antioxidant activity, resulting from an identical chromanol 
ring between racemic and RRR-a-Toc, only RRR-a-Toc (or a-Toe) is retained in our 
bodies by a hepatic tocopherol transfer protein (TTP) (reviewed in [14, 15]). 
2 
1.2.2. Vitamin E as antioxidant 
(X-Toc is a well known lipophilic antioxidant. Its primary role is to scavenge 
chain propagating lipid peroxyradicals, thereby protecting membranes from peroxidative 
damage. Peroxidation of polyunsaturated fatty acids consists of an initiation, chain 
propagation and chain termination reaction (reviewed in [16, 17]) outlined below: 
I+LH ~ L· +IH 
L· +02 ~ LOO' 
LOO' +LH ~LOOH+L' 
LOO' + Toc ~ LOOH + Toc' 
(slow initiation reaction) 
(fast chain propagation) 
(slower chain propagation) 
(chain termination) 
where I is the initiator, LH is the fatty acid, L· is the fatty acid alkyl radical, LOO' is the 
lipid peroxyl radical and LOOH is the hydroperoxide of fatty acid, Toc is the tocopherol 
and Toc' is the tocopheroxyl radical. The initiation reaction is a slow, rate limiting 
process [6]. The reactive oxidant species (ROS) including superoxide produced by 
NADPH oxidase are examples of first-chain initiators [18, 19]. The propagation oflipid 
peroxidation continues until it encounters a tocopherol molecule, which donates a 
hydrogen atom and converts itself to a relatively stable tocopheroxyl radical [20], thereby 
terminating the chain propagation reaction. 
It is well accepted that the antioxidant property resides in the 6-hydroxychroman 
head group [21] (also reviewed in [22-24]), and that the hydrocarbon chain has no 
antioxidant function other than keeping the molecule embedded in membrane bilayers or 
in hydrophobic lipoprotein cores [25, 26]. Burton et al. reported that vitamin E is the 
only major chain breaking antioxidant found in human plasma [26, 27]. Tappel and 
Zalkin [28, 29] observed that (X-Toc inhibited lipid peroxidation in liver mitochondria of 
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vitamin E deficient rabbits. In the iron-loaded rats, a-Toc was about 2 fold more 
effective than y-Toc in reducing pantane produced from lipid peroxidation [30]. The 
recycling efficiency of the chromanols from their chromanoxyl radicals appeared to 
impact the antioxidant activity of a-Toc. a-Toc with a shortened hydrocarbon chain [31] 
or a-tocotrienol with the unsaturated isoprenoid chain [32] have improved recycling 
efficiency thereby enhancing their antioxidant potency. In both studies, chromanoxyl 
radicals were produced from enzymatic oxidation involving lipoxygenase and linolenic 
acid in rat liver microsomes or liposomes. The recycling efficiency of chromanoxyl 
radical to chromanol in the presence of exogenous reductants such as ascorbate and 
NADPH was subsequently determined by Electron Spin Resonance (ESR) measurement. 
If the tocopheroxyl radical is not recycled, it can also undergo oxidative 
degradation into a-tocopheryl quinone (TQ) [33] (Fig. 2), which can be further reduced 
Toc TQ 
Figure 2: Structures of a-tocopherol (a-Toc) and its oxidative product a-tocopheryl 
quinone (TQ). These structures were re-drawn with Chemsketch software. 
to tocopheryl hydroquinone, also an antioxidant. The TQffoc ratio is typically used as a 
marker for oxidative stress, and has been found in higher concentrations in the inner 
membrane of rat mitochondria [33]. TQ can bind directly with glutathione-S-transferase 
(GST) and inhibit its activity [34]. 
1.2.3. Bioavailability of Vitamin E isoforms 
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Despite the higher "(-Toc content in the North American diet [2], the circulating a-
Toc in human serum is about 10 fold higher than "(-Toc (2, 35]. When vitamin E depleted 
rats were fed a diet containing a-Toc and "(-Toc at the ratio of 1:3, after 12 hours, their 
plasma concentration of a-Toc was more than 30 fold higher than "(-Toc [36]. Other 
animals, such as pigs and monkeys can also discriminate the naturally occurring RRR-a-
Toc from synthetic homologues such as all-rac-a-Toc and SRR-a-Toc [37,38]. 
The stereospecific retention of RRR-a-Toc in circulating plasma was similarly 
observed in humans [39-43]. Utilizing deuterium-labeled 3H6 -RRR-a-Toc and 3H3 -SRR-
a-Toc stereoisomers, the half lives for circulating RRR-a-Toc and SRR-a-Toc were 
determined to be 47.5 ± 21.9 hrs and 15.8 ± 5.7 hrs, respectively [39]. However, for 
patients with familial isolated vitamin E deficiency whom were unable to discriminate 
between these two stereoisomers, the half-lives measured for both tocopherols were 13 
hours. Although absorbed equally in chylomicrons, only RRR-a-Toc was enriched and 
secreted in VLDL (very low density lipoprotein) [40, 42]. Interestingly, the plasma 
concentration of a-Toc is maintained relatively steady; a maximum two-fold increase 
was observed when humans were supplemented with large doses of RRR-a-tocopheryl 
acetate [41, 43]. It is now generally accepted that hepatic a-tocopherol transfer protein 
(a-TTP) is critical to the homeostasis of a-Toc in circulation. 
1.2.4. a-Tocopherol in lipid membranes 
In order for a-Toc to act efficiently as a powerful antioxidant, it must be in 
proximity to both the source of peroxyradicals within the lipid bilayer and reductants near 
the aqueous interface. The location and antioxidant behavior of vitamin E in membranes 
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has been reviewed in great depth [22, 24, 44]. Fukuzawa [45] initially proposed three 
possible locations for the chromanol of (X-Toc (Fig. 3): 1) at the aqueous interface; 2) 
close to the aqueous phase and forming hydrogen bond(s) with the oxygen of lipid 
phosphate groups or the acyl-ester of neighboring phospholipids; 3) near the unsaturated 
double bond of the fatty acid acyl chain that is buried in the membrane. 
pope 
Figure 3: Three possible locations of a-Toc in pope membranes. This scheme was 
initially proposed by Fukuzawa,[45] and redrawn by Atkinson et al. (reviewed in [22]) 
Several methods were employed to investigate the location of the chromanol of (X-
Toc in membranes (reviewed in [22] [24]). Stearic acids labeled with Doxyl (N-oxy-4,4'-
dimethyloxazolidine-2-yl) [45] or (9-anthroyloxy) [25] at different positions along the 
hydrocarbon chain were used as probes. Quenching the intrinsic fluorescence of (X-Toc 
by the above labels indicated that the chromanol moiety of (X-Toc is optimally located 
between the 2 ~ and the r position of the acyl chain in the membrane bilayer. The minor 
quench of (X-Toc in DMPC liposomes by water soluble acrylamide was observed [45]. 
This observation further strengthened the conclusion that (X-Toc is indeed close to, but 
not fully exposed at the membrane surface. For the acyl chains with double bonds 
buried deep inside the hydrophobic core of the lipid bilayer, the large dipole moment of 
lipid alkylperoxyl radicals [24] causes the peroxyl radical portion of the lipid acyl chains 
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to be more hydrophilic. Thus, these peroxyl radicals are expected to move toward the 
aqueous interface and be reduced by a -Toc. 
The lateral diffusion of a-Toc in a lipid bilayer was determined to be 1.8 x 10-7 
cm2s-1 as measured by fluorescent quenching of a radical mimick Fluorazophore-L [46], 
which is much slower than 4.8 x 10-6 cm2s-1 reported by Fukuzawa et al. (reviewed in 
[24]). Fluorazophore-L IS a lipophillic derivative of azoalkane 2,3-
diazabicyclo[2.2.2]oct-2-ene (DBO) (Fig. 4), that contains a small fluorescent polar 
headgroup and a palmitoyl chain. The palmitoyl chain anchors the fluorophore to the 
o 
Fluorazophore-L 
Figure 4: Chemical structure of Fluorazophore-L 
lipid bilayer, while its polar reactive headgroup interacts with the phenolic hydroxyl of a-
Toc near the lipid:water interface [46, 47]. Quenching rate constants of DBO by 
tocopherols and tocotrienols are in the order of a>~='Y>8, similar to their activity against 
peroxyl radicals [47]. In the presence of 15% or higher cholesterol, the diffusion of a-
Toc was greatly reduced. The lateral diffusion of a-Toc also increased linearly with the 
temperature [47]. 
NMR spectra of deuterated a-Toc derivatives in organic solution revealed that the 
heterocyclic phenol ring of a-Toc exists in two half chair conformations in organic 
solutions [48]. In PC model membranes, the hydrocarbon tail of a-Toc rotates 
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perpendicularly to the membrane surface with gauche conformations at positions 5' and 
9', with the latter been more disordered since it is further along the phytal chain. 
1.2.5. Vitamin E uptake and metabolism 
Vitamin E is the only major lipid soluble antioxidant found in human plasma [27, 
49]. As illustrated in Fig. 5, upon dietary intake, vitamin E is first absorbed by 
enterocytes in the small intestine, then assembled and transported by chylomicrons into 
the circulatory system. In plasma, lipoprotein lipase (LPL) converts chylomicrons into 
chylomicron remnants by hydrolyzing triglyceride and some vitamin E and free fatty 
TIssue 
Vitamin E 
Uptake 
Figure 5: Uptake and secretion of Vitamin E in circulation system. This cartoon was 
created by Traber et al. [50]. 
acids are transferred non-specifically to various tissues [50]. Lipoprotein lipase mediated 
tocopherol transfer requires binding of this enzyme to the cell surface [51]. Heparin 
inhibits the binding of lipase to the cell surface [52], therefore it abolishes the y-Toc 
uptake by fibroblast cells when incubated in an artificial lipid emulsion containing only y-
Toc [51]. Bulk of the ingested a -Toc is delivered to liver by circulating low density 
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lipoprotein (LDL) via receptor mediated uptake [53]. Traber and Kayden stated that the 
LDL receptor-mediated mechanism was not the only route for vitamin E delivery based 
on the finding that homozygous familial hypercholesterolemia patients who are incapable 
of expressing LDL receptors were not deficient in vitamin E [53]. Traber et al. also 
reported that vitamin E is exchanged between high density lipoprotein (HDL) and LDL, 
with preferred transfer of vitamin E from LDL to HDL [54]. Similar to lipoprotein 
lipase, transfer of a-Toc by lipoproteins also requires the direct interaction between the 
protein and macrophage like p388DI cells [55]. Scavenger receptor class B, type I (SR-
BI), a plasma membrane glycoprotein, has been implicated in the uptake of HDL 
associated a-Toc and facilitates its movement across the blood brain barrier model [56]. 
Recently, SR-BI has also been shown to mediate vitamin E uptake in enterocytes. Anti-
SR-BI antibody treatment of cells greatly inhibited vitamin E uptake [57]. Different 
tissues demonstrate specific subcellular distribution of a-Toc [58, 59]. For instance, in 
adipose tissue, a-Toc was found mainly in lipid droplets, not in the plasma membrane or 
other bilayer membranes [58]. Conversely, Rupar et al. found a-Toc to be highly 
enriched in the membrane of rat liver lysosomes [59] . 
In the liver, prior to the re-secretion of a-Toc back to the circulation, the excess 
a-Toc along with other ingested tocols are metabolized and degraded. These tocopherols 
undergo phytyl side chain shortening by ro-oxidation followed by ~-oxidation to produce 
the water-soluble metabolites carboxyethyl-hydroxychroman CEHC derivatives (Fig. 6), 
which are excreted in urine [60-67] and bile [68]. The ro-oxidative pathway is likely 
regulated by cytochrome p450 isoforms CYP3A [60,61] and CYP 4F2 [64-67]. The 
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HO 
eOOH 
Figure 6: Structure of carboxyethyl-hydroxychroman derivatives. a-Toc: 
methylation at both Rl and R2; ~-Toc: methylation at Rl; 'Y-Toc: methylation at R2; 0-
Toc: non-methylated at both Rl and R2. 
secretion of a-CEHC was increased 5-fold upon treating the aU-rac-a-Toc primed 
human hepatoma HepG2 cells with rifampicin, a CYP3A stimulator [61]. In contrast, 
CYP3A inhibitor ketoconozole greatly inhibited metabolism of tocopherol isoforms in rat 
primary hepatocytes and HepG2/C3A cells [60]. More interestingly, tocopherols without 
methyl group at C-5' position such as 'Y-Toc and 0-Toc were preferentially metabolized 
[61, 64-67]. Tocotrienols share the same metabolic oxidative fate as their tocopherol 
counterparts, consequently produce the same metabolites [62]. The un-metabolized a-
Toc is selectively retained and diverted from lysosomal degradation pathway by a-
tocopherol transfer protein (a-TTP). The salvaged a-Toc is thought to be incorporated 
into nascent VLDL and recycled back to the circulation system [69, 70]. Exactly how a-
Toc is diverted from lysosomal degradation pathway is still a mystery and remains to be 
solved. 
1.2.6. Non-antioxidant properties of vitamin E 
During the last two decades or so, some apparently non-antioxidant related 
cellular functions of a-Toc have been proposed [71-73]. a-Toc appears to modulate cell 
proliferation, cell signaling as well as gene expression. The first non-antioxidant function 
of a-Toc was reported in 1991 by Boscoboinik et aI., who found that both protein kinase 
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C activity [71] and aorta smooth muscle cell proliferation were inhibited by a -Toc, and 
not by other similar antioxidants (Fig. 7) such as Trolox and a-tocopheryl esters 
including a- tocopheryl acetate [72]. Other enzymes inhibited by a-Toc are 
CH3 
Trolox a -Tocopheryl acetate 
Figure 7: Structure of Trolox and a-tocopheryl acetate 
phospholipase A2, cyclooxygenase, diacylglycerol kinase and NADPH oxidase 
(reviewed in [10]). Aside from the above biological functions, a-Toc also stabilizes 
membrane integrity by forming complexes with free fatty acids [74] and 
lysophospholipids [73]. Although similar structure but without a side chain, PMC 
(2,2,5,7,8-pentamethyl-6-hydroxychromane) was unable to protect membranes from the 
chaotropic effect introduced by free fatty acids in spite of its equally potent antioxidant 
activity [73]. a-Toe also prevents the Ca2+ induced fusion of PS vesicles and mixing of 
the aqueous contents, the effect increases with the concentration of a-Toe [75]. a-Toc 
appears to stabilize the transmembrane potential and increase membrane microviscosity 
in the phospholipase treated membrane [76]. 
1.3. Vitamin E binding proteins 
Besides the non-specific phospholipid transfer proteins, several unique and not 
well studied vitamin E binding proteins have been identified. The exact role of these 
vitamin E binding proteins is not well understood, but they are expected to be involved in 
the peripheral tissue distribution of vitamin E. 
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A small 14.2 kDa cytosolic tocopherol binding protein was discovered and 
studied primarily in Dutta-Roy's laboratory. This protein was first detected in rat liver 
and heart [77], then also found in rabbit heart, bovine heart and human placenta [78-80]. 
The function of this protein has not been elucidated. 
Afamin, is a 74 kDa glycoprotein from the albumin multi-gene family, found 
mainly in human plasma and follicular fluid and much less in cerebrospinal fluid. The 
concentration of afamin is correlated to that of vitamine E in the follicular and 
cerebrospinal fluids, but not in the plasma [81]. Afamin has a high binding capacity for 
both a- and y-tocopherol due to its multiple binding sites (maximum of 18 tocopherol 
molecule per molecule of afamin), despite the relatively low binding affinity of 18 11M 
[82]. Afamin facilitates a-tocopherol crossing the polarized brain capillary endothelial 
cells to basolaterally cultured astrocytoma cells in the brain [83]. Collectively, these 
observations imply that afamin might play an important role in vitamin E homeostasis in 
the central nervous system. 
1.4. a-Tocopherol Transfer Protein «X-TTP) 
1.4.1. a-Tocopherol transfer protein 
a-TTP is a 32 kDa cytosolic protein that was first found in rat liver cytosol [84]. 
Later, it was also detected in other tissues, such as heart, spleen, lung and placenta [85, 
86]. In 1992, Yoshida et al. successfully purified a-TTP from rat liver cytosol [87], and 
shortly after, a homolog of a-TTP was isolated from human liver [88]. a-TTP exhibited 
high binding affinity for a-Toc that can only be partially displaced by other tocopherol 
isoforms [89, 90]. The displacement of a-Toc by its homologues was: 38% by ~-Toc, 
9% by y-Toc and 2% by 8-Toc, respectively [89]. a-tocopherol acetate and a-tocopherol 
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qUInone also poorly competed for a-Toc with levels similar to 'Y-Toc. Overall, 
tocopherol binding affinity and antioxidant activity were directly correlated to the degree 
of methylation at the chromanol headgroup of a-Toc. Therefore, biological activity of 
vitamin E appears to be determined by their ability to bind a -TTP. 
Although vitamin E deficiency does not seem to alter a-TTP expression, 
administration of a- or ~-Toc to vitamin E deficient rats appeared to up-regulate a-TTP 
mRNA where both isoforms were equally effective [36] . In normal brain tissues, a-TTP 
is either absent or below detection level, while in the brains of patients suffering from 
AVED and other oxidative stress related neurodegenerative diseases, such as Alzheimer's 
disease and Down's syndrome, Copp et al. detected an increase in the expression of a-
TIP [91] . Whether oxidative stress truly modulates the a -TTP expression and thereby 
regulates the tissue redistribution of a -Toc in the brain or not requires more research 
attention before any firm conclusions can be made. 
1.4.2. Crystal structure of a-TTP 
The primary structure of a-TTP from rat liver was reported by Sato et al. [92] in 
1993. This protein contains 278 amino acid residues. In 2003, the crystal structure of a -
TTP was published by Meier et al. [93] and Min et al. [94]. Overall, the a-TTP 
structures deduced from both studies are very similar. a-TIP is composed of two 
domains: an N-terminal all-helical domain and a C-terminal lipid binding CRAL-TRIO 
domain with a ~a~a~a~ fold. The a-Toc binding pocket consists of mainly 
hydrophobic amino acids, and a few well-defined water molecules that form a tunnel 
connecting the binding pocket to the bulk solvent. Extensive Van der Waals contacts 
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form between the methyl groups of the chromanol moiety and the hydrophobic binding 
pocket of the protein. (l-Toc is buried deep in the binding pocket. In order for (l-Toc to 
enter and exit the binding site, (l-TTP must undergo a major conformational 
rearrangement. Furthermore, the isoprenoid side chain of (l-Toc bends back on itself 
around C4' and C8' positions when crystallized inside the binding pocket of (l-TTP. Fig. 
8 illustrates the two conformations of (l-TTP: the Triton X-100 bound open conformation 
and the (l-Toc bound closed conformation. What differentiates these two structures is the 
position of the mobile lipid exchange loop or lid (residues 198 - 221, colored in gray). 
The presence of the detergent molecules appears to induce an "open" conformation and 
expose the hydrophobic lipid binding pocket. Similar lid and conformational change can 
be found in other CRAL-TRIO proteins such as supernatant protein factor (SPF) [95], 
Sec14 and yeast Sfh1 [96,97]. 
Figure 8: Surface comparison of the open (left) and the closed (right) conformation 
of (l-TTP structure. Hydrophobic residues are colored in yellow, basic residues are 
colored in blue, acidic residues are red and polar residues are shown in cyan. The mobile 
lipid exchange loop (residues 198-221) are colored in light gray [93]. 
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The phenolic hydroxyl group of a-Toc forms a hydrogen bond with the carbonyl 
group of Val 182 and two water molecules [94]. Hence, a-Toc homologues without 
hydroxyl groups, such a-tocopherol acetate and a-tocopheryl quinone, cannot form 
hydrogen bonds with Val 182, are poor substrates for a-TTP, with only 10% binding to 
a-TTP. The methyl groups at C5' and C7' positions of the chromanol are also critical for 
a-TTP recognition. In comparison to a-Toc, the absence of the C5' or C7' methyl group 
as in ~-Toc and y-Toc reduce their binding to a-TTP by 62% and 90% respectively. 8-
Toc missing both C5' and C7' methyl groups, exhibited only 2% binding to a-TTP [89]. 
Stereospecific selection occurs primarily at C2' position, which prefers the RRR-
configuration. Similar preference is also given for the RRR-sterochemistry in the phytyl 
tail at 4' and 8' positions. Therefore, SRR-a-Toc, a-tocotrientol with unsaturated tail and 
trolox without phytyl chain all exhibited only 10% of binding to a-TTP in comparison to 
a-Toc. 
1.4.3. Role of a-TTP in the intracellular trafficking of a-Toc 
Several hepatoma cell lines that stably express a-TPP have been established [98-
100]. The intracellular transfer of a-Toc has been studied using radiolabeled and 
fluorescent tocopherol derivatives. Previous observations indicated that a-Toc is 
associated with VLDL before its secretion from rat hepatocytes [69, 70]. However, Arita 
et al. [98] concluded that a-TTP mediated transfer of a-Toc is independent of VLDL. 
Treating McARH7777 hepatoma cells with Brefeldin A, an antibiotic that disrupts the 
Golgi apparatus and inhibits VLDL secretion, has no effect on a-Toc secretion [98]. In 
contrast, the anti-malarial drug chloroquine reduced a-TTP mediated a-Toc secretion by 
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50% or higher [99, 100]. Since chloroquine is a membrane permeable agent that 
neutralizes the acidic environment of late endosomes/lysosomes, Horiguchi et al. 
concluded that the increase in the late endosomal pH induced the accumulation of a-TTP 
and also impaired its ability to transfer a-Toc. Furthermore, the N-terminal 21 to 50 
amino acid residues of a-TTP (rich in arginine) appeared to be important for its pH-
dependent localization [100]. Uptake of a-Toc from HDL was greater than LDL, and 
treatment with an antibody against scavenger receptor class B type I (SR-BI) inhibited a-
Toc uptake by approximately 40% into hepatocytes [99]. Qian et ai. [99] also found that 
a-TTP was colocalized with NBD-a-Toc as well a late endosomalllysosomal protein 
LAMP-I in the endocytic compartment. In the absence of a-TTP expression, most of the 
imported NBD-a-Toc failed to migrate to the plasma membrane where it would be 
excreted [99]. Both Ul8666A (lysosomal lipid trafficking inhibitor) and glyburide 
(ABC reporter inhibitor) reduced a-Toc secretion. Glyburide completely abolished the 
a-TTP activity. Interestingly, Brefeldin A only inhibited a-Toc secretion when 
apolipoprotein A-I (Apo AI) was absent. Overall, these findings suggest that a-TTP 
mediated secretion of a-Toc from the liver is likely to associate with Apo-AI, not VLDL. 
The exact mechanism which a-TTP employs to return a-Toc back to the circulation is 
currently unknown, and it is still under intensive investigation. 
1.4.4. Ataxia with Vitamin E deficiency (AVED) 
Mutations in the a-TTP result in the disorder called Ataxia with Vitamin E 
Deficiency (AVED). It is an autosomal recessive disorder characterized by very low 
concentration of circulating vitamin E. In normal healthy humans, the serum vitamin E 
concentration is 9 ± 4 mg/liter (i.e. approximately 20 J.lM). Whereas in A VED patients, 
16 
serum vitamin E concentration is highly correlated to the severity of the disorder [101-
105]. For milder AVED cases, patients retain about 50% or greater of the normal serum 
vitamin E level [101-103]. However, in the severe form of AVED, patients' serum 
vitamin E can be as low as 10% or less [102, 104, 105]. Even with plasma (l-Toc below 
the threshold of 30 - 40 J..lmol/L, A VED patients are incapable of retaining (l-Toc, which 
is evident in their increased urinary secretion of the (l-Toc metabolite (l-CEHC [106]. 
Patients suffering from A VED exhibited neurological symptoms similar to 
Friedreich's ataxia and abetalipoproteinemia disorder. Unlike the abetalipoproteinemia 
disorder, caused by fat mal-absorption in the small intestines, AVED patients experience 
normal absorption in the small intestines, but due to the mutations in (l-TIP, fail to 
selectively salvage (l-Toc and recycle it into the circulation system. Supplementation of 
(l-Toc acetate at 0.8 to 1 g per day during the early stage of the disease, helps to improve 
the patients' serum vitamin E concentration, thereby ameliorating the symptoms and 
preventing the disease progression [101, 107]. 
The A VED locus was first localized to chromosome 8q by homozygosity 
mapping analysis [104, 108], then refined to 8q13 by Arita et ai. [109]. The first AVED 
case was reported in 1981 by Burck et ai. [110]. Since then, 22 mutations in the a-TTP 
gene have been identified (reviewed in [15]). Mutations caused by incorrect initiation 
and termination of a-TTP gene transcription, result in a reduced level of functional (l-
TTP or defective (l-TTP of incorrect sizes. For instance, a single base deletion at 
position 744 that led to a frame shift in homozygous Moroccan patients, resulted in 
substitution of the last 30 amino acids with aberrant 14 amino acids [107]. Similarly, one 
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Japanese female patient with a mutation at an upstream initiation codon in the 5'-
untranslated region exhibited a 50% reduction in the level ,of (X-TTP protein. 
Figure 9: Location of missense A VED mutations on (X-TTP. Shown is the three 
dimensional structure of the protein with mobile lipid exchange loop (residues 198-221) 
in light gray color and the lipid binding cavity in orange. The original structural image 
was created by Min et al. [94]. Presented here is the redrawn cartoon by Morley et al. 
[111]. 
Alternatively, a single amino acid residue change in (X-TTP due to point mutation 
in a-ITP gene can also cause AVED of different levels of severity. The locations of the 
six major mutations of (X-TTP are highlighted in Fig. 9. As shown, three of these are Arg 
59, Arg 192 and Arg 221 located on the protein surface that from a positively charged 
cleft. His 101 and Glu 141 however are found in the interior of (X-TTP. Arg 59, Glu 141 
and Arg 221 are highly conserved residues among CRAL-TRIO family proteins. 
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Mutations at these residues cause the early onset and more severe forms of the disease. 
Conversely, mutations at the non-conserved His 101, Ala 120 and Arg192 are responsible 
for the late onset and milder form of the disease. Two additional point mutations have 
been reported, but are not shown in Fig. 9 are located at residues Leu 183 and Gly 246 
(reviewed in [15]). The only mutation that appears to alter the ligand binding pocket is 
Leu(183)Pro, this mutation not only reduces the hydrophobicity of the binding pocket, 
but also introduces a kink into helix 9, and thus disrupts the interaction between a-TTP 
and a-Toc [94]. Thus, it is not surprising that the Leu(l83)Pro mutation leads to a severe 
form of AVED [112]. 
The physiological relevance of A VED mutations has been tested in in vitro 
experiments. When six A VED mutants were tested for their abilities to transfer a-
tocopherol using purified recombinant a-TTP in a vesicle transfer assay by Morley et al. 
[111], Arg(59)Trp, Glu(141)Lys and Arg(221)Trp mutations introduced a modest 2-3 
fold reduction in ligand transfer. Similarly, the milder AVED mutants His(101)Gln, 
Ala(120)Thr and Arg(192)His behaved almost identical to the wild type a-TTP. These 
authors concluded that the functional defect in the A VED mutants may not be due to their 
ligand transfer ability, but rather it is caused by the failure of these variants to interact 
with other cellular proteins. Further investigation with transfected HepG2/C3A cells 
indicated that Arg(59)Trp, Arg(221)Trp, and Ala(120)Thr mutants were, similar to wild 
type, localized to endosomes/lysosomes, but failed to translocate to the plasma 
membrane, and thus inhibited a-Toc secretion by 33%,60% and 83%, respectively [113]. 
Interestingly, Arg(59)Trp, Arg(221)Trp, and Ala(120)Thr were more readily degraded 
than the wildtype a-TIP. It was recently suggested by Morley et al. [114] that the lack 
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of ability for Arg(221)Trp mutant to extract (X-Toc from the lipid bilayer might explain 
its inability to transfer (X-Toc. Therefore, the physiologically role of (X-TTP depends on 
its ability to direct the delivery of (X-Toc from endosome/lysosomes to the plasma 
membrane. 
Transgenic mice lacking a-TTP gene (TTP-I-) were created to explore the 
physiological significance of (X-TTP [115-118]. (X-TTP knock-out (KO) mice have less 
than 10% of normal (X-Toc concentrations in their lungs, plasma and brain compared to 
the wildtype mice [115, 116]. In mice fed a normal diet, both their plasma and brain (X-
Toc concentration appeared to be regulated by (X-TTP expression: with 100% for the 
wildtype a-TTP+I+, 50% for heterogyzous (X-TTP+I- and undetected for homogyzous a -
TTP-I- [117, 118]. Furthermore, male homogyzous a-TTp-I- mice were fertile, whereas 
female homogyzous a-TTp-I- mice failed to carry their embryo to full term. Diet 
supplemented with (X-Toc or synthetic antioxidant BO-653 prevented the miscarriage in 
the homogyzous a-TTp-I- pregnant mice [117]. The antioxidant effect of (X-Toc was also 
evaluated in the lungs of both wild type and (X-TTP knockout mice. Clusters of immune-
inflammatory genes were found to be down regulated upon exposure of this knockout 
mice to cigarette smoke [115]. 
1.5 CRAL-TRIO protein family 
(X-TTP belongs to a lipid binding protein family containing CRAL-TRIO domains 
(Pfam PF 00650) [119], also known as Sec14 domain (reviewed in [120] .) Other 
members in this family include: cellular retinaldehyde binding protein (CRALBP) which 
is expressed mainly in retina and binds to 11-cis-retinal with high affinity (~ = 15 nM) 
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[121, 122]; the yeast Sec14 protein which binds and regulates the transfer of 
phosphatidylinositol (PI) and phosphatidylcholine (PC) between Golgi and plasma 
membranes [96, 97, 123]; and supernatant factor (SPF) or tocopherol association protein 
(TAP), which stimulates the epoxidation of squalene to lanosterol during the cholesterol 
synthesis [124]. In addition to the CRAL-TRIO domain, TAP/SPF also possesses a C-
terminal jelly-roll barrel Golgi Dynamics (GOLD) domain [95, 125]. The GOLD 
domain is speculated to be essential in protein-protein interactions during vesicular 
trafficking from Golgi. All of these proteins are involved in intracellular transfer of 
different classes of lipids. Among a few CRAL-TRIO proteins tested, a-TTP exhibited 
the highest affinity for a-Toc binding [90] . A BLAST search has identified many others 
non-lipid transfer proteins which also contain the CRAL_TRIO lipid binding domain, 
such as Rho GTPase-activating protein 1 and MEG2 tyrosine phosphatase. 
1.6 Mechanism of hydrophobic ligand transfer 
Intracellular compartments are separated by lipid membranes. The transportation 
of small hydrophobic molecules such as free fatty acids and lipid soluble vitamins across 
aqueous barrier to its targeted destination is thermodynamically unfavorable. The routes 
that are known to facilitate the intracellular transportation of hydrophobic molecules are 
either based on vesicular or protein mediated transfer mechanisms. 
Protein mediated transfer of hydrophobic ligand to its acceptor membranes can be 
either collisional or diffusional. A collisional based transfer mechanism relies on the 
direct collisional interaction between the protein and the target membranes. Therefore, 
the rate of ligand transfer is dependent on both the concentration and the lipid 
composition of the membrane [126-131]. Conversely, the aqueous diffussional transfer is 
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determined predominantly by the ligand behavior and the aqueous environment, such that 
the rate limiting step is the dissociation of ligand from the protein [126, 132, 133]. Both 
diffusional and collisional modes of cholesterol transport have been demonstrated (Fig. 
10). Based on the study conducted by Cheruku et al. [134], lysosomal cholesterol export 
mediated by Niemann-Pick Type C2 protein (NPC2) is a collisional event. More 
interestingly, the rate of transfer was greatly enhanced in the presence of lyso-
bisphosphatidic acid (LBPA), a late endosomal specific lipid. In the early studies of 
cholesterol transport, the aqueous diffusion of cholesterol between serum HDL and LDL 
[135], or human erythrocytes and plasma [136] were reported. These studies suggested 
that the mode of cholesterol transportation is determined by its tissue or subcellular 
localization. 
Collisional Transfer 
Aqueous Diffusion 
Figure 10: Potential mechanisms of cholesterol transfer by NPC2 protein to 
membranes. This cartoon was created by Cheruku et al. [134], illustrates the collisional 
mechanism that is mediated by the interaction between NPC2 and membrane; whereas 
the aqueous diffusion is mediated by the dissociation of cholesterol from NPC2. 
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Other thoroughly studied lipid transfer proteins are fatty acid binding proteins 
(FABPs). Nine tissue specific fatty acid binding proteins have been identified so far 
(reviewed in [127]). All FABPs share similar tertiary structures, composed of a 10-
stranded anti-parallel ~-barrel and two short a-helices that form a lid on one side of the 
~-barrel which regulates the entry and exiting of free fatty acids. Unlike other members 
of its family that transfer one fatty acid per protein by a collisional mechanism, liver 
F ABP with the largest binding cavity, is capable of binding two fatty acids [137] or other 
larger hydrophobic ligands [137] and delivers its ligand(s) via the aqueous diffusion 
mechanism [138]. 
1.7 Membrane curvature sensing proteins 
From the above examples, the molecular forces that regulate protein-membrane 
interactions are electrostatic, hydrophobic and hydrogen bonding. These interactions are 
therefore essential in the collisional based mechanism of ligand transfer. However, in 
some scenarios, another type of specific interaction is required, in addition to the 
electrostatic and the hydrophobic interactions. For example, Saari et al. [122] 
demonstrated that the binding of CRALBP to phosphatidic acid (PA) was critical for the 
release of its ligand ll-cis-retinal. The apparent binding specificity of CRALBP for 
various phospholipids was: PA > PI (3,4,5)P3 > PS > PI (4,5) P2. Moreover, the efficacy 
of these phospholipids to facilitate ligand release by CRALBP matched well with their 
binding affinity leading the authors to speculate that binding was likely mediated by 
spatial recognition rather than simply electrostatic interaction. 
The ability of proteins to sense and induce membrane curvature has become an 
active research area in recent years. McMahon and Gallop published an excellent review 
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on membrane remodeling and the formation of membrane curvature [139]. Membrane 
curvature can be generated by a change in its phospholipid composition, by the 
introduction of phospholipids with inherently high curvature (reviewed in [22]). 
Alternatively, membrane curvature can also be formed during protein reorganization, 
such as the oligomerization of integral membrane proteins, the insertion of an 
amphipathic helix, or the dimerization of crescent-shaped BAR domains. Proteins with 
enhanced binding or functional activity toward highly curved membranes are: 
cytochrome h5 [140], acyl-CoA binding protein (ACBP) [141], Arf GTPase activating 
protein 1 (ArfGAPl) [142, 143], a-synuc1ein [144], glycolipid transfer protein [145] and 
annexin B12 [146]. Membrane curvature also appears to modulate the ability of 
Magainin 2 (an antimicrobial peptide) to recognize antigens presented by liposomes 
[147] and to facilitate pore formation within bacterial cell membranes [148]. 
1.8 Proposed orientation of (1-TTP in the lipid membrane 
The Orientation of Proteins in Membranes (OPM) database 
(http://opm.phar.umich.eduJ) is an excellent tool to explore the impact of hydrophobic 
forces in protein-membrane interactions. As long as the crystal structure of a particular 
protein is available, OPM can calculate the changes in free-energy (~G) of this protein 
upon its insertion into the membrane [149, 150]. The transfer energy is minimized based 
on the flexibility of side chains, not the backbone of the protein [149]. The lipid 
exchange loop has been hypothesized to interact with lipid membranes from the crystal 
structures of a-TTP published by Meir et al. [93], but the position of the protein on the 
lipid surface when it interacts with the lipid membrane, is still unknown at the present 
time. Therefore, the orientation of a-TTP with respect to the lipid membrane was 
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calculated, and the orientations with the maximum free energy change are presented in 
Fig. 11. According to this model, the gating helices A8 and AlO are submerged into the 
lipid bilayer, and the hydrophobic residues highlighted in red are predicted to undergo a 
deep insertion into the hydrophobic core. If this model is correct, then replacing the 
highlighted hydrophobic residues with charged ones would greatly reduce the binding of 
a-TTP to the membranes and thereby reduce the transfer of a-Toc. Guided by this 
model, a mutagenesis study was conducted to investigate the role of helices A8 and AlO 
on the membrane targeting and the ligand transfer of a-TTP. 
/ Met209 
" Helix AS Helix AIO Helix AS Helix AIO 
Figure 11: Orientation of a-TTP in a lipid membrane. The blue dots are the 
calculated hydrophobic membrane boundaries. A) Triton-XlOO bound apo-a-TTP 
(pdb:loiz) and B) a-Toc bound halo-a-TTP (pdb:lr51). Highlighted in red are the 
hydrophobic amino acids which are expected to inert into the membrane, and cyan sticks 
is a-Toc. 
Previous work from our group has demonstrated the preferential binding of a-
TTP for a-Toc over other dietary tocopherols. However, the relevance of this protein in 
the transfer of a-Toc to its target membranes has not been investigated in detail. Since 
a-TTP is thought to remain in the late endosomal/lysosomal compartment, yet, salvaged 
a-Toc must be returned to the plasma membranes before re-entering the circulation 
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system. The exact role of (X.-TTP in the transfer of (X.-Toc to plasma membranes is 
currently unknown. In order to gain more insights into this complicated question, we 
must first understand the mechanistic basics involved in (X.-TTP mediated transfer of (X.-
Toc and identify the factors that can impact rate of its ligand transfer. Using a 
fluorescent probe NBD-(X.-Toc, a fluorescent resonance energy transfer (FRET) assay was 
developed and utilized to investigate the mechanism of (X.-Toc transfer by (X.-TTP. The 
data acquired suggest that (X.-Toc transfer by (X.-TTP is not only collisional based but also 
sensitive to membrane curvature. Furthermore, the lipid binding domain(s) as well as the 
key amino acids that are essential in governing the translocation of (X.-Toc have been 
identified from this mutagenesis study. 
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2. RESULTS 
2.1. Transfer ofNBD-Cl-Toc to model lipid membranes evaluated with 6-His-Cl-
hTTP isolated from pET28b and pET21b expression vectors 
2.1.1. 6-His-UrhTTP with an extension expressed/rom hTTPlpET28b construct 
Human Cl-TTP was previously cloned by Panagabko et al. [151] (in our lab) into 
the pET28b vector with SalI and Not! restrictions sites. This construct produced soluble 
recombinant fJ..-TTP of 35 kDa with an N-terrninal 6-histidine tag, denoted here as 6-His-
28TTP. Due to the presence of an N-terminal40 amino acid extension from the pET28b 
expression vector, this protein was 3 kDa larger than the published size of 31.75 kDa of 
the native human fJ..-TTP [109]. In spite of the N-terminal extension, 6-His-28TTP bound 
to tritiated fJ..-Toc with high affinity (Ko = 25 ± 2.6 nM), and with much reduced affinity 
toward ~-, 'Y- and 8-tocopherol isoforms [90]. Using the nickel affinity purification 
protocol described in the Methods section, after the removal of several non-specifically 
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Figure 12: Nickel chelate affinity column purification of 6-His-28TTP expressed in 
E. coli BL21 (DE3) cells. Cell lysate and purified protein samples (- 5 Ilg per lane) 
were analyzed on 15% SDS-PAGE. Lane 1&10: protein marker (BioRad #161-0363); 
Lane 2: insoluble cell lysate; Lane 3: soluble cell lysate; Lane 4: nickel column flow 
through fraction; Lane 5: buffer wash; Lane 6 - 8: 250 mM imidazole wash fraction #1 to 
3; Lane 9: 400 mM imidazole elution fraction #2. 
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bound proteins in 250 mM imidzaole (lane #6 to 8), a highly purified 6-His-28TTP was 
eluted in 400 mM imidazole (lane #9) (Fig. 12). 
An unknown protein of 37-39 kDa typically co-eluted with 6-His-28TTP in the 
400 mM imidazole, as a minor contaminant. A hint of this protein is visible in lane #9 
(Fig. 12). In order to determine whether this 37-39 kDa protein contained a 6-His tag, 
western blot analysis was performed with an antibody recognizing the 6-His tag. This 
antibody detected only the major protein band at 35 kDa, but not the -39 kDa protein 
contaminant, suggesting that the 35 kDa protein is indeed 6-His-28TTP and the 39 kDa is 
an E. coli protein with high affinity for nickel ions. Interestingly, the level of 39 kDa 
unknown protein contamination varied among the preparations. A low level of 
contamination in a purified recombinant protein is generally accepted and it is not 
expected to alter the behavior of the recombinant protein. In our case, only one 
contaminating protein was found and accounted for - 5-10 % of the total recovered 
proteins. The purified 6-His-28TTP was therefore utilized for FRET assay development 
and optimization. 
2.1.2 Characterization of NBD- a-Toc fluorescent probe 
eH]-RRR-a-Toe was used as early as 1964 by Spencer and Bow [152] to measure 
the ability of vitamin E to cross the small intestine, and later was employed to identify the 
a-Toe binding sites on human erythrocytes [153] and its affinity to bind to a-TTP [90]. 
Utilizing radio labelled a-Toe to study its inter-membrane transfer is rather indirect and 
time consuming. Although the end point of transfer can be determined, the real time 
transfer data is lost during the sample handling and separation. To circumvent these 
potential complications, a fluorescent analog of a-Toe, (R)-2,5,7,8-tetramethyl-chroman-
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2-[9-(7 -nitro-benzo[ 1 ,2,5]oxadiazol-4-ylamino )-nonyl]-chroman-6-01 (NBD-a-Toc) was 
synthesized in our lab by Nava et al. [154]. As shown in Fig. 13, an NBD moiety was 
conjugated at the C9 position of an n-alkyl spacer in place of the a-Toc phytyl side chain. 
Although three carbons shorter than the natural a-Toc, the total molecular length of 
NBD-a-Toc (24.5 A) is almost same as that of a -Toc (22.1 A). NBD-a-Toc binds to 6-
His-28TTP with high affinity, with a dissociation constant (KD) of 56 ± 15 nM [154], 
which is slightly reduced compared to eH]-RRR-a-Toc at 25 ± 2.8 nM [90]. NBD-a-
Toc is self-quenched in aqueous solution, fluoresces only in hydrophobic environments 
such as organic solvents, lipid membranes, or within lipid binding proteins. In absolute 
ethanol, the maximum excitation and emission determined for NBD-a-Toc were 470 nm 
and 535 nm, respectively (Fig. 13). 
NBD-a-Toc 
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Figure 13: Chemical structure of NBD-a-Toc (top) and the spectra of NBD-a-Toc 
in absolute ethanol (bottom). The excitation spectrum of NBD-a-Toc (blue) was 
scanned from 400 to 500 nm with an emission wavelength set at 535 nm. The emission 
spectrum (red) was monitored from 500 to 600 nm with excitation wavelength at 460 nm. 
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It has been shown previously that a-Toc is buried in the binding cavity of a-TTP 
or near the lipid aqueous interface of lipid membranes [45, 93, 94]. In order to test 
whether NBD-a-Toc behaves similarly when bound to a-TTP or inserted in the lipid 
bilayer, a dithionite reduction experiment was performed. The dithionite reduction assay 
has been used frequently to study the kinetics of phospholipid flip-flop (transbilayer 
movement) and membrane fusion [155-157]. Dithionite, (Na2S204) is a non-membrane 
permeable reductant. It reduces the nitro group of NBD to an amine without opening the 
ring [158], and the quench of NBD fluorescence occurs rapidly in the presence of 25 mM 
dithionite. According to McIntyre and Sleight [158] , more than 95% of NBD-labeled 
lipid in the outer leaflet of an artificial membrane bilayer was quenched by dithionite. 
When NBD-a-Toc was added to 6-His-28TTP (Fig. 14A) or extruded PC vesicles 
(Fig. 14B), the fluorescent intensity increased to 125,000 and 300,000, suggesting the 
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Figure 14: Reduction of NBD-a-Toc by sodium dithionite. 0.5 JlM NBD-a-Toc was 
pre-incubated with 5 JlM 6-His-28TTP (A) or 1 mM pre-formed PC large unilamellar 
vesicles (LUVs) (B) in a total volume of 400 Jll for 15 min. The changes in the 
fluorescent signal were monitored before and after a stepwise addition of 50 Jll Na2S204 
at 1M stock concentration. Final Na2S204 concentrations are denoted with arrows. 
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insertion ofNBD-a-Toc into 6-His-28TTP and PC vesicles, respectively. Increasing the 
concentration of Na2S204 up to 400 mM did not reduce 6-His-28TTP bound NBD-a-Toc. 
The stepwise reduction in the fluorescent signal was due to the dilution effect caused by 
the added volume of sodium dithionite, as the same level of reduction was observed when 
sodium dithionite was replaced with mQH20 (data not shown). Therefore, NBD-a-Toc 
was protected from sodium dithionite reduction (Fig. 14A) and is likely buried deep 
inside 6-His-28TTP. In contrast, 300 mM Na2S204 completly ruptured PC vesicles, 
indicated by the sudden termination of fluorescent signal detection (Fig. 14B). In the 
latter case, no reduction of NBD-a-Toc fluorescence was observed up to 200 mM 
Na2S204. Unlike in 6-His-28TTP, the first addition of Na2S204 to PC vesicles appeared 
to enhance the fluorescence intensity by about 10%. It is unclear why the addition of 
Na2S204 would enhance the fluorescence intensity. We speculate that some of the self-
quenching was relieved by dithionite reducing some of the NBD at the surface of the 
bilayer before it accessed all of the NBD in the bilayer. Since the Na2S204 concentrations 
applied in this experiment far exceeded the effective concentrations reported in other 
studies, we concluded that the NBD-a-Toc was probably incorporated into 6-His-28TTP 
or lipid membranes in a similar manner as its natural analog, and the NBD moiety did not 
drastically alter its interaction with a-TTP or the membrane bilayer. 
The water soluble quencher, acrylamide, has been used previously to probe the 
location of the chromanol headgroup of a-Toc in lipid membranes [45]. It is not known 
whether the attachment of NBD to the tail of a-Toc would affect the location of 
chromanol in the membrane. Therefore, the acrylamide quenching of the intrinsic 
fluorescence of the chromanol headgroup of NBD-a-Toc and a-Toc in the PC vesicles 
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was compared. As shown in Fig. 15A & B, acrylamide gradually quenched NBD-a-Toc 
and a-Toc in the lipid vesicles, with 79% and 87% of total fluorescence being quenched 
in the presence of 1.5 M acrylamide. Acrylamide quenching was also used in an attempt 
to characterize the location of NBD within the lipid membranes. The change in NBD 
fluorescence was monitored with an excitation wavelength of 466 nm. As depicted in 
Fig. 15C, only 15% of the total fluorescence signal was quenched in the presence of I M 
acrylamide. All three sets of acrylamide quenching data are presented in Fig. 15D as a 
plot of FJF versus quencher concentration. The quenching constant ksv can be calculated 
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Figure 15: Acrylamide quenching of the natural a-Toc or the florescent NBD-a-Toc 
in PC vesicles. Bovine PC LUVs (1 mM) containing 3% NBD-a-Toc (A) or 0.5 /-lM a-
Toc (B) were quenched with 7.5, 30, 45, 60, 75, 100, 125, 150, 200, 275, 350, 500, 750, 
1000 and 1500 mM acrylamide, excitation wavelength was set at 295 nm. C) PC LUVs 
(40 /-lM) containing 3% NBD-a-Toc were quenched with 15,30,45,100,175,400,700, 
1000 mM acrylamide with excitation wavelength of 466 nm. D) Stem Volmer's plot 
analysis from the maximum fluorescence at each condition tested. 
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as the slope from the Stem-Volmer's plot, according to the Stem-Volmer's equation 
[159]: 
FJF = 1 + ksv [Q] Eqnl 
where Fo and F are the observed fluorescence in the absence and presence of quencher, 
ksv is the Stem-Volmer constant, [Q] is the quencher concentration. The quenching 
constants calculated for NBD-a-Toc were 2.63 M-1 and 0.17 M-1 for the chromanol and 
NBD moiety, respectively. The fluorescence quenching of a-Toc was linear up to 0.75 
M acrylamide, which (with the two highest quenching concentrations removed) resulted 
in a quenching constant of 3.30 M-1, indicative of a slightly more aqueous exposed 
chromanol moiety compared to NBD-a-Toc. The negligible quench of NBD 
fluorescence by acrylamide reconfirmed that this moiety is inserted inside the bilayer and 
at a location that is away from the aqueous phase. 
2.1.3. Development and optimization of Fluorescence Resonance Energy Transfer 
(FRET) assay 
An efficient FRET assay requires the energy donor and the energy acceptor to be 
in close proximity - between 1 to 10 nm. Moreover, the emission band of the donor must 
overlap with the excitation band of the acceptor. Therefore, in this study, NBD-a-Toc 
(Aexmax 470 nm, Aem max 535 nm) and TRITC-DHPE (Aexmax 555 nm, Aem max 580 nm) were 
chosen as energy donor and acceptor, respectively. The energy acceptor 
tetramethylrhodamine TRITC was linked to the free amine on the head group of 
dihexadecanoyl phosphatidylethanolamine, DHPE (Fig. 16). Thus, TRITC is expected to 
protrude from lipid membranes and to be exposed to the aqueous phase. The rates of 
inter-vesicular transfer as well as the transmembrane movement of various NBD labeled 
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phospholipids have been reported previously [160-162] . These studies concluded that 
the fluorescently labeled phospholipids were transferred only to the outer leaflet of the 
bilayer, and the transbilayer migration of phospholipids was unlikely or occurred at 
extremely slow rates that lasted (Tl/2 = 11 days) for days [162]. It is, therefore, 
reasonable to expect that NBD-a-Toc transferred from a-TTP is inserted only into the 
outer leaflet. The Forster distance between NBD-a-Toc and TRITC-DHPE is 37.3 A 
when incorporated into the same membrane [163] and the membrane thickness was 
determined to be 61 ± 10 A by Huang and Thompson [164]. Since TRITC-DHPE is 
uniformly distributed in both leaflets of model PC membranes, it will be able to quench 
NBD-a-Toc in the membrane bilayers regardless of the leaflet in which it is located. 
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Figure 16: Chemical structure of lipid quencher TRITC-DHPE. N-
(tetramethylrhodarnine-6-thiocarbamoyl)-1 ,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolarnine. It was purchased from Invitrogen. 
a-TTP mediated NBD-a-Toc transfer is likely bidirectional, as illustrated in Fig. 
17. Ligand bound a-TTP delivers and inserts NBD-a-Toc into the target membranes 
containing quencher TRITC-DHPE, thereby reducing the fluorescence signal of NBD-a-
Toc. In the reverse direction, the unbound a-TTP binds to and picks up NBD-a-Toc, 
relieving quenching of the fluorescence signal as NBD-a-Toc leaves the 
quencherffRITC-PE containing membrane. 
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, NBD-Toe ~ TRITC-DHPE 
Figure 17: Cartoon illustration of NBD-Toc delivery by (l-TTP detected by 
Fluorescence Resonance Energy Transfer (FRET) assay. The forward insertion and 
the reversed pick up of NBD-a-Toc (green) by a-TTP (orange) are indicated by black 
and grey arrows respectively. NBD-a-Toc is quenched by TRITC-DHPE (pink), when it 
is within the Forster distance of 37.3 A. 
In this study, the rate of a-hTTP mediated transfer of NBD-a-Toc to membranes 
was determined by following the fluorescence decay as NBD-a-Toc bound to a-hTTP 
was transferred to TRITC-PE containing PC vesicles. A stopped-flow device was 
employed to monitor the fluorescence change when NBD-a-Toc bound a-hTTP was 
mixed with the extruded PC vesicles containing TRITC-DHPE. During assay 
development and optimization, 3% TRITC-DHPE was chosen. To ensure that all of 
NBD-a-Toc was bound to a-hTTP, the ratio ofNBD-a-Toc to a-hTTP was kept at 1:10. 
Thus, the fluorescence decay reflected the transfer of NBD-a-Toc from a-hTTP to the 
modeled membranes. Similarly, the molar ratio of a-hTTP to bovine PC vesicles was 
1:50 or greater to guarantee a unidirectional transfer from a-TTP to lipid vesicles. 
2.1.4. Kinetics ofNBD-lYrToc transfer by 6-His-28TTP 
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Initially, the FRET assay was performed with the final concentrations of 0.5 ~M 
NBD-a -Toc, 5 ~M 6-His-28TTP and 250 ~M liver PC (ratio = 1:10:500). Under these 
assay conditions, 30-35 % of the initial fluorescence signal was lost. The mixing time for 
the SPF-17 stopped-flow device is - 20 ms. Therefore, it is possible that the NBD-a.-Toc 
transfer was too fast to be monitored by our instrument. If this was so, then we expected 
that diluting the reagents to slow down transfer would solve the problem. To test our 
hypothesis, the ratios of NBD-a-Toc/a-hTTPlliver PC were kept at 1: 10:500, while their 
concentrations were diluted two- to four-fold. Thus, the transfer rates were expected to 
reduce by 8 fold and 64 fold, respectively. To our surprise, in response to the 64 fold 
dilution in reagents, the rates of transfer were only slightly reduced (0.064 ± 0.0004 S- l to 
0.054 ± 0.0001 S-l). Even at the lowest assay concentration, the initial 20% of total 
fluorescence was still missing, as shown in Fig. 18A. The top green line denotes 100% of 
fluorescence when NBD-a.-Toc was bound to 6-His-28TTP. Transfer of NBD-a.-Toc to 
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Figure 18: Time-dependent NBD-a-Toc transfer from 6-His-28TTP to bovine liver 
Pc. A) 0.125 ~M NBD-a-Toc was pre-incubated with 1.25 ~M a.-hTTP for 15 min, the 
transfer of NBD-a-Toc was monitored for 80 seconds after mixing with either SET 
buffer (green) or 62.5 J.lM bovine liver PC (pink). B) 0.5 J.lM NBD-a-Toc 15 J.lM 6-His-
28TTP 1250 J.lM PC (High), 0.25 J.lM NBD-a.-Toc 12.5 J.lM 6-His-28TTP 1125 J.lM PC 
(Medium) and 0.125 J.lM NBD-a.-Toc 11.25 ~M 6-His-28TTP 162.5 J.lM PC (Low). 
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TRITC-DHPE containing vesicles resulted in an exponential decay of fluorescence (pink 
curve). The system's lack of response to the change in both donor and acceptor 
concentrations, as shown in Fig. 18B, can only be explained by the spontaneous transfer 
of NBD-a-Toc from 6-His-28TTP to PC vesicles. However, the missing initial transfer 
cannot be explained by these results. As mentioned previously, 6-His-28TTP has an N-
terminal extension, including the 6-His tag. This extension was predicted to contain only 
12.5% extended sheet and 87.5% loops [151]. Thus, it was not expected to introduce 
significant secondary structure which may cause protein aggregation or misfolding [151]. 
Whether or not this extension interfered with the binding of a-hTTP to PC vesicles had 
not been resolved conclusively. With this concern in mind, we decided to switch our 
research effort to using the 6-His tagged a-hTTP expressed without the 40 amino acid 
extension from a-hTTP/pET21b construct. The a-hTTP/pET21b construct was a gift 
from Dr. Stephen Hyland at DSM Nutritional Products. 
2.1.5. 6-His-arhTTP without an extension isolatedfrom a-hTTPlpET21b construct 
The 837 bp human a-TTP gene was engineered with a 3~-NdeI and a Y -XhoI 
restriction sites, before being inserted into the 5.44 kb pET21 b expression vector to create 
the a-hTTP/pET21 construct of - 6.28 kb. In order to verify the integrity of the 
construct, the plasmid DNA of a-hTTP/pET21 was digested with two pairs of restriction 
enzymes: NdeI and EcoRI or NdeI and Xhol. Two small fragments of approximately 700 
bps and 900 bps respectively were obtained from the above double digestions (Fig. 19, 
left panel, lane #3 & 4) that were close to the calculated size of 762 bp and 890 bp 
expected. Interestingly, the majority of the uncut plasmid (lane #2) migrated between 
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molecular size of 4 kb to 5 kb, instead of its true size of 6.3 kb, where two faint bands 
with retarded speed were also visible in the same lane. The irregular migration pattern 
was likely due to the formation of supercoil (major lower band) and partially nicked 
strands (upper two bands). The sequence of this plasmid was later confirmed by 
sequencing (Robarts Research Institute, London, ON). 
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Figure 19: Restriction digestion of a-hTTP/pET21b plasmid DNA (left) and the 
purification of 6-His-a-hTTP from nickel affinity column (right). Left panel: (1-
hTTP/pET21b plasmid digested with NdeI and EcoRI or NdeI and XhoI. Lane 1: 1 kb 
DNA ladder; Lane 2: uncut plasmid; Lane 3: NdeI and EcoRI digestion; Lane 4: NdeI 
and XhoI digestion. Right panel: Analysis of 6-His-a-hTTP on 15% SDS-PAGE. Lane 
1 & 9, marker; Lane 2, insoluble cell fraction; Lane 3, soluble cell fraction; Lane 4, flow 
through; Lane 5, buffer wash; Lane 6 - 8, purified 6-His-a-hTTP eluted in 400 mM 
imidazole, fraction #2 - #4. 
Expression of hTTP/pET21b construct resulted in the over-production of a - 32 
kDa protein, lane #2 in the right panel of Fig. 19 as would be expected for the fusion 
protein with a calculated size of 32.4 kDa. Although the majority of this 32 kDa protein 
remained in the insoluble fraction (lane #2), a small level was found in the soluble 
fraction (lane #3). After subjecting the soluble cell lysate to a nickel affinity column 
purification, the protein eluted in 400 mM imidazole was very pure, with less than 5% 
contamination of a - 37-39 kDa unknown protein, shown in lane #6 to #8 in the right 
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panel of Fig. 19. a-hTTP expressed from pET21b contains an N-terminal 6-His tag, 
denoted as 6-His-a-hTTP. Purified 6-His-a-hTTP was s~bsequently tested for its ability 
to bind and transfer NBD-a-Toc. The binding affinity was determined to be 83 ± 7 nM, 
slightly higher than that of 6-His-28TTP (56 ± 15 nM). However, unlike 6-His-28TTP, 
6-His-a-hTTP enabled us to monitor the complete transfer of NBD-a-Toc as illustrated 
in Fig. 20. In the absence of bovine liver PC vesicles, 6-His-a-hTTP bound NBD-a-Toc 
fluoresced steadily with insignificant photobleaching (blue line). Upon mixing of 
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Figure 20: Time-dependent NBD-a-Toc transfer by 6-His-a-hTTP. 0.25 /-lM NBD-
a-Toc was pre_incubated with 2.5 /-lM 6-His-a-hTTP for 15 min, the transfer of NBD-
a-Toc was monitored for 80 second after mixing with either SET buffer (blue line) or 
125 /-lM bovine liver PC (pink curve). 
the preloaded 6-His-a-hTTP with bovine PC LUVs, NBD-a-Toc fluorescence underwent 
a time dependent exponential decay. The half life calculated from the single exponential 
decay equation was 1l.86 ± l.02 s, reflecting a transfer rate at 0.059 ± 0.004 S-l (n=3), 
similar to the pET28ITTP of 0.064±0.004 S-l. 
2.1.6. Kinetics of NBD-a-Toc transfer by 6-His-a-hTTP 
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The interaction between protein and lipid membranes is regulated primarily by 
electrostatic and hydrophobic forces. a-TTP possesses a large number of charged surface 
exposed residues, which divide the protein into two distinctive regions of electrostatic 
potential as depicted in Fig. 21, with the positive patch formed by mainly arginine and 
lysine residues. The membrane exchange loop (a.a. 198 to 221) is composed of mainly 
hydrophobic residues, three acidic residues and five basic residues, with His 204 and Lys 
211 situated right on the membrane interacting mobile helix AlO. We initially proposed 
that both His 204 and Lys 211 could potentially mediate the electrostatic interaction 
between a-TTP and the negatively charged phospholipid headgroups in the membranes. 
H204 
~ 
/" K211 
/" K217 
Figure 21: Electrostatic potential map of a.-Toc bound holo-a.-TTP (pdb:loip) 
calculated and presented by Deepview. Areas of positive electrostatic potential are 
highlighted in blue, and negative in red. a-Toc is shown in pink. Basic residues on the 
lipid exchange loop (residues 198-221) are shown as space filled molecules and indicated 
by arrows. 
To test our hypothesis that electrostatic interactions are important to a-hTTP 
binding to membranes, bovine liver PC LUVs were prepared containing 15% of anionic 
phospholipid, such as phosphatidylinositol (PI), phosphatidylserine (PS) or cardiolipin 
(CL), then the transfer rates of NBD-a-Toc to these vesicles were compared. A minor 
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enhancement was observed for PS containing vesicles versus pure PC vesicles, such that 
the rates increased from 0.062 ± 0.005 S-l to 0.072 ± 0.008 S-l, while PI and CL had no 
impact on the transfer (Fig. 22). If electrostatic interaction were truly involved, CL 
should have had a much greater impact than both PI and PS, because CL possesses two 
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Figure 22: Effect of anionic phospholipid on the transfer of NBD-a-Toe. NBD-a-
Toc was pre_incubated with 6-His-a-hTTP for 15 minutes prior to mixing with 100% 
liver PC or in the presence of 15% of phosphatidyl inositol (PI), phosphatidyl serine (PS) 
and cardiolipin (CL). Presented are the averages ± the standard deviation. n=8 for PC 
and PI, n=9 for PS and n=6 for CL. 
negatively charged phosphate groups, rather than one. Therefore, we chose to examine 
other characteristics of the membrane that may influence its recognition by a-hTTP. 
Until then, we had used only 100 nm extruded large unilamellar vesicles (LUVs) in all 
experiments. Knowing that membrane curvature could impact the membrane binding 
ability of some proteins including ArfGAPI [142, 143], and that membrane curvature or 
lipid packing density could be also influenced by the acyl chain composition of 
phospholipids, we investigated the effect of membrane curvature and acyl chain 
composition on the rates of NBD-a-Toc transfer. Soy PC has a much greater (ratio of 
SIU = 0.30) percentage of unsaturated fatty acids than the routinely used bovine liver PC 
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(ratio of S/u = 0.91). The transfer rates for both soy and liver PC were similar for 25 nm 
sonicated vesicles, 50 nm and 100 nm extruded vesicles (shown in Fig. 23). These 
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Figure 23: Effect of vesicle size and curvature on the transfer of NBD-a-Toc. Lipid 
vesicles of different sizes were prepared by extrusion or sonication method as described 
in the Methods section. The average of three determinations are shown ± the standard 
deviation. 
results were not completely unexpected, considering that only a very few curvature 
sensing proteins have been reported. It was possible that curvature alone was not 
sufficient to introduce major impact on the binding of a-hTTP to the acceptor 
membranes. Thus, electrostatic interaction was also tested in SUVs by including 15 % of 
various anionic phospholipid in SUVs and LUVs preparations (Fig. 24). To our surprise, 
in the presence of PS, PI or CL, the average transfer rates to the anionic SUVs were 
decreased. Due to the large variation in the PC SUV controls, the difference observed for 
CL SUVs may not be as significant. In contrast, the transfer rates to LUVs were similar 
whether in the presence or the absence of anionic lipids. These data suggested that 6-His-
a -hTTP mediated transfer of NBD-a-Toc was independent of membrane curvature and 
electrostatic interaction between protein and membranes. 
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Figure 24: Effect of anionic lipids and vesicle curvature on the transfer of NBD-a-
Toc. NBD-a-Toc was pre-incubated with 6-His-a-hTTP for 15 minutes prior to mixing 
with liver PC containing 15% of various anionic phospholipid. 
In the liver, a-TTP is localized to late endosomes and lysosomes [99, 100]. The 
internal membranes of late endosomes contains a very unique lipid called bis(mono-
acylglycero) phosphate or LBPA [165]. This lipid accounts for 15% of the total late 
endosome lipid extracts. LBP A promotes the formation of multilamellar vesicles 
(MLVs) at acidic pH but not at neutral pH [166]. LBPA has been implicated in the 
endosomal sorting of lipids and proteins [165]. Recently, LBPA has been also shown to 
mediate the lysosomal cholesterol export by NPC2 [134, 167]. Hence, it would be 
interesting to know whether LBPA or an endosomal lipid mixture also assists a-hTTP 
mediated ligand transfer. Thus, transfer experiments were conducted using LUV s 
simulating the membrane composition of late endosomes [168] (65% DOPC, 20% 
DOPE, 5% sphingomyelin (SM), 5% liver PI and 5% PS) in the presence and the absence 
of 15% LBP A. These lipid compositions were compared directly to the PC containing 
20% PE or 15% LBPA. As shown in Fig. 25, in the absence and the presence of 15% 
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LBPA (En-LBPA vs En+LBPA), the transfer rates to endosomal lipid mixture were 
0.051 ± 0.002 S-l and 0.054 ± 0.001 S-l respectively. These rates were similar to both the 
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Figure 25: Effect of endosomal lipid mixture on the rate of NBD-Toe transfer to 
LUVs. LUV's were prepared from pure endosomal mixture (En-LBPA) consisting of 
65% DOPC, 20% DOPE, 5% sphingomyelin (SM), 5% liver PI, 5% PS as indicated or 
from bovine liver PC with the additon of PE or LBP A. 
PC control (0.049 ± 0.002 S-l) and PC with 20% DOPE (0.049 ± 0.004 S-l) . Interestingly, 
the inclusion of 15% LBPA in PC LUVs displayed the lowest transfer rate, 0.043 ± 0.002 
S-l. Clearly, these results indicated that the endosomallipid mixture and LBPA did not 
significantly influence a-hTTP mediate transfer of NBD-a-Toc. 
So far, the rate of NBD-a-Toc transfer appeared to be independent of acceptor 
lipid composition, which was indicative of a diffusional mediated transfer mechanism. A 
true testimony for the diffusional transfer in our FRET system would be the lack of 
response to the change in the acceptor vesicle concentrations. Therefore, the transfer rate 
of NBD-a-Toc to PC LUV s from 5 /lM to 1250 /lM was compared. As illustrated in Fig. 
26, the rates calculated for the 5 /lM and 1250 /lM LUVs were 0.033 ± 0.0002 S-l and 
0.053 ± 0.0005 S-l respectively. When the acceptor concentration was increased by 250-
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fold, the transfer rate was only increased by 60%. This result clearly suggested that the 
forward transfer and insertion of NBD-a-Toc into membranes was mediated by aqueous 
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Figure 26: Effect of vesicle concentration on the rate of NBD-a-Toc transfer. 0.25 
J..lM NBD-a-Toc pre_incubated with 2.5 J..lM 6-His-a-hTTP for 15 min., then mixed with 
PC LUVs at indicated concentrations. 
diffusion. It was tempting for us to draw the conclusion that a-hTTP mediated ligand 
transfer is diffusional, since all of the parameters tested so far had failed to introduce any 
changes to the rate of ligand transfer. However, the collisional based transfer of a-Toc 
by lipoproteins and a-TTP has been suggested [55, 89]. Therefore, we decided to 
conduct a series of troubleshooting experiments to ensure that we were investigating the 
correct rate limiting step for changes, and our FRET transfer assay was free from any 
systematic errors. 
2.1. 7. Troubleshooting experiments 
2.1.7.1 Removal of NBD-a-Tocfrom membranes by 6-His-a-hTTP 
Perhaps the rate limiting step of a-Toc transfer is not its insertion into the 
membrane, but rather its removal from the membrane. If so, we expected that the rate of 
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ligand pickup would be altered in response to the change in the protein concentration and 
lipid composition. To test this hypothesis, a "pick-up" assay was developed and 
optimized. In this assay, donor vesicles contained both NBD-a-Toc and the quencher 
TRITC-DHPE. Thus, the fluorescence of NBD-a-Toc increased as it was extracted from 
the quencher containing lipid vesicles by a -hTTP. The optimal lipid concentration was 
composed of 50 /-lM PC, 2% NBD-a-Toc and 6% TRIC-DHPC. The rate of a-Toc 
pickup by 6-His-a-hTTP was measured at the increasing concentrations of 6-His-a-
hTTP. Fig. 27 A shows the time dependent increase in the fluorescence signal when a-
hTTP was added to the NBD-a-Toc containing LUVs. Moreover, the absolute signal 
enhancement was proportional to 6-His-a-hTTP concentration. The raw data fit better to 
a two-phase exponential association model consisting of a fast and slow phase. The pick 
up rates (fast) were calculated and are displayed in Fig. 27B. The R2 values generated 
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Figure 27: Reversed transfer of NBD-a-Toc from PC LUVs to a-hTTP. 50 /-lM PC 
LUVs contained 2% NBD-Toc and 6% TRITC-DHPE were prepared by extrusion. The 
change in fluorescence intensity was monitored after mixing with the indicated 
concentration of 6-His-a-hTTP. The data shown are the average ± the standard 
deviation, n=2 for 2.5 /-lM TTP and n= 3 for other concentrations. 
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were greater than 0.95 for all concentrations, except for 2.5 ~M (R2 = 0.71). The pick up 
by 2.5 ~M 6-His-a.-hTTP was 0.023 S-I, and the rates for other concentrations determined 
ranged from 0.032 ± 0.004 S-1 to 0.034 ± 0.004 S-I. 
Subsequently, the effect of electrostatic interactions on ligand pickup was 
examined with 5%,10% and 15% PS or CL in bovine PC LUVs. As shown in Fig. 28, 
10% 15% 
mole% of anionic lipid 
Figure 28: Effect of anionic lipid on NBD-a.-Toc pick up by 6-His-a-hTTP. 50 ~M 
PC LUVs contained 0.25 ~M NBD-a.-Toc and 3% TRITC-DHPE and anionic lipid as 
indicated. Shown are the average ± standard deviation, n =9 for 100% PC, n=5 and n=8 
for 10% CL and 5% PS, respectively, n=6 for all other conditions tested. 
no significant difference in the pick up rates was observed for the PC vesicles with or 
without PS or CL. The pick up data collectively also supported the spontaneous 
diffusional transfer of NBD-a.-Toc to or from lipid membranes. 
2.1.7.2. Examination of NBD-a-Toc probe 
We then directed our attention to NBD-a.-Toc, which was expected to be less 
hydrophobic and more water soluble than a.-Toc. Based on the calculated lipophilicity 
index, the 10gP values calculated were 7.34 and 9.60 for NBD-a.-Toc and a.-Toc, 
respectively. We hypothesized that, perhaps, the increased aqueous solubility of NBD-a.-
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Toc was to blame for its apparent spontaneous diffusion from a-hTTP to the membranes. 
To test our hypothesis, the spontaneous transfer of NBD-a-Toc between donor and 
acceptor vesicles of different sizes was investigated. Illustrated in Fig. 29, in the absence 
of a-hTTP, the spontaneous rate of transfer was greater with SUVs as donor vesicles. 
Vesicle fusion was unlikely during the monitored assay time as both SUVs and LUVs 
were expected to be stable for more than 20 hours at 37°C [169]. The highest rate was 
observed for the movement ofNBD-a-Toc from donor SUVs to acceptor SUVs, which 
was 0.041 ± 0.002 S-I, and the rate was lowered to about 50%, when LUVs were the 
donor vesicles. When both the donor and the acceptor were LUV s, the rate of NBD-a-
Toc transfer was greatly reduced to 0.012 ± 0.0003 S-I, which was equivalent to 30% of 
the transfer rate from SUVs to SUVs. Therefore, the enhanced transfer to SUVs was due 
likely to their reduced phospholipid headgroup packing density, rather than to the 
solubility ofNBD-a-Toc. 
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Figure 29: Intervesicle transfer of NBD-a-Toc from acceptor vesicles to donor 
vesicles. l/lM NBD-a-Toc incorporated in 100 /lM donor PC SUVs or LUVs was 
transferred to 100/lM acceptor bovine liver PC SUVs or LUVs containing 3% TRITC-
PE. The data shown represents an average of six determinations ± the standard deviation. 
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The concern about the enhanced water solubility of NBD-a-Toc was partially 
resolved when the transfer ofNBD-a-Toc was tested with human SPF, another member 
from the CRAL-TRIO family, capable of binding to a-Toc. Interestingly, the 
fluorescence signal of NBD-a-Toc bound SFP was not quenched, when mixed with 
TRITC-PE containing PC vesicle (data not shown). This data implied that NBD-a-Toc 
bound to SPF, but failed to transfer to the lipid vesicles. In spite of its improved water 
solubility, the transfer of NBD-a-toc by protein was strictly regulated. Thus, NBD-a-
Toc is unlikely to undergo a simple diffusion from protein to vesicles. 
2.1.7.3 Examination of6-His-a-hTTP 
The binding of natural ligand a-Toc was predicted to induce a conformational 
change in a-TTP. A conformational change in a protein can be detected simply by 
following the intrinsic tryptophan fluorescent change, resulting from the change in the 
environment and solvent accessibility of the residues in ligand_bound and free states. a-
hTTP has five tryptophans that are located at residues 67, 76, 122, 163 and 259. In the 
absence of a-Toc, the maximum fluorescence of 6-His-a-hTTP peaked at 332 nm, while 
in the presence of a-Toc, the maximum fluorescent peak shifted to 326 nm (Fig. 30). A 
similar wavelength shift upon a-Toe binding to 6-His-28TTP (TTP with the N-terminal 
40 amino acid extension) was detected previously by others in the lab. A blue shift of 6 
nm to the left suggested that the tryptophan residues became less exposed to the solvent 
upon a-Toc binding, indicative of a conformational change. This change is likely 
introduced by tryptophan residues 122 and 163, because they are located near a-Toc 
binding site. The fluorescence of a-Toc is negligible in aqueous buffer. However, in the 
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organic environment, the fluorescence characteristics of a-Toc (Oex =295nm, Oem =325nm) 
[170] overlap with tryptophan. Therefore, we expected . the total fluorescence intensity 
would increase in the presence of a-Toc. Instead, when a-Toc was bound to a-TTP, we 
observed an approximately 10% reduction. Such reduction in the absolute fluorescence 
was likely caused by a small amount of ethanol (less than 1 %) when a-Toc in ethanol 
solution was added to a-TTP in SET buffer. 
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Figure 30: Intrinsic tryptophan fluorescence spectrum of 6-His-a-hTTP. The 
fluorescence of 1 f.lM 6-His-a-hTTP alone (red) or in the presence of 10 f.lM a-Toc 
(blue). The excitation wavelength was set at 295 nm. 
To compare the solvent accessibility of protein bound to either a-Toc or NBD-a-
Toc, an acrylamide quenching experiment was performed and the quenching constant ksv 
was determined from the Stern Volmer's plot. As shown in Fig. 31, the quenching plots 
for both ligand bound 6-His-a-hTTP were super-imposable, with an identical quenching 
constant of 7.8 M-'. The ligand free a-TTP was slightly more solvent exposed, with a 
quenching constant of 8.9 M-'. All of the above evidence implied that NBD-a-Toc was a 
suitable probe to be used for the FRET assay. We next decided to inspect the source of 
the protein more critically. 
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Figure 31: Stern Volmer's plot of a-hTTP quenched with acrylamide. 6-His-a-hTTP 
(2.5 !J,M) in the presence or the absence of 7.5 !J,M NBD-a-Toc or a-Toc was quenched 
with the indicated acrylamide concentrations. 
2.1.8 Identification of E. coli Outer Membrane Porin F (OmpF) 
We had always noticed a 37-39 kDa E. coli protein co-purified with 6-His tagged 
a-hTTP expressed from both pET28b and pET21b expression vectors (Fig. 12 & 19 & 
32A). This 39 kDa unknown protein typically accounted for 5% to 10% of the total 
purified protein. Ideally, only 6-His tagged a-hTTP can be absorbed to the metal affinity 
column. It was possible that protein degradation occurred during purification, and thus, 
the 39 kDa and 32 kDa protein bands represented the full length 6-His-a-hTTP and its 
degradation product. Although the calculated molecular weights of both versions of 
Histidine tagged a-hTTP (from pET21b and pET28b bacterial vectors) were less than 39 
kDa, the elevated molecular weights of these purified proteins were perhaps due to their 
retarded migration on the SDS-PAGE or normalized to the non-precise protein marker. 
To prevent protein degradation, a protease inhibitor cocktail was included in the lysis 
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buffer during purification of 6-His-a-hTTP. Unfortunately, this modification did not 
help to increase the yield of the full length protein of 37-39 kDa. Subsequently, western 
blot analysis of the 6-His-a-hTTP was performed, utilizing a primary antibody 
recongnizing 6-His tag. Only the 32 kDa protein band was recognized by the 6-His 
antibody, suggesting that this protein contained the engineered 6-His tag and it was most 
likely 6-His-a-hTTP, whereas the 39 kDa protein was an E. coli protein with high 
affinity for nickel ions. Therefore, it co-eluted with 6-His-a-hTTP in 400 mM imidazole. 
At the time, we were not particularly alarmed by this protein contaminant, due to its 
insignificant presence in the total purified protein. 
We continued our troubleshooting with 6-His-a-hTTP. According to Meier et al. 
[93], in the absence of a-Toc, two monomers of a-TTP form a dimer through the contact 
of their lipid exchange loops during crystalization. Based on the structure of a-TTP 
dimer, the membrane binding lids were locked in an open position. This conformation 
may have allowed a-Toc to move freely in and out of a-TTP. Thus, a-TTP dimers were 
presumably less active than the monomers in regulating the exchange of a-Toc. 
Although no evidence suggested a-TTP forms a dimer in the cell, but we did not want to 
rule the possibility that dimers form during purification in a similar way as observed 
during crystallization. Our next attempt was to separate the active a-TTP monomers 
from the inactive dimers. To do so, 6-His-a-hTTP, obtained from the nickel affinity 
purification was subjected to a further purification on a sephacryl S-300 gel filtration 
column by FPLC. Three peaks were resolved, as shown in Fig. 32A, the first narrow 
peak indicated a homogenous protein population. When normalized to the calibrated 
protein standards, this protein was determined to be -130 kDa. The second peak was 
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slightly broader, indicating a more heterogeneous protein population, with average 
predicted size of -35 kDa. Imidazole was eluted in the last peak. The fractions # 18 to 
22 from the first peak, and fractions #89 to 95 from the second peak, were each pooled. 
Sample of these two peaks were subjected to SDS-PAGE and western blot analysis. 
Shown in Fig. 32B, lane #1 contains the mixture of 32 kDa 6-His-a-hTTP and 39 kDa 
contaminant prior to the size exclusion FPLC separation. FPLC purification appeared to 
produce pure 6-His-a-hTTP (lane #4) corresponding to peak #2. However, a small level 
of 6-His-a-hTTP co-purified with the 39 kDa contaminant (lane #3). It was uncertain 
whether a complex formed between 6-His-a-hTTP and the 39 kDa contaminant. The 
western blot analysis with the 6-His antibody detected only 6-His-a-hTTP, not the 39 
kDa contaminant (Fig. 32C). Based on these results, fractions 18 to 22 were composed 
mainly of trimers of 39 kDa, and fractions 89 to 95 contained only pure 6-His-a-hTTP. 
When both proteins were tested in FRET transfer assay (Fig. 32D), to our surprise, the 
fluorescence intensity of NBD-a-Toc bound to the 39 kDa contaminant was -250,000 
(top purple & blue lines), which was 5 times of a-hTTP bound (bottom yellow line). 
More interestingly, the transfer of NBD-a-Toc was observed from the 39 kDa 
contaminant to PC LUVs (Fig. 32D, Fr #18-22), with an observed rate of 0.05 S-l. The 
rate was increased to 0.073 ± 0.005 S-l when the acceptor vesicles were 15% PS SUVs 
(data not shown). These rates were fairly similar to the rates we had observed for the 
unfractionated 6-His-a-hTTP (e.g. 0.059 s-I, Fig. 20). In the same experiment, the 
transfer mediated by pure 6-His-a-hTTP (pink line) was insignificant, due to the 
overwhelminlyg high fluorescence signal from 39 kDa contaminant. It is also possible 
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Figure 32: FPLC separation of 39 kDa unknown protein from 6-His-a-hTTP and 
the subsequent analysis. A) Approximately 3 mg of 6-His-a-hTTP eluted from the 
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nickel affinity column were further separated on a sephacryl S-300 high resolution gel 
filtration column. The chromatogram of protein elution was recorded at 280 nm. 
Running buffer contained 25mM P04, 0.5M NaCI, pH 7.5. The peaks for 39 kDa 
unknown protein and 6-His-a-hTTP were observed at retention volumes of 37.16 ml and 
72.96 ml respectively. The pooled fractions #18-22 and fractions #89-95 were subjected 
to analysis by SDS-PAGE (B) and western blot with anti 6-His antibody (C), Lane #1: 
marker; Lane #2 6-His-a-hTTP (5 Jlg per lane) prior to FPLC separation; Lane #3: 
pooled fraction #18-22 (- 0.5 Jlg per lane); Lane #4: pooled fraction #89-95 (-1 Jlg per 
lane); star denotes a different molecular weight marker BioRad 161-0363. D) FRET 
transfer activity of pooled fractions 18-22 and 89-95 respectively. Top straight lines are 
the duplicates ofNBD-a-Toc bound to Fr. 18-22, the bottom yellow straight line is NBD-
a-Toc bound to Fr. 89-95. 
that the purified 6-His-a-hTTP became less active during the lengthy FPLC purification 
at room temperature. 
To confirm that 39 kDa E. coli contaminant is capable of binding and transferring 
NBD-a-Toc, hTTP/pET21b transformed BL21(DE3) E. coli were induced in the absence 
and the presence of 400 JlM IPTG. Only IPTG induced E. coli would produce 6-His-a-
hTTP. Both cultures of E. coli were lyzed, and the fractionated supernatant samples 
were subjected to the nickel affinity purification. Probond metal affinity purification 
protocol (Invitrogen) was followed in an attempt to cleanly separate the 39 kDa E. coli 
protein from 6-His-a-hTTP. Fig. 33A shows the expression of the 39 kDa contaminant 
(red dashed boxes) in both E. coli cultures. Unfortunately, the Probond protocol did not 
improve the purity of 6-His-a-hTTP. The semi-purified 39 kDa contaminant (-IPTG), 
eluted in 200 mM imidazole, was able to transfer NBD-a-Toc (Fig. 33B), with transfer 
rates increasing from 0.029 ± 0.005 to 0.058 ± 0.002 S-l in response to a 5 fold increase in 
protein from 80 Jlg to 400 Jlg. In the IPTG induced E. coli sample, 200 mM imidazole 
elution resulted in a semi-purified sample containing both 39 kDa contaminant and 6-His-
a-hTTP (Fig. 33A). As illustrated in Fig. 33C, 2.5 JlM (-18 Jlg) of highly purified 6-
55 
His-a-hTTP eluted in 300 mM imidazole (pink curve), transferred NBD-a-Toc at a 
slower rate than that of 80 J..lg (green grey curve) and 160 J..lg (yellow curve) of the protein 
mixture eluted in 200 mM imidazole. 
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Figure 33: Comparison of the ligand transfer activity of 39 kDa E. coli protein and 
6-His-a-hTTP. A) SDS-PAGE analysis of protein fractionations from the Nickel 
affinity purification of 39 kDa E. coli protein in the absence and the presence of 6-His-a-
hTTP. B) FRET activity of semi purified 39 kDa E. coli protein and C) FRET activity of 
the mixture of 39 kDa protein and 6-His-a-hTTP. 
More strikingly, binding assays with the 39 kDa protein using NBD-a-toc 
indicated the 39 kDa E. coli contaminant not only bound to NBD-a-Toc with high 
affinity (KD = 89 nM vs 48 nM for a-hTTP) (Fig. 34A), but the binding also appeared to 
be specific, as it could only be replaced by natural a-Toc, not cholesterol (Fig. 34B). 
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This evidence further strengthened our hypothesis that the 39 kDa E. coli protein was not 
simply a minor contaminant. Its presence overpowered the fluorescence assay's 
sensitivity to a-hTTP. In order to properly study a-hTTP and its ligand transfer ability, 
the 39 kDa contaminant had to be completely removed. Yet, the number of methods 
employed to separate these two proteins proved unsuccessful. 
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Figure 34: Specific binding of NBD-a-Toc to 39 kDa contaminant. A) Stepwise 
titration of 200 nM 39 kDa protein or a-TTP with NBD-a-Toc. B) Displacement of 
NBD-a-Toc bound to 39 kDa protein by the increasing concentration of a-Toe or 
cholesterol. 
Due to the limited knowledge we had about this contaminating protein, we had to 
perform a literature search for a 39 kDa E. coli protein with propensity for metal ions and 
a tendency for trimer formation. We quickly identified our suspect as one of the E. coli 
outer membrane porins, OmpC or OmpF [171-173]. OmpC binds to divalent Mg2+ and it 
shares 74% sequence homology with OmpF [171]. These proteins are integral membrane 
porins that regulate the osmotic pressure between cells. They facilitate the passive 
diffusion of small, polar molecules of 600-700 Da through the outer membrane of E. coli. 
In 1989, Veeraragavan et al. [172] identified OmpF as one of the two major 
contaminating proteins in E. coli inclusion bodies. However, during the high cell density 
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cultivation, OmpF was also found to secret into the culture medium [173]. We generally 
allowed 18-hour IPTG induction, so as to increase the expression of a-hTTP. The cell 
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Figure 35: Matrix-assisted laser desportion/ionization MALDI time of flight (TOF) 
spectrum of trypsin digests of the unknown 39 kDa E. coli porin (top) and a-hTTP 
(bottom). Peptides are indicted as peaks with monoisotopic masses. Shown are 
representative spectra from several trials. The peak lists are reported in the Appendix I. 
density before harvest was usually very high, and therefore, it was not unexpected to find 
soluble OmpF in the culture medium. Since OmpF is capable of binding to both 
monovalent and divalent ions [174, 175], it was therefore bound to the nickel affinity 
column during fusion protein purification. 
To identify the 39 kDa E. coli contaminant experimentally, MALDI-TOF mass 
spectroscopy analysis of the trypsin digested 39 kDa protein with a-hTTP as a control, 
were performed. Shown in Fig. 35 are representatives of the spectra from several trials. 
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The trypsin digested peptides YDANNIYLAANYGETR (m.w. 1847.992) (top panel) and 
EAGVPLAPLPLTDSFLLR (m.w.1908.948) (bottom panel) were used to search for their 
prospective proteins in mass spectrometry protein database (MSDB). The unknown 
contaminant was subsequently identified as OmpF, with a molecular weight of 39,309 
Dalton, based on a high match score of 89% to the trypson digested peptide. Similarly, 
the control protein was identified as human a-TTP of 31,844 Dalton with a match score 
between 65-72%. The detailed peak lists of ions can be found in Appendix I. 
Figure 36: Structure of E. coli Outer Membrane Porin F (OmpF). Left panel is the 
top view and right panel is the side view of the protein. 
Two different views of OmpF are depicted in Fig. 36. As shown in this figure, 
OmpF is barrel shaped. It is structurally similar to but larger than the fatty acid binding 
proteins. OmpF consists of 3 a-helix strands, 16 antiparallel ~-helix strands, and looping 
strands that connect the ~-helixes to each other. The large cavity allows its ligand to 
diffuse out of the E. coli outer membrane. This explains the apparent diffusional transfer 
of NBD-a-Toc in the presence of the OmpF contaminant. 
2.2. NBD-a-Toc transfer by a-hTTP is mediated through a collisional mechanism 
2.2.1. Characterization of a-hTTPpurifiedfrom a-hTTPlpGEX4T 
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In order to completely avoid OmpF contamination, it was necessary to seek 
another mean of expressing a-hTTP without a His-ta~. Our collaborators provided a 
GST-a-TTP fusion construct, hTTP/pGEX4T, which consisted of the human a-TTP gene 
fused to the gene for glutathione-S-transferase in the pGEX-4T-3 vector. This construct 
would produce GST (26 kDa) followed by a linker region containing a thrombin cleavage 
site (LVPRtGS), four amino acids before hTTP due to the presence of the multiple 
cloning sites. Thrombin recognizes the linker sequences LVPRG or LVPRGS [176], and 
cleaves after arginine, leaving a-hTTP with an extra GS plus four amino acids (PNSR) at 
the N-terminus after thrombin digestion [111]. A non-metal containing glutathione 
agarose purification method was employed to purify the GST -a-hTTP fusion protein 
following expression of the a-hTTP-GST fusion protein from the a-hTTP/pGEX4T 
construct. As shown in Fig. 37 A, after buffer washes to remove non-specifically bound 
proteins, only two major proteins plus 4 to 5 minor ones remained on the glutathione 
column (lane #5). The top band represented the ~56 kDa GST-a-hTTP, and the bottom 
~ 26 kDa band was likely the GST fusion tag. The two hours on-column thrombin 
digestion produced a 32 kDa a-hTTP (lane #6 & 7) and a 26 kDa GST (lane #8 & 9). In 
addition, an E. coli protein of ~65 kDa « 2%) was found to co-purify with a-hTTP. 
Although thrombin cleavage is fairly specific, it can also digest proteins at other 
sequences [176]. To prevent secondary protein degradation during storage, the protease 
inhibitor, phenylmethylsulphonyl fluoride (PMSF), was always added to the purified a-
hTTP fractions. After three days of storage at 4°C, no change in a-hTTP was observed 
(Fig. 37B, lane 7 & 8) compared to the freshly cleaved a-hTTP (Fig. 37B, lane 5 & 6). 
a -hTTP was typically used within the first few days of purification. 
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Figure 37: Glutathione affinity purification of GST-a.-hTTP expressed from 
hTTP/pGEX4T (A) and the integrity of a.-hTTP during storage (B). Crude lysate 
fractions and purified protein samples (- 5 J.lg per lane) were analyzed on 15% SDS-
PAGE. Protein markers are shown in Lane I for both gels. A) Lane 2: insoluble cell 
lysate; Lane 3: soluble cell lysate; Lane 4: flow through fraction; Lane 5: full length 
GST-hTTP; Lane 6 & 7: cleaved hTTP fractions #1 and 2; Lane 8 & 9: GST fraction #1 
and 2. B) Lane 3: total cell lysate; Lane 4: insoluble fraction; Lane 5 & 6: hTTP day 1; 
Lane 7 & 8, hTTP 3 days after purification. 
The same experiments previously performed with 6-His-a-hTTP were repeated 
with the thrombin cleaved a-hTTP. This version of a-hTTP had high affinity for NBD-
a-Toc (Fig. 38), with a dissociation constant (Ko) at 18.9 ± 0.4 oM (n=3), improved from 
6-His-a-hTTP (Ko = -48 nM) or 6-His-28TTP (Ko = 56 ± 15 nM). 
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Figure 38: Titration of a-hTTP with NBD-a-Toe. Thrombin cleaved a-hTTP (200 
nM) was titrated with 1 ilL additions of NBD-a-Toc (in EtOH) of various stock 
concentrations until saturation was achieved. Shown is the fluorescence recorded at 535 
nm with excitation at 466 nm. 
2.2.2 Partitioning of NBD-a-Toc betwen a-hTTPandlipidvesicles 
Next, the transfer ofNBD-a-Toc by this a-hTTP was assessed by detennining the 
partition of NBD-a-toc between a-hTTP and vesicles for vesicles of two different sizes 
as illustrated in Fig. 39. The slopes of the lines for both LUVs and SUVs over the 
indicated lipid concentration range are very similar and shallow. From these assays, the 
average values of the detennined partition coefficient, Kp, of NBD-a-Toc between a-
hTTP and bovine liver PC vesicles were 0.064 ± 0.026 for LUVs and 0.098 ± 0.035 for 
SUVs, respectively. These values are not significantly different from each other. As the 
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Figure 39: Partitioning of NBD-a-Toe between O-hTTP and SUVs or LUVs. 
Titration ofNBD-a-Toc (0.225 OM) bound to a-hTTP (2 OM) with PC SUVs (+) or LUVs 
(_) at the concentration of 50 OM, 100 OM, 200 OM and 400 OM. The change in 
fluorescence intensity between NBD-a-Toc bound to O-hTTP and at each lipid 
concentration is expressed as OF. The partition coefficients determined for this particular 
experiment are 0.122 and 0.082 for SUVs and LUVs respectively. 
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units of Kp are (mol lipid-bound NBD-a-Toc/mol phospholipid)/(mol protein-bound 
NBD-a-Toc/mol protein), the magnitude of Kp shows that NBD-a-Toc binds to a-hTTP 
with ~ 10-15 times greater affinity than to lipid vesicles. Thus, for our transfer assay 
conditions to reflect unidirectional movement from protein to vesicle, an excess of 
phospholipids must be provided. Our assays used a 50-fold molar excess of 
phospholipids over a-hTTP to ensure unidirectional transfer, and also maintained the rate 
of transfer within the kinetic window of our stopped-flow device (mixing dead time ~ 20 
ms). At equilibrium, the assays showed a ~ 50% loss of the original fluorescence from 
protein-bound NBD-a-Toc. 
2.2.3. Kinetics ofNBD-trrToc transfer by trrhTTP 
We then determined whether a-hTTP ulitizes a collisional mechanism, which 
requires the binding of the protein to the membranes. To do so, the concentration of 
acceptor vesicles was increased, while the protein and ligand concentration was kept 
constant. If protein-membrane collision is required, then the rate of transfer should 
increase with the increasing concentration of phospholipid. As shown in Fig. 40, the rate 
of transfer of NBD-a-Toc from a-hTTP is quite insensitive to LUV concentration. 
However, the rates did increase about 50% (0.011 ± 0.0017 sol to 0.017 ± 0.005 sol), when 
the LUV concentration was increased from 50 JlM to 750 JlM. When SUVs were the 
ligand acceptor, the enhancement of transfer was much more dramatic. The transfer rate 
increased ~ 4.5-fold from 25 JlM to 625 JlM phospholipids. We also noted a 4 nm red-
shift of the intrinsic tryptophan fluorescence of a-hTTP, when bound to PC SUVs [114], 
suggesting that a-hTTP binding to these vesicles was accompanied by a significant 
environmental change around tryptophan residues. 
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Figure 40: Effect of lipid concentration on the rate of NBD-a-Toc transfer from a-
hTTP to PC SUVs and LUVs. Transfer of 0.125 J.lM NBD-a-Toc from 1.25 J.lM a-
hTTP to SUVs (D) or LUVs (_) at the indicated concentration was monitored at room 
temperature (20°C). Results are the average of 3 determinations ± the standard deviation. 
Supporting evidence for a collisional versus diffusional mechanism can be 
obtained if the rate of transfer is affected by an increase in ionic strength of the medium. 
If the ligand must first leave the protein and diffuse to a nearby membrane, high ionic 
strength slows the rate of transfer. Hydrophobic compounds such as a-Toc and NBD-a-
Toc, which already have very low aqueous solubility, should be even less likely to exist 
freely in buffer due to the increased solvent polarity of the high salt buffer. This has been 
demonstrated for the liver FABP [128]. Fig. 41 shows that there is no reduction in the 
rate NBD-a -Toc transfer from a-hTTP to SUVs (100% PC or 15mol% PS in PC) in up to 
1.0 M salt. 
We hypothesized that a-hTTP would show enhanced rates of ligand transfer to 
membranes that contained anionic lipids, since this has been noted for other lipid transfer 
proteins such as the FABPs [131, 177-180], and cellular retinol binding protein I [181]. 
Thus, the effect of anionic lipids on the transfer ofNBD-a-toc by a-hTTP to SUVs and 
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Figure 41: Effect of ionic strength on the rate of NBD-a-Toc transfer to PC or PS 
SUVs. 0.225 ~M NBD-a-Toc transferred from 2 ~M a-hTTP to 100 ~M PC SUVs (e) 
or PC SUVs containing 15% PS (_) in the presence of increasing concentration of KCl. 
Data shown represents an average ± the standard deviation, n=12 for PC at 100 mM KC1, 
n=3 for other conditions tested. The data shown are compiled from separate experiments 
with different protein and lipid preparations. 
LUVs was investigated. However, when SUVs were prepared, containing 15% of 
amomc phospholipids, such as bovine liver phosphatidylinositol (PI), 
dioleoylphosphatidylserine (DOPS), lysobisphosphatidic acid (LBPA), or 
dioleoylphosphatic acid (DOPA), the transfer rates of NBD-a-Toc by a-hTTP showed 
only minor rate variations (Fig. 42, open bars). Transfer rates from a-hTTP to LUVs 
were on average 4-10 times slower than for SUV s. An increase in the concentration of 
PS from 15 to 25% did not significantly increase the observed rate (data not shown). In 
contrast to SUVs, the transfer ofNBD-a-Toc was enhanced to the anionic phospholipid 
containing LUVs (hatched bars). The rates increased 1.2 to 8-fold above transfer to PC 
LUVs, but most notably in the presence of CL, which was almost equivalent to the rate 
obtained for SUV s. Transfer to CL containing SUV s was also investigated (data not 
shown). To our surprise, upon mixing of a-hTTP and the acceptor SUVs, instead ofthe 
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Figure 42: NBD-a-Toc transfer from a-hTTP to anionic SUVs or LUVs. Transfer of 
0.225 J.lM from 2J.lM a-hTTP to 100 J.lM bovine liver PC LUVs (hatched bars) or SUVs 
(open bars) containing 15 mol% of PI, PS, LBPA and DOPA. Results are the average of 
average ± the standard deviation, n=3 for PI, PS, LBPA, DOPA and CL and n=12 for PC 
only controls. P values for SUVs were calculated with unpaired t-tests, there is no 
significant difference between the SUV s tested. 
usual fluorescence decay, the fluorescence signal was actually increased. It was not clear 
why TRITC-PE when present in CL SUV s failed to quench NBD-a-Toc. 
Electrostatic interactions clearly played an important role in the transfer of NBD-
a -Toc to the anionic LUVs, but not to the SUVs. It is possible that the planar lipid 
surface ofLUVs has higher packing density, the orientation of a -hTTP is thus influenced 
by the headgroup environment of lipid bilayer. As the electrostatic potential map 
indicated in Fig. 21, a-hTTP is divided into regions of positive and negative potential. 
We speculated that the anionic surface could also interact with the positively charged 
lipids. For this reason, cationic 1,2-dioleoyl-3-trimethylammonium propane, DOTAP 
was tested. Transfer of NBD-a-Toc to LUVs was enhanced by up to ~79% (0.019 ± 
0.003 S-1 to 0.034 ± 0.005 S-I) in the presence of 10% DOTAP, but it was not significantly 
altered by DOTAP containing SUVs (Fig. 43). 
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Figure 43: Effect of cationic lipid on the transfer of NBD-a-Toc. A) Chemical 
structure of DOTAP. Acceptor liver PC LUVs (B) and SUVs (C) contained the indicated 
amount of DOTAP were tested for their effect on the rate of NBD-a-Toc transfer. P 
values calculated with t-tests using the two-tailed distribution are: 2.81 x 10-6 for 5% 
LUVs; 5.23 x 10-7 for 10% LUVs; 0.28 for 5% SUVs and 0.025 for 10% SUVs. 
To explore the effect of membrane surface curvature further, vesicles of differing 
SIze were prepared by liposome extrusion through specific pore size filters and by 
sonication. The rates of a-hTTP mediated NBD-a-Toc transfer to PC vesicles of 50, 
100, or 200 nm diameters were similar (k = ~ 0.017 ± 0.0009 S-I), as shown in Fig. 44. 
F or the probe-sonicated vesicles, the rate was 0.114 S·l ± 0.023 S·l, and for bath sonicated it 
was 0.098 ± 0.005 S-I. Sonicated vesicles, using either an immersion probe or bath 
sonicator, are generally expected to yield SUV s of about ~ 25 nm in diameter [182, 183]. 
a-hTTP mediated ligand transfer to 25 nm vesicles consistently showed 8-10 fold faster 
than to 100 nm LUVs, whereas transfer to 30 nm vesicles was 2.2 fold greater than 
transfer to 50 nm vesicles yet only 50-60% of the transfer rate to 25 nm SUVs. 
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Figure 44: Effect of vesicle size on the rate of NBD-a-Toc transfer from a-hTTP. 
PC vesicles were prepared by probe sonication, bath sonication or extrusion. 0.225 J..LM 
NBD-a-Toc transferred from 2 J..LM a-hTTP to 100 J..LM vesicle of various sizes was 
monitored. The data shown represent the average ± the standard deviation, n= 12 for the 
probe sonicated PC SUV, n=18 for 100nm PC LUV, n=3 for other conditions tested. The 
data shown are compiled from separate experiments with different protein and lipid 
preparations. 
To assess the influence oflipid packing (bilayer fluidity) on the transfer process, 
the rate of NBD-a-Toc transfer to acceptor phospholipid vesicles of differing degrees of 
unsaturation is shown in Fig. 45. Three different sources of phosphatidylcholine were 
tested: soy PC with a saturated to unsaturated lipid ratio (SIU) of 0.30 and consisting 
predominately of 18:2 acyl chains; synthetic dioleoylphosphatidylcholine (DOPC); and 
bovine liver PC with a SIU ratio of 0.91 and a higher proportion of 18:0 acyl chains. 
Regardless of the lipid composition, the rates of a-hTTP mediated ligand transfer were 
faster to SUV than LUV acceptors, and soy PC lipids that contained the larger fraction of 
unsaturated acyl chains supported a transfer rate twice as fast as either DOPC or bovine 
liver PC. 
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Figure 45: Effect of lipid saturation on a-hTTP mediated NBD-a-Toc transfer. 
Transfer of 0.225 flM NBD-a-Toc from 2 flM a-hTTP to 100 flM PC LUVs (closed 
bars) and SUV s (hatched bars) of soy PC, DOPC and liver PC was monitored. Data 
shown represents an average ± the standard deviation, n=3 for soy PC and DOPC, n=12 
for PC SUV sand n= 18 for PC LUV s. The data shown are compiled from separate 
experiments performed with different protein and lipid preparations. 
Cholesterol is known to regulate the fluidity of lipid membranes; it fills in the 
void space between the fatty acyl chains in the membrane, thereby making the disordered 
conformations of unsaturated acyl chains more rigid, while increasing membrane fluidity 
in the more ordered environment. We speculated that cholesterol would reduce the 
membrane fluidity of bovine liver PC and thus hinder NBD-a-Toc transfer to the 
membrane. In order to assess the effect of cholesterol on a-hTTP-mediated transfer, 
vesicles were prepared from the heterogenous bovine liver PC that contains of ~9% each 
of the highly unsaturated fatty acids 20:3 and 20:4, and a few percent of 20:6. For 
comparison, addition of cholesterol to bovine liver PC was compared to an even more 
heterogenous lipid mixture of the total liver lipid extract. The liver total lipid extract was 
composed of 42% PC, 7% cholesterol, 22% PE, 8% PI, 1% lysoPI and 21% others, 
including neutral lipids. As shown in Fig. 46, the inclusion of 15 % cholesterol in bovine 
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liver PC LUV s but not SUV s modestly enhanced the rate of transfer when compared to 
vesicles without cholesterol. The most striking result was observed in the vesicles 
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Figure 46: Effect of other lipids on a-hTTP mediated NBD-a-Toc transfer. Transfer 
of 0.225 IlM NBD-a-Toc from 2 IlM a-hTTP to 100 IlM PC SUVs (closed bar) and 
LUVs (hatched bar). Lipids tested are indicated in the graph. Data shown represents an 
average ± the standard deviation, n=3 for 15% Chol and total liver lipids, n=12 for PC 
SUVs and n=18 for PC LUVs. 
prepared from the total liver lipid extract, where a-hTTP could no longer discriminate 
between SUVs and LUVs, as the transfer rate to SUVs and LUVs were determined to be 
0.160 ± 0.011s-1 and 0.179 ± 0.033s-1, respectively. We have tested cholesterol, PE and 
PI, individually, and they were found to have minimal impact on the transfer ofNBD-a-
Toc to both SUVs and LUVs. Whether a particular unique lipid component in the 21 % 
unspecified lipids, or the unique combination of this total lipid exact creates a similar 
membrane packing effect for LUVs and SUVs is unknown, and demands further 
investigation. 
The above data suggested the importance of the membrane curvature in regulating 
the ligand transfer. However, our knowledge regarding the vesicle size was based on the 
assumption that sonication and extrusion with a filter of certain pore size would produce 
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the vesicles of desired size. To ascertain that the vesicles tested were true to their 
predicted sizes, vesicles were subjected to Quasi Elastic Light Scattering (QELS) 
analysis. Light scattering detects the Brownian motion of small particles. The 
hydrodynamic radii measured are presented in Table 1. The LUVs of 100 nm in Tris and 
SET buffer were determined to be 113.8 nm and 158 nm, respectively. The sizes 
determined for vesicles of 80 nm or less were higher than expected, with the SET buffer 
alone produced a high background value. Therefore, the higher vesicle size estimates 
were possibly due to the viscosity of the SET buffer that contained 8.6% sucrose. The 
viscosity of this buffer was determined to be 1.28. The average diameter for SUVs 
prepared in HEPES buffer containing 9% sucrose was reported to be approximately 72 
nm determined by electron microscopy [184] . The dynamic radius ~is related to the 
Table 1: The hydrodynamic radii of lipid vesicles measured by Dynamic Light 
Scattering (DLS) at McMaster University 
PC vesicle sample ACR Polydispersity Eff. Diameter 
(kcps) index (nm) 
SET background 13.7 0.452 78.1 
30nm 153.5 0.122 91.4 
50nm 227.9 0.119 106.7 
100nm 120.4 0.116 158 
200nm 210.1 0.103 219.5 
Probe sonicated SUV 184 0.273 107 
Bath sonicated SUV 150 0.266 134 
Tris background 6.2 undefined undefined 
100nm LUV Tris 221.4 0.085 113.8 
translational diffusion coefficient DT (of the particle to be measured) through the Stokes-
Einstein equation [185], and therefore, it is also related to the solution viscosity: 
Eqn2 
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where K8 is the Boltzmann's constant, T is the temperature,,, is the viscosity of the 
medium. The parameters used for hydrodynamic radius analysis were: a 90° scattering 
angle e, a 628.3 nm wavelength, and 0.89 buffer viscosity. Because the viscosity was 
not corrected to 1.28, the vesicles' radii determined were therefore not as precise as 
expected. 
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Figure 47: Dynamic Light Scattering (DLS) analysis of extruded 30 nm SUVs (A) 
and probe sonicated SUVs (B). Samples were measured at 2SoC at 660 nm in a 
Dynapro NanoStar Instrument. Presented are the duplicate runs ofSUV samples. 
Since NBD-a-Toc transfer was greatly enhanced to the sonicated SUVs and 30 
nm extruded SUV s, we were particularly interested in learning the accurate size of these 
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vesicles. Due to the small size of these vesicles, any particles of equal size or greater 
would introduce error in the measurement. Thus, SET buffer was first vacuum filtered 
through a 30 nm filter to remove potentially larger aggregated sucrose prior to vesicle 
preparation. Both sonicated and extruded SUV samples were then shipped to be analyzed 
by Wyatt Technology Inc. (Santa Barbara, CAl. As illustrated in Fig. 47, the duplicate 
runs of both extruded and sonicated samples were fairly reproducible, and the results are 
summarized in Table 2. Extrusion through 30 nm membranes produced uniform SUVs, 
with a polydispersity index between 0.031 and 0.037, and a cumulative radius of ~ 55nm. 
Greater than 96% of the population were vesicles smaller than 60.1 nm, and the rest were 
large aggregates of ~ 6 J.lm. Sonication, on the other hand, produced a rather 
heterogeneous population of vesicles indicated by the high polydispersity index of 0.326. 
Three populations of vesicles were detected: 9.2 to 13.5% vesicles of20 nm and smaller, 
~ 75% median size vesicles of 80 nm, and ~ 12% large aggregates. Due to the 
Table 2: The hydrodynamic radius of extruded and sonicated SUVs determined by 
Wyatt Technology Inc. 
Sample Cumulants Analysis Regularization Analysis 
Radius Polydispersity Peak Peak Peak Peak 
(nm) Index # Renm) %Pd % Int 
Extruded 1 55.4 0.037 1 60.1 36.9 98.2 
2 6329.0 25.1 1.8 
Extruded 2 55.5 0.031 1 56.5 27.9 96.0 
2 296.5 20.4 2.9 
3 7820.2 33.4 1.0 
Sonicated 1 67.5 0.326 1 15.7 4.1 9.2 
2 82.3 43.4 76.5 
3 785.0 58.2 12.8 
4 5422.1 35.9 1.5 
Sonicated 2 67.5 0.326 1 18.5 13.8 13.5 
2 88.5 32.5 75.3 
3 1614.9 79.3 11.3 
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heterogeneity in vesicle preparation, the actual average size was detennined to be 67.5 
nm, not 25 nm or less, as expected. The effective diameter detennined from QELS in 
general tends to be higher than values obtained by freeze fracture electron microscopy 
[169, 186]. Although the actual sizes measured were higher than expected, the size 
relationship was consistent among the extruded vesicles (Table 1), 200 nm > 100 nm > 
50 mm > 30 nm. Due to the high polydispersity index, sonicated SUVs should not be 
directly compared to the extruded vesicles. 
To ensure that the enhanced transfer ofNBD-a-Toc to SUVs was introduced by 
the increase in membrane curvature and not by the increase in the total lipid surface 
available, we calculated the total number of liposomes and outer surface area that could 
be produced from a particular lipid sample using the equations (3-5) listed below. The 
estimated surface area for a molecule of PO PC is approximately 70 A2 [187]. 
# lipids per liposome = [4n:*(Yzd)2 + 4 n:*(Yzd-hi]/a Eqn 3 
# ofliposomes = (Mlipid * NA)lNtotal*Vol. Eqn4 
Total outer surface area = # ofliposomes*4n:(Yzd)2 Eqn 5 
where h is the thickness of bilayer (8 nm), a is the heagroup area of PC (0.7 nm2), NA is 
Avogadro's number (6.02 x 1023), d is the diameter of vesicles, M lipid is the molar 
concentration of lipid sample, and Ntotal is the total number of lipids per liposome. The 
total number of liposomes increased by appoximately 14 fold when the vesicle size was 
decreased from 100 nm to 30 nm (Table 3), yet the total outer surface area increased by 
only 40%. According to the calculated surface values using the theoretical sizes of LUV s 
(l00 nm) and SUVs (30 nm) , the 8 to 10 fold enhancement in NBD-a-Toc transfer to 
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SUV s versus LUV s could not have been caused by such a minor increase in the total 
outer surface area of the smaller vesicles. 
Table 3: Total outer surface area of various sized liposomes and the surface ratio in 
relative to 100 nm L UV s. Please note the above equations used in calculation were 
obtained from web site: www.liposomes.orgI2009101lnumber-of-lipid-molecules-per-
liposome.html. 
Vesicle diameter Total # of lipids # of Iiposome Outer surface area Surface Ratio 
(run) per liposome (ImL @ 200 uM) (run2) 
200 33146 1.82E+12 2.28E+17 0.92 
100 7655 7.86E+12 2.47E+17 1.00 
50 1641 3.67E+13 2.88E+17 1.17 
30 492 1.22E+14 3.46E+17 1.40 
20 187 3.22E+14 4.05E+17 1.64 
2.3. Membrane insertion of gating helix AS and helix AIO are essential for the 
binding of a-hTTP to the target membranes and the delivery of NBD-a-Toc 
2.3.1. Creation of hydrophohic mutants 
The orientation of 0,,-TTP with respect to the lipid membrane can be calculated by 
estimating the free energy change (~G) when a portion of the protein surface is 
transferred from water to the lipid bilayer. The calculation was performed by our 
collaborator Dr. Andrei Lomize (Univerity of Michigan) using a program called PPM 
(Positioning of Proteins in Membranes). The details of the calculations have been 
published [149]. Briefly, the transfer energy (~G) was calculated as a function of four 
variables d, Zo, '!, and cp (Fig. 4S) in a coordinate system with Z-axis coincides with the 
membrane normal: 
Eqn6 
where ASAi is accessible surface area of atom i, O"iW-M is the salvation parameter of atom i 
and !(Zi) is interfacial water concentration profile. The optimal spatial arrangement of a 
75 
protein in membrane is determined by minimizing its transfer energy from water to the 
hydrophobic solvent such as decadiene [149]. 
y 
Figure 48: Schematic representation of a transmembrane protein in a hydrophobic 
slab. Parameters that defined the arrangement of a TM protein in the membrane 
hydrocarbon core: d, shift along the bilayer normal; T, tilt angle; cp, rotational angle, and 
D = Zo, hydrophobic thickness of the protein. This image was created by Lomize et al. 
[149]. 
Fig. 49A illustrates the proposed orientation of u-TTP (ligand bound, closed) in 
relation to the lipid bilayer and the immersion of the two gating helices: helix A8 and 
helix AlO into the membrane. Helix A8 is spatially fixed, while the helix AlO is mobile, 
which allows ligand to enter and exit the protein. The hydrophobic residues of helix A8 
(F165 and F169) and helix AlO (1202, V206 and M209), shown in Fig. 49B, are 
predicted to penetrate deep into the lipid membrane. In the open conformation, helix 8 
and helix 10 are further apart. Calculations of change in transfer energy show that when 
the open, ligand-free form of u-TTP binds to the membrane, the initial penetration into 
the membrane is estimated to be 8.4 ± 0.9 A deep, with a change in free energy (~G) of-
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20.7 kcallmol. The binding of a-hTTP to the bilayer stabilizes the "closed" conformation 
of the protein, which reduces the depth of penetration to 4.0 ± 0.5 A and the free energy 
change of binding to - 10.6 kcallmol. 
Guided by this model, the hydrophobic residues highlighted in Fig 49 were 
mutated to either the acidic aspartate or hydrophobic alanine. The acidic aspartate 
residues were expected to produce the greatest effect on the free energy of transfer 
(making ~G more positive) due to the cost of insertion of these charged residues into the 
hydrophobic membranes. ResidueM264 located on the opposite side of the protein away 
from helices A8 and AlO was chosen as a control. The substitution of M264 with an 
aspartate should have minimal impact on the membrane binding of a-hTTP if the above 
Figure 49: Hydrophobic residues predicted to penetrate into lipid bilayer. The left 
panel is the side view of a-hTTP (a-Toc bound, pdb:IR51) highlighted with the 
membrane penetrating hydrophobic residues to be mutated and the control residue M264. 
The right panel is the view of these amino acids from the hydrophobic core of the 
membrane bilayer. The space filled molecules shown are: M209 and M264 in yellow, 
V206 in deep blue, F165 and F169 in white and 1202 in cyan. a-Toc is the molecule 
shown in green sticks. These images were created with ViewerLite. 
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model has correctly located the face of a-hTTP that directly touches the membrane. The 
mutant proteins created were assessed for their ability tQ transfer ligand to lipid vesicles 
and to adsorb to both immobilized planar lipid bilayers and highly curved unilamellar 
vesicles. 
All hydrophobic mutants were created successfully using Turbo Pfu polymerase 
and the Quikchange mutagenesis protocol, as described in the Methods. The sequences 
determined by Robarts Research Institute (London, ON) were aligned with the a-hTTP 
nucleotide sequence obtained from the Pubmed database to verify the presence of the 
desired mutations. The alignments produced by BioEdit are included in Appendix II. 
All mutants were expressed in BL21 (DE3) and purified to homogeneity using 
glutathione affinity chromatography of the soluble cell fractions. Both I202A and 
V206D were over-expressed in the same vector, but based on SDS-PAGE of total cell 
lysates. V206D was expressed almost exclusively in inclusion bodies, and I202A 
resulted in a soluble but apparently mis-folded protein that failed to bind to the 
glutathione affinity column. Extremely low levels of purified protein were recovered for 
I202A and V206D, and they were, therefore, not included in most of the testing. All 
purified proteins were analyzed on SDS-PAGE. As shown in Fig. 50, in addition to the 
major a-hTTP band migrating at the correct size of 32 kDa, two minor contaminants 
were also detected at ~25 kDa and ~ 65 kDa respectively. 
Initially, glutathione agarose (pre-swelled) from Invitrogen was employed for 
affmity purification of a-hTTP wild-type and the mutants. The protein recovery rate was 
fairly low -less than 0.5 mg a-hTTP was obtained from each gram of E. coli cells. We 
then tested glutathione agarose provided by Sigma, and the protein recovery was 
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Figure 50: Purified protein samples of wild type (X-hTTP and the hydrophobic 
mutants visualized on 15% SDS-P AGE. Typically, 5 to 10 J..lg per lane (except 1202A 
and V206D) were analyzed on SDS-PAGE gel. Note: protein samples shown are for 
qualitative purpose only, amount of protein visible varied due to sample preparation and 
handling. 
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improved by several fold to 1.59 ± 0.19 mg of wild-type a-hTTP per gram of E. coli 
cells. The amount of protein recovered for most of the. hydrophobic mutants was fairly 
similar to the wild-type a-hTTP, except for I202A and V206D, with the recovery rate at 
0.06 and 0.08 mg per gram of E. coli cells, respectively. The purification recovery data is 
summarized in Appendix III. 
2.3.2. Membrane binding of hydrophobic mutants and their ability to deliver NBD-a-
Toe 
The ability of the hydrophobic mutant proteins to bind and transfer NBD-a-Toc 
to acceptor membranes was determined and compared to the wild-type (Table 4). Most 
of the mutants exhibited similar abilities to bind NBD-a-Toc as the wild-type protein, 
except for F169D and M209A, which demonstrated a 3 to 4 fold reduction in their 
binding affinities. Nevertheless, the dissociation constants (Kn) determined for Fl69D 
and M209A were very low, at 79 nM and 89 nM, respectively. These data indicated that 
the mutated residues did not introduce major changes to the ligand binding pocket of a-
hTTP. 
We subsequently determined the ability of these hydrophobic mutants to deliver 
NBD-a-Toc to both SUVs and LUVs of bovine liver pc. As shown in Table 4 and Fig. 
51, all aspartate mutants except M264D (control) had greatly reduced abilities to transfer 
NBD-a-Toc (Fig. 51A, open bars). Substitution of a single phenylalanine by aspartate at 
either residue 165 or 169 decreased ligand transfer by 90%, which was equivalent to that 
of the double mutant I202D1M209D. The I202D/M209D mutant was designed to 
completely disrupt the binding of mobile helix AlO to the lipid bilayer. However, 
replacing V206 or M209 with conservative alanine residue had virtually no impact on the 
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Table 4: Vesicle binding and rate of NBD-a-Toc transfer by wild-type and mutant 
forms of a-hTTP. KD values shown are averages of duplicate measurements, with 
expected error within 20% of the reported values. 
NBD-a-Toc Transfer to SUVs % Transfer to LUVs % 
TTP KD (nM) (S-I) WTRate (S-I) WTRate 
WT 19 0.127 ± 0.012 100 0.016 ± 0.002 100 
F165D 17.23 0.013 ± 0.001 10 0.009 ± 0.005 56 
F169D 79.38 0.015 ± 0.002 12 0.000 0 
1202D 26.06 0.028 ± 0.002 22 0.005 ± 0.005 31 
Ml09D 12 0.047 ± 0.004 37 0.013 ± 0.001 81 
F165DIM209D 28.84 0.034 ± 0.003 27 0.010 ±. 0.001 63 
1202DIM209D 24.75 0.014 ± 0.001 11 0.008 ± 0.003 50 
Ml64D 29.22 0.116 ± 0.013 91 0.008 ± 0.001 50 
F165A 51.75 0.037 ± 0.002 29 0.005 ± 0.002 31 
V206A 23.37 0.154 ± 0.012 121 0.016 ± 0.002 100 
Ml09A 89.35 0.140 ± 0.012 110 0.025 ± 0.005 167 
ligand delivery of these mutants (Fig. SIA, hatched bars). In contrast, substitution of 
F165 with alanine reduced the transfer rate by 71 % compared to the wild-type protein. 
These findings clearly indicated the significance of the hydrophobic interaction between 
helices A8 and AIO and acceptor lipid membranes. In addition, the deep insertion and 
anchoring of helix A8 appears to be essential for a-hTTP membrane binding since the 
replacement of the bulky phenylalanine (F 165) with a much smaller hydrophobic alanine 
compromised the ability of a-hTTP to bind to membranes and consequently, to transfer 
its ligand. 
The rates of NBD-a-Toc transfer from aspartate mutants to LUVs were also 
reduced, but to a much lesser extent, as compared to that ofSUVs. Interestingly, F169D 
completely lost its ability to transfer NBD-a-Toc (Fig. SIB). Two other mutants with 
significantly decreased transfer rates were F165A and I202D. The conservative mutation 
F165A exhibited -70% reduction in its transfer rate. Moreover, the control mutant 
M264D also exhibited -50% reduction in the rate of transfer ofligand to LUVs compared 
to the wild-type protein. Due to the very low rate of ligand transfer mediated by the wild-
81 
__ 0.1 A 
.... 
~ 
'-" 
~ 
VJ. 
o 
.... 
.. 
~ 
rI} 
= = .. 
.... 
c,.., 
o 
~ 
~ 
0.04.....---------------------------. 
Figure 51: Transfer of NBD-a-Toc from a-hTTP wildtype and mutants to SUVs 
(A) and LUVs (B) of bovine liver PC. Shown are averages of six to nine detenninants ± 
the standard deviation. The data for the wild-type protein is presented in closed bar, the 
aspartate mutants in open bars, and alanine mutants in hatched bars. 
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type a-hTTP to LUVs (k = ~ 0.017 ± 0.0009 S-1 ), it is possible that the rate differences 
observed for measurements involving LUV s were simply data fluctuation - essentially 
small changes in small numbers. The low rate of ligand transfer to LUV s could be 
caused by the weak association between the wild-type a-hTTP and the tightly packed 
lipid bilayer of LUVs. a-hTTP is expected to rotate randomly on the planer lipid bilayer 
until it is able to insert hydrophobic residues F165 and F169 into the membrane. 
The collisional mechanism of ligand transfer predicts that the ability of a-hTTP to 
transfer ligand is directly correlated with the ability of the protein to bind to lipid 
membranes. Specifically, this would only be true if membrane binding (rather than 
ligand delivery) was the rate limiting step. To test this, an optical biosensor technique, 
called Dual Polarization Interferometry (DPI) was utilized. This method has been used 
and characterized previously by other researchers [188, 189]. As described in the 
Methods, a lipid bilayer was created after vesicles were absorbed onto a sensor chip and 
ruptured to form a stable bilayer. Subsequently, protein samples at various 
concentrations were introduced over the immobilized lipid surface and the real time 
protein adsorption was monitored and recorded, enabling determination of the binding 
affinity of a-hTTP for the bilayer. The binding curves of mutated proteins containing 
aspartate residues in the mobile gating helix Al 0 were obtained and are illustrated in Fig. 
52. The maximum protein adsorption detected was ~0.6 ng/nm2 for wild-type a-hTTP as 
well as the V206D mutant. Wild-type a-hTTP bound to the immobilized lipid bilayer 
with an apparent binding affinity KD calculated to be 0.342 ± 0.055 J..lM. V206D had 
slightly decreased binding affinity, compared to the wild-type. However, V206D total 
adsorption continued to increase in response to further increases in protein concentration, 
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suggesting that V206D had not yet reached saturation at these protein concentrations, 
whereas the wild-type exhibited saturable binding. At ,5 J..lM concentration, the total 
amounts of protein bound to the lipid bilayer were almost the same for V206D and the 
wild-type. On the other hand, both the I202D and I202D/M209D proteins showed 
minimal binding to the lipid bilayer, even at 10 J..lM protein concentration. Similar to 
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Figure 52: Concentration dependent binding of a-hTTP wild-type and selected 
aspartate mutants to the immobilized lipid bilayer. The protein adsorption was 
analyzed by Dual Polarization Interferometry (DPI). Presented are averages of 
quadruplicate analyses ± the standard deviation. 
I202D and I202D/M209D, the apparent KD calculated for F165 AID and F169D mutants 
appeared to be 5- to 10-fold lower, as compared to the wild-type protein (data not 
shown). Many of the mutants demonstrated reduced binding to the bilayer evident from 
the lower adsorbed masses. Since the mutated proteins did not reach the same total mass 
adsorbed as the wild-type, the dissociation constants reported by the curves were not 
meaningful for comparing their lipid binding affinities. 
The absolute binding of wild-type a-hTTP and the mutants were therefore 
compared at 0.5 J..lM and 1 J..lM protein concentrations. At these concentrations, 
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adsorption of a-hTTP was approaching saturation (Fig. 52). The data are summarized in 
Table 5 and plotted in Fig. 53. As shown, the binding patterns observed for these 
proteins were remarkably similar to their transfer of NBD-a-Toc to SUV s (Table 4 & 
Fig. 51A) measured in the FRET transfer assays. Also, aside from M209D and M264D 
(control), the aspartate mutations had much reduced lipid binding. At 0.5 JlM protein 
concentration, less than 20% of wild-type binding was observed for these mutants. 
Table 5: Binding of various mutants to the planer PC bilayer measured by DPI 
0.5 fJ.M TTP 1.0 IlM TTP 
TTP oglom 2 %ofWT oglom 2 %ofWT 
WT 0.338 ± 0.058 100 0.383 ± 0.089 100 
F165D 0.038 ± 0.02 11 0.071 0.004 19 
F169D 0.062 ± 0.032 18 0.086 ± 0.047 22 
I202D 0.097 18 0.103 27 
M209D 0.132 39 0.162 42 
F165DIM209D 0.002 ± 0.003 1 0.069 ± 0.035 18 
1202DIM209D 0.044 ± 0.02 13 0.028 ± 0.009 7 
M264D 0.224 ± 0.015 66 0.31 ± 0.083 81 
F165A 0.126 ± 0.069 37 0.172±0.018 45 
V206A 0.314 ± 0.031 93 0.436 ± 0.057 114 
M209A 0.34± 0.039 101 0.43 ± 0.049 112 
Increasing protein to 1.0 JlM did not drastically improve the level of binding relative to 
wild-type. The conserved alanine mutations, such as V206A and M209A, fully retained 
their binding capability, whereas the conserved mutation F165A once again had less than 
50% binding at both protein concentrations. 
Overall, the calculated change in the transfer energy (MG) of protein that have 
had key hydrophobic resides mutated correlated well with the experimentally determined 
rates ofligand transfer to SUVs and the levels of protein binding to planar lipid 
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Figure 53: Protein adsorption to the immobilized phospholipid bilayer determined 
by Dual Polarization Interferometry (DPI). Wildtype and mutant a-hTTPs at 0.5 JlM 
(open bars) and 1.0 JlM (dotted bars) were tested for their binding to phospholipid 
bilayers consisting of 10% DOPS and 90% DOPe. Data presented are averages of 
quadruplicate ± the standard deviations. 
membrane (Table 6). The mutant proteins with the greater change in their transfer 
energy such as F165D (~~G = 11.1 kcallmol), I202D/M209D (MG = 13.2 kcallmol) and 
Fl65DIM209D (MG = 15.4 kcallmol), exhibited much reduced rate of ligand transfer 
(10 to 27%) and protein binding (7 to 19%) compared to the wildtype. In general, the 
binding of a-hTTP to the membrane appears to stabilize the closed conformation of this 
protein, reflected in the lower change in transfer energy (MG) compared to its open 
conformation. The only mutant that exhibited inconsistent changes in the free energy of 
transfer and lipid binding and ligand transfer capability is the conserved F165A mutant, 
which had a calculated ~G of 0.8 kcal/mol and 1.2 kcallmol for the closed and open 
conformation, respectively. Yet, the ligand transfer rate to SUVs and lipid binding were 
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Table 6: Comparison of calculated change of transfer energy (L\G) of a-hTTP 
mutants, rates of NBD-a-Toc transfer (to SUVs) and protein adsorption at 1 JlM 
protein concentration relative to wildtype a-hTTP. The change in transfer energy 
values were calculated by Dr. Andrei Lomize (Univerity of Michigan). 
Ir5l: L\G loiz: L\G Ir5l: loiz: Ratemutf Adsmutf 
mutant kcallmol kcallmol MG MG Ratewt Adswt 
(closed) (open) kcallmol kcallmol 
(closed) (open) 
WT -10.6 -20.7 0 0 1 1 
F165D -7.0 -9.6 3.6 11.1 0.10 0.19 
F169D -7.1 -13.5 3.5 7.2 0.12 0.23 
1202D -7.9 -11.2 2.7 9.5 0.22 0.42 
M209D -7.0 -10.8 3.6 9.9 0.37 0.27 
1202DIM209D -3.9 -7.5 6.7 13.2 0.11 0.07 
F 165DIM209D -3.6 -5.3 7 15.4 0.27 0.18 
V206D -10.6 -12.7 0 8.0 nla 0.69 
F165A -9.8 -19.5 0.8 1.2 0.29 0.45 
V206A -10.6 -20.5 0 0.2 1.21 1.14 
M209A -9.6 -19.6 1 1.1 1.10 1.12 
reduced by 71% and 55%, respectively. This discrepancy may be caused by the 
simplification of the current computational model (PPM 1.0) that does not account for the 
increased flexibility when a bulky membrane anchoring residue is replaced by a much 
smaller one. 
Ideally, it would have been more logical to compare the lipid binding data 
generated from DPI experimens directly to the rates of ligand transfer to LUVs, given 
that both assays utilized the planar lipid membranes. However, due to the very small 
rates of transfer measured for LUV s accompanied by large errors, the correlation between 
these two sets of data is not well defined. Therefore, the transfer rates to SUV s were 
chosen for direct comparison. 
Since a -hTTP mediated transfer of NBD-a-Toc was much more efficient to the 
highly curved smaller vesicles, and the DPI technique in our case was designed to 
evaluate the binding of a-hTTP to a planar lipid surface, we decided to perform size 
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exclusion vesicle binding assays, to compare the lipid binding affinity to both sonicated 
SUV s and extruded 100 nm vesicles, the two vesicle sizes investigated in the FRET 
transfer assay. In the vesicles binding assay, 31.5 /lg (or - 1 nmole) of a-hTTP samples 
were incubated with increasing concentrations of SUVs or LUVs for 30 minutes. At the 
end of incubation, the lipid-bound a-hTTP was . separated from the free a-TTP using 
YM-100 Microcon filters (with the molecular weight cutoff at 100 kDa). Vesicle bound 
protein was retained by the filter and free protein passed through it. Both bound and free 
a-hTTP fractions were visualized by SDS-PAGE electrophoresis and the intensity of the 
stained protein bands were analyzed using Scion Image software (Scion Corp.). The two 
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Figure 54: Binding of wildtype a-hTTP and helix AS mutants to SUV s as assessed 
by the size exclusion vesicle binding assay. a-hTTP (31.5 /lg) bound to small 
unilamellar vesicles of DOPC were separated from the free proteins. The samples were 
visualized on SDS-PAGE (top panels), stained, and the protein bands subsequently 
analyzed by densitometry (bottom panels). Data was normalized to the total protein, the 
combined lipid bound and free protein at the highest lipid concentration. Shown are 
averages of measurements ± the standard deviation, n= 4 for WT, n=3 for mutants. 
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mutants with the most compromised ligand transfer and lipid binding capabilities (F165D 
and F169D) were tested in this assay, along with the conservative F165A mutant and 
wild-type a -hTTP. As illustrated in the top panel of Fig. 54, the binding of wild-type a-
hTTP increased in response to the increased concentration of PC SUV s, until saturation 
occurred at 0.75 mM phospholipid in the form of SUVs. Interestingly, at saturation, all 
a -hTTP was bound to SUV s, and protein was no longer detected in the unbound 
fractions. Although the binding of the mutant proteins was also sensitive to phospholipid 
concentration, protein saturation was never achieved, and the majority of these mutant 
proteins remained in the unbound fractions, even at the highest lipid concentration. The 
densitometric analyses of protein bands were normalized and compared to the total 
protein available for binding (bottom panels). Compared to the wild-type (with an 
apparent KD at 0.12 ± 0.06 f.LM, R2 = 0.92, which represented the lipid concentration at 
the half maximal protein bound), binding affinity of F165A was reduced by -45 fold (KD 
- 5.04 f.LM, R2= 0.76), and more than 75 and 7 fold, for F165D (KD - 8.29 f.LM, R2= 0.58) 
and F169D (KD - 0.84 f.LM, R2= 0.77), respectively. 
When the same vesicle binding assay was employed to assess the binding of a-
hTTP wild-type to PC LUVs, no saturation was observed (Fig. 55). At the highest LUV 
concentration tested, only 60% of wild-type or 20% of mutant proteins were lipid-bound. 
These results illustrated that a-hTTP bound to the highly curved SUV s more avidly than 
to LUV s, and the preferential binding is thus responsible for the enhanced transfer of 
NBD-a.-Toc to SUVs. 
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Figure 55: Binding of a-hTTP wildtype and helix AS mutants to LUVs assessed by 
size exclusion vesicle binding assay. All values were normalized to the total protein, the 
combined lipid bound and free protein at the highest lipid concentration. Shown are the 
averages of three determinations ± the standard deviation, except the WT, which was 
tested in duplicates. 
Comparing to the DPI method, size exclusion vesicle binding assay certainly was 
much less sensitive and unable to resolve the fine difference between F165A/D and 
F169D, for their ability to bind to LUVs. According to DPI analysis, at 1 J..lM protein 
concentration, conserved mutant F165A bound to the planer lipid membrane (45% of WT 
binding) better than both F165D (19%) and F169D (22%). In the vesicle binding assay, 
at the highest LUV concentration, F169D exhibited 50% of the wild type a-hTTP 
binding, which was greater than both F165A (30%) and F165D (30%). The weak 
correlation between DPI and LUV vesicle binding results are mainly due to the weak 
interaction between a-hTTP and LUVs. In contrary, the binding of these mutants to 
SUVs correlated much better with DPI results, in which F165A exhibited greater binding 
affinity (66%) than both F165D (25%) and F169D (29%). 
2.3.3. Role of three positively charged hinge residues on the membrane binding and 
subsequent delivery of NBD-a-Toc 
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According to Dr. Lomize's computed orientation of a-hTTP in relation to the 
lipid membrane, several positively charged lysine residues were found near the 
membrane boundary, which may interact with the charged head groups of phospholipids, 
thereby regulating the movement of the mobile gating helix AlO (a. a 198-221). The 
functional significance of residues near the membrane within the positively charged 
surface of a-hTTP was investigated with mutants R192H, K211A and K217A shown in 
left panel of Fig. 56. These mutants were made available to us by our collaborators Dr. 
Danny Manor and Dr. Samantha Morley (Case Western Reserve University). K217 was 
of particular interest to us as it was located on the critical "hinge" that controlled the 
movement of the mobile helix AlO. K217 may form ionic interactions with the 
negatively charged residues on helix A9, thereby stabilizes the "open" conformation of 
the protein. The mutation of K217 to alanine would disrupt this electrostatic interaction 
and promote the protein to switch between the "open" and the "closed" conformations, 
thereby increase its rate of ligand exchange. It is worth noting that the interactions 
between a-TTP and highly curved membrane of SUV s appeared to be dominated by a 
few hydrophobic residues on Helix A8 (F165 & F169) and AlO (1202) as shown in the 
previous section. R192 is located slightly further away from the membrane boundary. 
Since the effect of electrostatic interaction is only apparent with LUVs, the positively 
charged R192 may come in contact with membrane surface only when a-hTTP is rotating 
randomly on the surface of LUV. 
All three mutants (RI92H, K211A and K217A) were purified to a high degree 
(Fig. 56, right panel). Two minor contaminating proteins at 65 to 70 kDa were visible. 
Compared to the wild-type a-hTTP, K211A and K217 A had slightly reduced (but likely 
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insignificant) ligand binding affinities (Table 7) and the rates of NBD-a-Toe transfer to 
LUVs. The transfer to SUVs was not affected by these mutations (Table 7). 
-
Rl92H K211A K217A 
Figure 56: The positively charged residues on or near the hinge region that may 
control the movement of the mobile gating helix AIO. Left panel: Cartoon 
representation of a-hTTP (pdb:loiz) with the binding cavity a~a~ sheet colored in 
green. Membrane penetrating hydrophobic residues are colored in red. Basic residues 
that may form electrostatic interaction with lipid bilayer are colored in blue. The first 
methylene of the acyl chains in the membrane are shown in blue dots. Right panel: 
SDS-PAGE analysis of the purified hinge mutants. R192H and K211A were analyzed on 
the pre-cast 10% Tris'HCI mini gel, followed by ProtoBlue Safe Colloidal Coomassie G-
250 staining. K217 was analyzed on 15% Tri'HCI, followed by Coomassie Brillian blue 
staining. 
Table 7: Binding and rate of NBD-a-Toc transfer by a-hTTP wildtype and hinge 
mutant of a-TTP. Ko values shown are averages of duplicate measurements, with an 
expected error of 20% within the reported values. 
NBD-a-Toc Transfer to SUVs % Transfer to LUVs % 
TTP KD (nM) (S-I) WTRate (S-I) WTRate 
WT 19 0.127 ± 0.012 100 0.016 ± 0.002 100 
R192H 21.98 0.106 ± 0.008 83 0.012 ± 0.003 75 
K21IA 36.37 0.105 ± 0.008 83 0.011 ± 0.001 69 
K217A 32.08 0.130 ± 0.011 102 0.010 ± 0.004 63 
Interestingly, when these mutants were assessed for their ability to bind to lipid 
membranes by DPI, both R192H and K217A (at 0.5 IlM) experienced 58 and 71 % 
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Table 8: Adsorption of a-hTTP wild-type and hinge mutants of a-hTTP to the lipid 
bilayer measured by DPI. Values for the adsorbed protein mass (ng/nm2) at the 
indicated protein concentration injected are shown. 
0.5 OM TTP % 1.0 oM TTP % 
O-hTTP ng/nm 2 WT binding ng/nm2 WT binding 
WT 0.534 100 0.762 100 
R192H 0.843 ± 0.103 158 1.141 ±0.149 150 
K211A 0.655 ± 0.215 123 0.721 ± 0.162 95 
K217A 0.912 ± 0.149 171 1.368 ± 0.213 180 
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Figure 57: Comparison of mutant V217A to a-hTTP wild-type for their binding to 
SUVs assessed by size exclusion filtration assay. Shown are the averages of four 
determinations ± the standard deviation for wild-type and average of two measurements 
for K217A. 
increased binding to the planar lipid bilayer (Table 8), respectively. Doubling of protein 
to 1.0 ~M did not further increase the level of protein binding to the lipid membrane. In 
comparison, the binding of K217 A to SUV s by the size-exclusion assay was essentially 
same as the wild-type (Fig. 57). It is hard to reconcile the discrepancies between the 
increased binding of the hinge mutants to the planar bilayers with the reduced rate of 
transfer to the LUVs unless the differences observed were due to the data variation, and 
these hinge residues are not directly involved in modulating the movement of the mobile 
helix AID. Alternatively, the increased binding of these hinge mutants to the lipid 
93 
bilayer may reduce the dynamic of the mobile helix, thereby compromise their ability to 
transfer ligand. 
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3. DISCUSSION AND CONCLUSIONS 
(X,-TTP plays a critical role in vitamin E homeostasis. Mutations in the ttpA gene 
render (X,-TTP less active, and as a consequence, patients with the inherited Ataxia with 
Vitamin E deficiency (A VED) disorder have significantly reduced circulating vitamin E. 
(X,-TTP binds specifically to (X,-Toc [89, 90]. In hepatocytes, (X,-Toc co-localizes with (X,-
TTP in late endosomes prior to its secretion at the plasma membrane [190]. The exact 
mechanism utilized by (X,-TTP to transport (X,-Toc has not been fully elucidated. In the 
current study, which utilizes a fluorescence resonance energy transfer (FRET) assay, we 
sought to characterize the mechanism of (X,-TTP mediated transfer of (X,-Toc and identify 
the factors that may influence the rate of (X,-Toc transfer. 
Protein mediated transportation of small hydrophobic ligands typically utilizes 
one of the two well-characterized mechanisms: free aqueous diffusion of ligand from 
protein to lipid membranes or collisional interaction between protein and phospholipid 
bilayer. These two mechanisms can easily be distinguished based on the kinetics of the 
rate limiting step. For instance, liver FABP transfers free fatty acids facilitating aqueous 
diffusion, and the rate-limiting step occurs when ligand dissociates from the protein. 
Thus, the rate of transfer is greatly dependent on the properties of both the ligand and the 
aqueous phase [126, 128, 133]. In contrast, all other members of FABP family utilize a 
collisional mechanism of transfer, which requires the direct interaction between protein 
and acceptor lipid membrane. In this case, the rate of transfer is dependent on the 
concentration and the composition of the phospholipid bilayer [127-130, 179]. In 
general, collisional transfer is believed to target the ligand to a specific subcellular 
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location [134, 191], rather than merely equilibrating the ligand concentration in the same 
cellular compartment. 
3.1. FRET transfer assay with 6-His-a-hTTP from pET28 and pET21 expression 
vectors 
Initially, 6-His-a-hTTP with an N-terminal extension of 40 amino acids from the 
expression vector pET28b was tested in a FRET assay. With this protein, 35% of total 
fluorescence was missing in the early times when a-hTTP bound NBD-a-Toc was 
transferred to the quencher containing lipid vesicles. The initial -25% of total 
fluorescence signal was still missing after diluting the overall reagent concentration by 64 
fold (Fig. 18A). It was unclear whether the N-terrninal extension was responsible for 
missing of the initial fluorescence detection. It was nevertheless cumbersome to have an 
extension with an undefined function that might potentially complicate the data 
interpretation. Fortunately, the hTTP/pET21b construct was made available to us, and 
this construct produced an N-terrninally 6-His tagged protein without the extra 40 amino 
acids. A transfer curve without the initial lost of fluorescence signal was attained with 
this version of 6-His-a-hTTP (Fig. 20). Interestingly, the rate of NBD-a-Toc transfer by 
this protein appeared to be independent of the composition, concentration and curvature 
of the acceptor vesicles. These observations supported the aqueous diffusion of NBD-a-
Toc from a-hTTP to the acceptor membranes. However, according to the crystal 
structure of a-TTP [93, 94], a-Toc is buried deep in the hydrophobic binding pocket and 
a major conformational change is required for the ligand to enter and exit the protein. It 
is therefore highly unlikely for a-Toc to simply diffuse from the protein to lipid 
membranes. The collisional based transfer of a-Toc by lipoproteins was previously 
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reported by Asmis [55]. Similarly, a-Toc transfer from liposomes to crude liver 
membrane fraction appeared to be correlated directly to a-TTP concentration [89]. 
Recently, Morley et al. reported the increased rate of a-Toc extraction from lipid bilayers 
in response to increased a-TTP concentrations [114]. The discrepancy between our data 
and the findings reported in the literature implied a systematic error(s) in our FRET 
assay, which might have been responsible for the deceptive observations. We decided to 
closely examine the potential suspects: fluorescent ligand NBD-a-Toc and a-hTTP. 
NBD fluorescent probes have been used widely to determined the rates of 
spontaneous transfer of various lipids to and from membranes [158, 161, 162, 192]. The 
off-rate of NBD-Iabeled phospholipids from lipid vesicles is significantly influenced by 
the acyl chain length. Thus the half-time for C12-NBD-PA increased by -226 fold 
compared to C6-NBD-PA [161]. Phospholipids with shorter hydrocarbon chains are 
typically chosen to allow the timely investigation of the lipid diffusion between artificial 
lipid vesicles or biological membranes [158, 161, 192]. The NBD group is substantially 
more water soluble than boron-dipyrromethene (BODIPY) analogs [193]. When NBD 
was attached to the sn-2 position of the acyl chain of POPC, it was found to loop back to 
near the lipid-water interface [194]. In this case, NBD induced lipid chain disorder by 
adding -2.0 A2 to POPC molecule, which accounted for a -3% increase in the surface 
area of the lipid molecule. Moreover, the calculated lipophilicity index 10gP for NBD-a-
Toc was calculated to be 9.60, which was more hydrophilic than that of a-Toc (7.34). 
Therefore, we were concerned that NBD-a-Toc might have increased solubility and 
bulkiness compared to a-Toc. The enhanced solubility and bulkiness may have 
prevented NBD-a-Toc from entering deep into the hydrophobic binding pocket of a-
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hTTP, thus allowing it to diffuse freely from protein to its lipid acceptor. At the time, we 
considered replacing NBD-a-Toc with C9-AO-a-Toc for the FRET studies. The 
anthroyloxy probe is expected to be more hydrophobic than NBD, and it has been used 
extensively in the fatty acid transfer studies [126, 127, 138]. However, in our research, 
C9-AO-a-Toc underwent significant (-30%) photobleaching during a relatively short 
interval of 60 seconds (data not shown). Thus, it was not a suitable probe to be used in 
our FRET assay. As expected, NBD-a-Toc underwent spontaneous transfer between 
donor and acceptor vesicles. The rate of transfer was dependent on the size of both donor 
and acceptor vesicles and thus the curvature of the lipid membrane (Fig. 29). 
Mter critically examining the protein source purity, we identified a minor 
contaminant of the 39 kDa E. coli outer membrane porin F (OmpF) as the source of the 
problem. OmpF had been previously identified as one of two major contaminants during 
the purification of a LacZ-papain fusion protein from inclusion bodies [172]. OmpF 
normally remains in the insoluble pellet fraction. However, during high cell density 
cultivation, OmpF was found to excreted into the culture medium [173]. We typically 
allowed 18-hours of IPTG induction to increase soluble a-hTTP production, and the cell 
density at the time of harvesting was usually very high. Thus, it was not surprising to 
have some OmpF remained with the cell pellets after centrifugation, which then 
contaminate the cell lysate prior to purification. More importantly, nickel-affinity 
chromatography was utilized to purify 6-His tagged a-hTTP. At neutral pH, OmpF is 
cation selective; it binds to both monovalent and divalent metal ions including nickel and 
magnesium [174, 175]. 
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Although OmpF accounted for only about 5-10% of total recovered protein, the 
high fluorescence signal observed when NBD-a-Toc bound to OmpF overwhelmed the 
lower fluorescence produced by the majority of the protein, a-hTTP (Fig. 32D). The 
approximately four-fold greater fluorescence signal observed for OmpF was likely due to 
the ability of each OmpF monomer to bind multiple molecules of NBD-a-Toc. OmpF is 
a barrel protein elliptical in cross section. The pore dimensions of OmpF determined 
from the crystal structure are 11 x 19 A at the mouth, llx7 A in a central constriction 
zone formed by the internal L3 loop, and 22 x 15 A at the smooth end [195]. The height 
for the inner wall of the barrel is 30 A. As shown in Fig. 58, the length of a-Toc is 
estimated to be 13.43 A, and due to the tendency of NBD moiety of NBD probes to loop 
back to align with the chromanol moiety when present in membranes, conjugation of 
NBD to the tail of a-Toc is unlikely to increase the length of the molecule. The bent 
hydrocarbon chain has a width of 7.9 A, which is about 2 A larger than the chromanol 
head group. Based on the height of OmpF, it can accommodate 2 molecules of 
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Figure 58: Dimension of (X-Toe estimated from Deepview. 
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NBD-a-Toc stacked head to tail vertically. Horizontally, OmpF should be able to 
accommodate 2 or more NBD-a-Toc. Thus, the high ,stoichiometery may explain the 
apparent high affinity of OmpF for NBD-a-Toc and the subsequent high fluorescence 
signal observed when NBD-a-Toc bound to OmpF. 
Several methods were employed to remove OmpF contamination (data not 
shown). One attempt was to cleave 6-His-a-hTTP with factor Xa, then elute a-hTTP in a 
buffer without imidazole. OmpF was expected to stay on the nickel column until elution 
with imidazole solution. To our surprise, a small level of OmpF still co-eluted with the 
cleaved a-hTTP, indicating a weak association between OmpF and immobilized nickel 
ions. Alternatively, 6-His-a-hTTP purified from nickel affinity column was subjected to 
further purification with DEAE anion exchange column. Again, no clean separation of 
OmpF from 6-His-a-hTTP was achieved. It is possible that the resolution would have 
been improved if a larger column had been used. However, utilizing a 120 ml (16 x 600 
mm) Sephacryl S-300 high resolution gel filtration column and FPLC, we were able to 
completely separate a-hTTP from OmpF, though OmpF still contained tiny traces of a-
hTTP (Fig. 32 B&C). Unfortunately, due to the lengthy purification procedure at room 
temperature, the pure a-hTTP obtained seemed to have lost most of its activity. These 
results suggest that OmpF is not only able to bind nickel ions, but it also is likely to form 
a complex with 6-His-a-hTTP, perhaps through its association with the positively 
charged histidine tag. The only way to eliminate OmpF contamination was to avoid a 
hexahistidine tagged a-hTTP. Therefore, the hTTP/pGEX-4T construct producing GST-
a-hTTP was tested. A full length a-hTTP without the GST tag was obtained after a 2-
hour on-column digestion of GST -a-hTTP with thrombin protease, and OmpF was no 
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longer found in the purified a-hTTP (Fig. 37). This version of a-hTTP had slightly 
improved affinity for NBD-a-Toc (KD = 18.9 ± 0.4 nM),compared to both 6-His-a-hTTP 
(KD = -46 nM) and 6-His-28TTP (56 ± 15 nM). 
3.2 Transfer of NBD-a-Toc by a-hTTP to acceptor membranes utilizes a collisional 
based mechanism 
The results from FRET transfer assays demonstrated that a-hTTP mediated a-Toc 
transfer requires a collisional interaction between the protein and the lipid bilayer. Thus, 
the rate of transfer was increased in response to an increase in the concentration of lipid 
vesicles (Fig. 40). The transfer of NBD-a-Toc to SUVs was much more sensitive to the 
change in lipid concentration compared to LUVs. Furthermore, the transfer rate 
increased as vesicle size decreased (Fig. 44). Compared to the extruded 100 nm LUVs, 
the rate increased by -4 fold when 30 nm extruded SUV s were used and -8-10 fold for 
probe sonicated SUV s. To make sure that the observed rate difference was not due to the 
difference in the methods of vesicle preparation, bath sonicated SUV s were also included 
in the comparison. Bath ultrasonication usually produces SUV s of 20 to 50 nm diameter 
[196, 197] similar to the size generated by probe sonication. Comparable rates ofligand 
transfer were observed for SUV s prepared from both sonication methods. For vesicles 
of 50 nm and larger, ligand transfer was no longer sensitive to the change in the vesicle 
SIze. 
The enhanced ligand transfer of anthroyloxy-Iabeled fatty acid to SUVs has also 
been reported for adipocye and heart fatty acid binding proteins [129]. The authors 
suggested that the lO-fold increase in the transfer rate observed was likely due to the 
greater number of SUVs available for protein binding. However, they did not rule out the 
possibility that the reduced transfer to LUVs was due to the increase in the packing of the 
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phospholipid acyl chain caused by the flatter bilayer structure. This hypothesis was 
supported by the reduced in the rate of fatty acid transfet: to the lipid bilayer contained the 
fully saturated dimyristoyl-PC (DMPC) as compared to the unsaturated I-palmitoyl-2-
oleoyl-PC (POPC). Furthermore, the transfer rate was also reduced when cholesterol and 
sphingomyelin (SM) was present [129]. 
According to the lipid surface area calculation (data summarized in Table 3), for 
the same amount of lipid, about -14 fold greater number of 30 nm SUV s can be 
produced, compared to 100 nm LUV s. At the same time, the total outer lipid surface is 
increased only by 40%. Thus, the 10 fold increase in transfer rate to smaller vesicles 
cannot be explained by an increase in lipid surface area. Instead, this suggests that the 
enhanced transfer results from the reduction in the phospholipid acyl chain packing 
density in response to the increase in the membrane curvature. This is consistent with our 
previous observation that LUVs were both poor acceptors and donors during the 
spontaneous transfer of NBD-a-Toc (Fig. 29). Furthermore, we have shown that a-TTP 
binds better to SUVs than to LUVs (Fig. 54 & Fig. 55). All evidences suggest that the 
enhanced NBD-a-Toc transfer to SUV by a-hTTP was due to the ease of protein and 
ligand insertion into the membrane with high curvature [198]. 
The interactions between soluble cytosolic proteins and lipid membranes are 
typically regulated by both electrostatic interactions and hydrophobic forces. Proteins 
which rely predominantly on the electrostatic interaction with anionic lipids are fairly 
common. For instance, the binding of cellular retinaldehyde-binding protein to 
membranes containing phosphatidic acid PAis responsible for the release of bound 
ligand ll-cis retinal [122] . A number of signaling proteins including myristoylated 
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alanine rich C-kinase substrate protein, MARCKS rely on a basic motif for targeting to 
the plasma membrane [199-201]. Fatty acid binding proteins also contain a cluster of 
basic residues on the portal lid that are key for their recognition of anionic membranes 
[138, 178]. On the other hand, soluble proteins that depend solely on the hydrophobic 
force to interact with the membrane are rare, unless they also contain membrane 
recognition domains, such as the FYVE, zinc finger, Pleckstrin-homology (PH) or Phox 
(PX) domain [202-205]. These domains interact with the anionic phosphoinositides in 
the membranes. The sensitivity of membrane binding proteins to the curvature of 
membranes has also been identified. As previously mentioned, increased ligand transfer 
from protein to SUVs has been observed for fatty acid binding protein [132,206]. Sterol 
carrier protein 2 [207] and glycolipid transfer protein [208] also preferentially bind to the 
highly curved membranes. ArfGAPI (Arf GTPase activating protein 1) consists of two 
disordered ArfGAPI lipid-packing sensors (ALPS) that fonn ampithatic helices when 
docking onto membranes of high curvature and subsequently increases the actity of Arf-
GTP [142, 143]. The soluble monomer of Annexin B12 undergoes a membrane 
curvature induced "inside-out" confonnational change, exposing internal hydrophobic 
residues at the surface upon binding to a highly curved phospholipid membranes [146]. 
NBD-a-Toc transfer by a-hTTP appears to be regulated by the size of the 
acceptor vesicles. Electrostatic interaction clearly plays an important role in ligand 
transfer to LUV s with flatter lipid surface (Fig. 42) since the rate of transfer increased 
(58% for PI &PS; 145% and 124% for LBPA & DOPA) in the presence of 15% anionic 
lipid. The most drastic increase in the rate of transfer was introduced by cardiolipin 
(CL), which caused -8 fold increase in the rate of ligand transfer. Similar or even greater 
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effects of CL for the fatty acid transfer by intestinal and adipoctye F ABP have been 
reported [126, 209, 210] in studies which employed PC; SUVs containing 25% CL. In 
our hands, the transfer of NBD-a-Toc to CL SUV s could not be determined. 
Unexpectedly, the fluorescence of NBD-a-Toc was not quenched when the ligand bound 
a-hTTP was mixed with quencher containing SUV s. CL is known to undergo a lamellar 
to inverted hexagonal phase transition in the presence of high concentration of divalent 
ion such as Ca2+ or Mg2+ [211, 212]. The lamellar to hexagonal phase transition occurs 
when the binding ratio of Ca2+ to CL increases from 0.35:1 to 1:1 [212] . The SET buffer 
used in our FRET transfer assay did not contain any divalent ions. Moreover, only 15% 
CL was incorporated in the SUV preparation, hence a phase transition was highly 
unlikely. However, we can't rule out the possibility of a-hTTP induced aggregation in 
CLSUVs. 
Unlike anionic lipids, the cationic DOTAP (Fig. 43) only increased the transfer 
rate to LUVs by -80%. These observations suggested that acidic residues of a-hTTP 
were less effective than the basic protein surface in forming electrostatic interactions with 
the charged head groups of the phospholipid bilayer. The slower ligand transfer to the 
zwitterionic PC LUVs implied that a-hTTP forms transient contacts with the densely 
packed flatter lipid bilayer. The binding to the lipid bilayer was greater when a-hTTP 
encountered anionic lipids such as PA and CL. On the other hand, the ligand transfer to 
SUV s appeared to be dominated by the combination of hydrophobic interactions and the 
preference of a-hTTP for membranes of higher curvature, suggesting that a specific 
region or domain of the protein might be critical for such an interaction. The 
incorporation of 15% anionic phospholipid in the acceptor SUVs had no affect on the rate 
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of transfer. The lipid acyl chain packing also influenced the ligand transfer to SUVs and 
LUV s, as a-hTTP transferred NBD-a-Toc to soy PC with much greater (S/U ratio = 
0.30) percentage of unsaturated lipids exhibited a greater rate of transfer, compared to 
both bovine liver PC (S/U ratio = 0.91) and synthetic DOPC (Fig. 45). 
In the current study, we relied solely on dynamic light scattering (DSL) to 
determine the hydrodynamic radius of vesicles, with the assumption that membrane 
curvature stress is inversely proportional to the radius of the vesicle. Although the 
average size measured for the sonicated SUVs was -12 nm larger than the extruded 30 
nm SUV s, the rate of ligand transfer to these vesicles nevertheless was higher. It is worth 
noting that the probe sonication produced two populations of SUVs, -75% of 80 nm and 
-11 % of tiny vesicles of 20 nm or less (Table 2 and Fig. 47). The extrusion through 30 
nm filter produced a homogenous population of SUVs, -98% of 60 nm vesicles. The 
increased ligand transfer to the sonicated SUV s versus 30 nm extrude SUV s was likely 
due to the presence of the small population of 20 nm SUV s. In order to accurately 
determine the rate of ligand transfer to these 20 nm vesicles, they must be separated from 
the larger SUVs by Sephacryl S-500 to S-1000 size exclusion chromatography [213]. 
Throughout the study, we consistently observed ~ 10 fold enhanced transfer to 
SUVs versus LUVs. However, when the total liver lipid extract was used to prepare 
LUVs and SUVs, a-hTTP was no longer able to discriminate LUVs from SUVs (Fig. 
46). Besides 42% PC, the total lipid extract also contains 7% cholesterol, 22% PE, 8% 
PI, 1% lysoPI, and 21 % others unspecified lipids. When tested individually, cholesterol, 
PE or PI had minimal impact on the transfer of NBD-a-Toc to both SUVs and LUVs. 
The similar ligand transfer to SUV sand LUV s can probably be explained by the 
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localized membrane defects and curvature introduced by the unique lipid composition of 
the total lipid exact, or the existence of lipid(s) with high binding affinity toward (l-
hTTP. As illustrated in Fig. 59, when the membrane consists of only homogenous 
cylindrical PC, its phospholipid head group packing density can be altered only by the 
change in membrane curvature. However, in a heterogeneous lipid mixture such as the 
total liver lipid extract, the phospholipid head group packing density depends on both the 
Liver PC SUV Total liver lipid SUV 
Liver PC LUV Total liver lipid LUV 
Figure 59: Proposed membrane structure of vesicles prepared from liver PC versus 
total liver lipid extract. 
curvature and the lipid composition of the membrane. Due to the similar local membrane 
environment such as head group and acyl chain packing in both SUVs and LUVs, (l-
hTTP was expected to interact similarly to these vesicles and therefore similar transfer 
rates were observed. To test this hypothesis, the size difference between these SUV sand 
LUVs needs to be confirmed by dynamic light scattering (DLS). These vesicles will then 
be subjected to differential scanning calorimetry measurement to determine whether the 
vesicle size difference can cause any changes in phase transition temperature of the lipid 
mixture. The impact of membrane curvature on membrane properties, such as the phase 
transition temperature, has been reported previously [214]. Differential scanning 
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calorimetry detected a 3°C reduction in Tm (gel to liquid transition) for SUVs that 
contained pure dimyristoyl-PC (DMPC) or distearoyl-PC (DSPC) compared to much 
larger multlamellar vesicles (MLV). In the mixture of DMPC and DSPC (1: 1), the phase 
separation for these two lipids increased as the membrane curvature increased from 640 
nm to 60nm. 
3.3 The direct interaction between a.-hTTP and lipid membrane is regulated by the 
anchoring helix AS and the mobile helix AIO 
a-TTP and Sec14p share similar tertiary structures. However, the distance 
between the two corresponding helices that cover the ligand binding pocket are different 
[94]. In Sec14p, helices AlO and All are 25 A apart, which makes the binding pocket 
more exposed. A "bulldozer" model has been hypothesized for Sec 14 mediated 
exchange of phospholipid [96]. Sec14p was proposed to insert its helix AlOtr4 (lipid 
binding lid) deep into the outer leaflet of the lipid bilayer, and it then exchanges its cargo 
lipid with the membrane lipid. However, in a-TTP, the corresponding helices A9 and 
AlO are much closer in distance, only 10 A apart [94]. Thus, the ligand is shielded away 
from the solvent. Based on the free energy change (~G), calculated when a protein is 
transferred from water to the lipid bilayer, a model was generated to predict the most 
stable orientation of a-hTTP with respect to the lipid membrane. From this model, a-
hTTP is expected to have both helices A8 and AlO submerged into the lipid bilayer (Fig. 
49). It is possible that a-hTTP also utilizes a "bulldozer" like mechanism to deliver a-
Toc, which requires the insertion of the mobile helix AlO into the membrane, followed 
by the opening of this lid to deposit or extract a-Toc from the lipid membrane. 
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The results of our measurements of the ligand transfer rate of mutant forms of a-
hTTP support the hypothesis that ligand delivery by a-hTTP requires a direct interaction 
between the protein and lipid bilayer. The collisional interaction appears to be regulated 
by the lipid binding helices A8 and AlO since substitution of residues within these helices 
diminished the ability of a-hTTP to interact with lipid membrane. When the 
hydrophobic residues F165 and F169 of the docking helix A8, that are proposed to deeply 
penetrate the membrane, were substituted with acidic aspartate, the binding of these 
mutants (1.0 JlM) to the flatter lipid on the DPI chip surface was reduced by 
approximately 80%, compared to the wild type protein (Table 5 & Fig. 53). 
Interestingly, alanine mutation of the conserved Fl65 also reduced its lipid binding by 
~55%. Clearly, preserving the hydrophobicity of Fl65 alone was not adequate to retain 
its lipid binding capability. This suggests the depth of lipid penetration is diminished in 
the Fl65A mutant when the bulky phenylalanine was replaced with a much smaller 
alanine. When these mutants were assessed for their binding to SUV s, the binding 
affinity of F169A was reduced by ~8 fold and more than 20 fold for Fl65D and F169D, 
compared to that of the wild type protein. As a consequence, the rates of transfer by 
Fl65D and Fl69D were reduced by ~90% to SUVs, and Fl69D completely lost its 
ability to transfer to LUVs. Similarly, the rate of transfer by Fl65A was reduced by 70% 
to both LUVs and SUVs (Table 4 & Fig. 51). 
The lipid insertion of the mobile helix AlO appears to be more superficial, 
compared to the docking helix A8, as the conserved alanine mutation of V206 or M209 
still faithfully retained their full capacity to bind to membranes and to transfer NBD-a-
Toc. Fig. 60 illustrates how the mobile helix AlO opens and closes the entrance to 
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Figure 60: Superposition of structures of human (l-TTP in "open" and "closed" 
conformations. Top panel: Protein backbone is shown in a cartoon representation with 
helices from N-terminal domain colored in yellow, from C-terminallipid-binding domain 
colored in green and from "gating" helices A8 and Al 0 colored in purple; residues that 
penetrate into lipid acyl chain region are shown by sticks colored in purple and pink for 
"open" and "closed" conformation, respectively. (l-Toe bound to the closed 
conformation is shown by sticks colored in green. Calculated boundaries between lipid 
head groups and acyl chain region are shown by dots colored green for 10iz (open) and 
grey for lr51 (closed). Bottom Panels: Close up of the membrane penetrating residues. 
Pictures were drawn using PyMol. 
the ligand binding pocket and thus allows the ligand exchange between the protein and 
the lipid membrane. Based on the model, this movement leads to the deeper penetration 
of residues V206 and M209 into the hydrocarbon core of the lipid bilayer, thereby 
slightly altering the orientation of the protein with respect to the lipid membrane. 
According to this model (Fig. 60, bottom panels), both 1202 and M209 appeared to have 
similar depths of lipid penetration in both open and closed conformations. However, 
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Figure 61: Comparison of protein adsorption to phospholipid bilayers measured by 
DPI (at 1 J.1M TTP) and the rate ofNBD-a-Toc to SUVs with the calculated energies 
of transfer (A) Closed conformation and (B) open conformations. 
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aspartate mutation of 1202 (l202D) caused a greater perturbation in the ability of protein 
to bind and transfer its ligand. This is perhaps due to the fact that during the membrane 
anchoring of the helix A8, 1202 is required for the stable insertion of other residues on the 
mobile helix AlO. Unfortunately, due to difficulties in purification, the 1202A mutant 
protein was not available for testing. Overall, the experimental data correlated slightly 
better with the calculated transfer energy change for the "closed" conformation of the 
protein (Table 6 & Fig. 61). Thus the closed conformation is likely preferred upon a-
hTTP binding to the phospholipid bilayer and subsequently delivers its ligand. The 
observed correlation between the rates of NBD-a-Toc transfer and the membrane binding 
of a-hTTP also clearly suggests that the membrane binding is the rate limiting step. 
The role of the three charged hinge residues (R192H, K211A and K217 A) 
remained inconclusive. These mutants had improved binding (23% to 71%) to 
membranes as measured by DP1, yet their rates of transfer to LUVs were slightly reduced 
(by 25 to 37%). The ligand transfer from these mutants to SUVs was not significantly 
different from the wildtype protein. These contradicting observations are difficult to 
explain, unless the data inconsistency was due to the experimental variation, or K211 and 
K217, though located close to the lipid bilayer, were not actively participating in the 
phospholipid binding. These preliminary data implied that these hinge residues probably 
had no functional impact on the movement of the mobile helix AlO. 
Based on our data, we propose the following steps for the interaction of a-TTP 
with lipid membranes: 1) ligand bound a-hTTP rolls randomly on the membrane until it 
inserts helix A8 onto the lipid bilayer; 2) membrane contact of the mobile lid helix AlO 
leads to the opening of the hydrophobic ligand binding cavity; 3) deep insertion of the lid 
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helix AlO into the hydrocarbon core of the membrane; 4) deposition of ligand into the 
membrane; 5) ligand free protein is stabilized in the "open" conformation; 6) desorption 
of a-TTP from membrane. 
3.4 Proposed recycling of a-Toc facilitated by a-hTTP 
Vitamin E is packaged in chylomicron remnants or lipoproteins when circulating 
in serum plasma prior to its arrival at liver [50]. In liver, a-Toc was found to localize to 
the late endosomes along with a-hTTP [99, 113]. The membrane structure of late 
endosome is highly dynamic, cocomposed of tubular, cisternal and multivesicular 
structures, with an average diameter of 500 nm [215]. Late endosomes serve as the last 
sorting station in the endocytic pathway, which determines whether internalized 
molecules are to be recycled back to the plasma membrane or to be degraded in 
lysosomes. In late endosomes, the internalized lipoproteins and chylomicron remnants 
are hydrolyzed in the acidic environment (pH 5.0 - 5.5), which likely results in the 
release of the bound vitamin E. a-hTTP in the cytoplasm binds to a-Toc and is retained 
in the late endosome, while other isoforms continue their journey to lysosomes for 
degradation. Fig. 62 illustrates the proposed transfer of a-Toc by a-hTTP in late 
endosomes. Due to its high affinity for the highly curved small vesicles, a-hTTP delivers 
its bound ligand a-Toc to the highly curved intraluminal vesicles that are enriched in 
LBPA, a late endosome specific phospholipid [165, 191]. LBPA is known to promote 
the formation of multivesicular bodies (MVB) in the acidic environment [166, 216]. 
These intraluminal vesicles are typically about 20 to 25 nm in diameter [215] . The co-
localization of a-hTTP with LBP A is presumably due to the curvature effect in these 
small vesicles and not due to the direct interaction between a-hTTP and LBP A. Other 
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Figure 62: Proposed recycling of (1-Toc from endocytic pathway. This drawing is 
modified from the cartoon created by Van der Goot and Gruenberg [217]. The a-Toe 
bound lipoprotein or chyromicron remnant undergoes receptor mediated endocytosis. 
Early endosome contains introlumenal vesicles rich in PI3P and cholesterol (purple). In 
late endosome, a-TTP (red stars) selectively binds and delivers a-Toe to LBPA enriched 
intralumenal vesicles (blue). These LBPA rich vesicles undergo back fusion via ABCAI 
transporter (green bars) containing limiting membrane (the outer membrane of late 
endosomes). ABCAI presumably delivers a-Toe to the plasma membrane during the 
fission/fusion events. 
small non-LBPA containing intraluminal vesicles are also found in the late endosomes to 
which a-TTP can presumably also bind. However, only intracluminal membranes 
enriched in LBPA are capable of back fusion with the limiting membrane (outer 
membrane) of the late endosomes. Several lines of evidence suggested that ATP-binding 
cassette protein-AI (ABCAl) transporter is involved in a-TTP dependent secretion of a-
Toe [99,218], moreover, a-Toe efflux mediated by apoA-l lipoprotein is dependent on 
the expression of ABCAI [219]. ABCAI shuttles between the plasma membrane and 
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endocytic comparments [220, 221] and is known to regulate the cholesterol efflux to 
apoA-l to form high density lipoproteins (HDL). Therefore, ABCAI in the limiting 
membrane of the late endosomes may facilitate the secretion of a-Toc from late 
endosomes to the plasma membrane during the ABCAI mediated fusion/fission events. 
This may help to explain why the treatment with ABCAI inhibitors glyburide and 
probucol reduced a-hTTP mediated a-Toc secretion [99, 2lS]. 
3.5 Conclusions 
The data from this study demonstrated the preference of a-TTP for the highly 
curved small unilamellar vesicles (SUVs) of -25 nm, as shown by the ten-fold increase in 
the rate ofNBD-a-Toc transfer compared to the flatter large unilamellar vesicles (LUVs). 
Although binding of a-TTP to SUVs and LUVs are both collisional, the mechanisms of 
interaction appeared to be different. Binding of a-TTP to LUVs is influenced by the 
electrostatic interaction between the basic residues of the protein and the anionic 
phospholipids in the membrane. In constrast, a-TTP binding to SUV s appeared to be 
dominated by the hydrophobic interaction and a greater ease of membrane penetration 
when curvature is high. The mutagenesis study guided by the calculated transfer energy 
model allowed us to identify two membrane interacting helices, AS and AlO, which are 
critical in the binding of a-TTP to phospholipid membranes. Mutation of the 
hydrophobic residues F165, F169 (helix AS) and 1202 (helix AlO) to negatively charged 
aspartates nearly completely abolished the ability of a-TTP to interact with the 
phospholipid bilayer and subsequently to transfer its ligand. The propensity of a-TTP 
for the highly curved membrane provides a connection to its colocalization with a-Toc to 
the small intraluminal vesicles in the late endosome. The back fusion of LBP A enriched 
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intraluminal vesicles containing (l-Toc via ABCAI containing limiting membrane may 
be the key to the secretion of (l-Toc from late endosome to plasma membrane. 
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4. FUTURE DIRECTIONS 
In the current study, we have demonstrated that the propensity of a-hTTP to bind 
to small and highly curved lipid membrane requires the deep insertion of the membrane 
binding helices A8 and AlD. The data we have obtained so far have relied exclusively on 
artificial lipid vesicles. We speculated that a-hTTP targets a-Toc to the LBPA enriched 
small intralumenal vesicles of the late endosomes prior to its secretion by ABCAI 
transporter to the plasma membrane. To test our hypothesis, it would be necessary to 
isolate these intraluminal vesicles from HepG2 cells and measure the binding affinity of 
a-TTP (wildtype and hydrophobic mutant proteins) for these small vesicles. 
Furthermore, two unresolved phenomena observed during the membrane curvature study 
remain to be addressed in future studies: the unexpected lack of fluorescence decay when 
NBD-a-Toc loaded TTP was mixed with vesicles containing a quencher and CL and the 
inability of a-hTTP to distinguish LUVs from SUVs prepared from total liver lipid 
extract. The probe sonicated vesicles yielded two populations of SUVs, -75% of 80 nm 
and -11 % of tiny vesicles of 20 nm or less. The rates of transfer to SUV s reported in this 
study was the average from both sizes, yet the transfer to the 20 nm vesicles is likely to 
be much faster than the reported value for the mixture of sizes. Since 20 nm SUV s are 
comparable in size to the intraluminal vesicles, it is therefore important to separate 20 nm 
SUV s from the -80 nm SUV s in order to accurately determine the rate of ligand transfer 
to these tiny vesicles. 
In vitro, the mutations in the anchoring helix A8 exhibited the most compromised 
lipid binding and consequently the most impaired ability of a-TTP to transfer NBD-a-
Toc. To validate the physiological relevance of the catastrophic mutations such as 
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F165D and F169D, the DNA construct of these mutants and the conserved mutation 
F165A will be created and stably expressed in the human hepatoblastoma HepG2 cell 
line. The expression level of these mutants as well as their ability to facilitate a-Toc 
secretion will be examined. The intracellular localization of these mutants will be also be 
followed by an immuno-fluorescence microscopy study. If the preference of a-hTTP to 
bind to the small and highly curved lipid vesicles is indeed due to the ease of the deep 
membrane insertion of helix A8, F165D and F169D are predicted to have much reduced 
binding to the small LBPA enriched intraluminal vesicles in the late endosomes and 
consequently less a-Toc will be secreted to the cell surface. The colocalization of NBD-
a-Toc and ABCAI transporter will also be assessed using a GFP (green fluorescence 
probe) tagged ABCAI. 
These studies will hopefully advance our understanding on the membrane binding 
behavior of a-hTTP both in vitro and in vivo. They will also help to determine whether 
LBPA and ABCAI transporter are directly involved in a-TTP dependent secretion of a-
Toc. 
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5. MATERIALS AND METHODS 
5.1. Chemicals and Stock Solutions 
5.1.1. Antibiotics and other chemicals (stored at -30°C) 
Ampicillin - 100 mg/mL in milliQ purified sterile H20 (mQH20) (BioShops) 
Chloramphenicol -20 mg/mL in EtOH 
Kanamycin - 30 mg/mL in mQH20 (BioShops, Mississauga) 
Ethidium Bromide (EtBr) -10 mglmL in mQH20 (Sigma, Oakville) 
Ethylenediaminetetraacetic acid (EDTA) - 500 mM in mQH20 
Phenylmethylsulphonyl fluoride (PMSF) - 100 mM in EtOH (stored at -30°C) 
Triton X-IOO (Sigma, Oakville) 
5.1.2. Enzymes (Stocks solutions were stored at -3ifC in single use aliquots) 
Lysozyme - 100 mg/mL in mQH20 
RNAse (Ribonuclease) - 50 mg/mL in mQH20 
DNase I (Deoxyribonuclease I) 375 UIDL (Invitrogen, Burlington, ON). 
Pfu Turbo DNA polymerase - 2.5 U/JlL (Stratagene, Cedar Creek, TX) 
Fushion hot start polymerase - 2 units/JlL (New England Biolabs, Pickering, ON) 
Thrombin - 50 units in PBS (GE Healthcare, Baie D'Urfe, PQ) 
Trypsin Gold, Mass Spectrometry Grade - I Jlg/JlL in 50 mM acetic acid (Promega) 
5.1.3. Chemicals used in to generate peptidesfor MAWI-TOF protein analysis 
Acetonitrile (ACN) (Fisher, stored at room temperature in the fume hood) 
Ammonium bicarbonate (N~HC03) - 250 mM in mQH20 freshly prepared (Sigma) 
Acetic acid - 50 mM in mQH20 
a-cyano-4-hydroxycinnamic acid (Sigma, stored at 4°C) 
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Iodoacetimide - 55 mM in 25 mM N&HC03 (Sigma, stored at 4°C) 
Sinapinic acid (Sigma, stored at 4°C) 
Trifluoroacetic acid (TFA) (Sigma, stored at 4°C) 
5.1.4. Solutions used to process SDS-PAGE gels 
Fixing solution: 40% EtOH and 10% acetic acid in mQH20 
Staining solution: 0.1 % Coomassie R-250, 25% MeOH and 10% acetic acid in mQH20 
Destain solution: 5% MeOH and 7% acetic acid in mQH20 
Gel drying solution: 40% MeOH, 10% glycerol and 7.5% acetic acid in mQH20 
5.1.5. Solutions employed to regenerate glutathione agarose affinity column (Sigma) 
Cleansing solution 1: 0.1 M borate acid, 0.5 M NaCI, adjust to pH 8.5 with 1 M NaOH 
Cleansing solution 2: 0.1 M sodium acetate, 0.5 M NaCI, adjust to pH 4.5 with acetic 
acid 
5.2. Phospholipids from Avanti Polar Lipids (Alabaster, AL) 
These phospholipids in chloroform were stored in -30°C until use: 1,2-dioleoyl-
sn- glycerol-3 -phosphocholine (DO PC), 1 ,2-dioleoy l-sn-glycerol-3-phosphate (DOPA), 
1 ,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP), bovine liver L-a-phosphatidylcholine (liver 
PC), bovine liver phosphatidylinositol (PI), soy L-a-phosphatidylcholine (soy PC), 
porcine brain L-a-phosphatidylserine (PS), oleoyllysobisphosphatidic acid (LBPA) and 
bovine heart cardiolipin (CL) and sphingomyelin (SM). 
5.3. Other reagents 
5.3.1. Miscellaneous reagents 
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Fluorescent lipid quencher seN -teramethylrhodamine-6-thiocarbamoyl)-1-2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt (TRITC-
DHPE) -lyophilized powder or 810 J..lM in chloroform stored at -30°C (Molecular 
Probes, Eugene, Oregon) 
Glutathione agarose linked through sulfur, provided in 20% EtOH, stored at 4°C 
(Invitrogen, Burlington, ON) 
Lyophilized glutathione agarose - swelled to 1 g/ mL in mQH20 prior to use, after 
the initial usage, it was stored in 2M NaCI at 4°C (Sigma, Oakville, ON) 
Microcon YM-100 filters (Millipore, Billerica, MA) 
Polycarbonate membranes (> =50 nm) (A vestin, Ottawa, ON) 
Polycarbonate membranes (30 nm) (Avanti Polar Lipids, Alabaster, AL) 
Precast 10% Tris·HCI mini gels (BioRad Laboratories, Mississauga, ON) 
Prestained broad range protein marker (New England Biolabs, Pickering, ON) 
ProtoBlue Safe Colloidal Coomassie G-250 Stain (National Diagnostics, Atlanta, GA) 
Qiaprep Spin Miniprep kit was from Qiagen (Mississauga, ON) 
mouse anti 6-His antibody and horse anti-mouse secondary antibody conjugated to 
alkaline phosphatase were purchased from Cell Signaling Technology (Pickering, ON) 
Unmodified sensor DPI chips (Farfield Sensors Ltd (Manchester, England) 
All other reagents were from BioShop Canada Inc. (Burlington, ON). 
5.3.2. Bacterial Strains 
The bacterial strains utilized in the study were: NovaBlue was purchased from 
Novagen (Madison, WI), and XLI-Blue and BL2I (DE3) were from Stratagene (Cedar 
Creek, TX). Both NovaBlue and XLI-Blue strains were employed for routine cloning 
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due to their high transformation efficiency and the blue/white screening capability. The 
deficient in endonuclease (endA) and recombination protein (recA) enable these host 
strains to produce high quality plasmid DNA. BL2I (DE3) strain promotes the 
production of more stable recombinant protein due to its lack of Ion (a heat shock 
protein) and OmpT proteases, it also carries a copy of the T7 RNA polymerase under 
control of the IPTG inducible lacUV5 promoter, therefore, this host strain was utilized 
for the controlled expression of 6-His a-hTTP and GST -a-hTTP recombinant proteins. 
5.3.3. Bacterial Expression Vectors 
The three bacterial expression vectors containing the a-hTTP gene investigated in 
this project were: pET28b produced a-hTTP with an N-terminal 6-His-tag followed by 
an extension of 40 amino acids, pET2Ib produced a-hTTP with an N-terminal 6-His-tag 
followed by a factor Xa cleavage site and pGEX-4T-3 produced a-hTTP with an N-
terminal GST tag plus six extra amino acids. A few characteristics of these vectors are 
listed in Table 7. The expression vectors pET-28b and pET-2Ib were used during the 
Table 9: Characteristics of the a-hTTP bacterial expression vectors 
Vector Backbone insertion sites Selection Source 
Size (bp) marker 
pET-28b 5369 SalIINotI Kanamycin Donated 
pET-21b 5443 NdeIlXhoI Ampicillin DSM 
pGex-4T-3 4968 NotIlSalI Ampicillin Collaborator 
(Dr. Manor) 
early stage of this research project to produce 6-His tagged a-hTTP with and without an 
N-terminal linker between the gene and the tag respectively. The a-hTTP/pET-2Ib 
construct was created by Stephen Hyland (DSM Nutritional Products), whom amplified 
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the human a-hTTP gene by peR with 5' -primer starting with an Ndel restriction site 
(compring the start codon), followed by an N-terminaI6-His tag and a factor Xa cleavage 
sit and 3' -primer containing a Xhol -site and the stop codon. Thus, the pET -21 b construct 
generated a-hTTP with an N-termina16-His tag. 
5.4. Molecular methodologies 
5.4.1. Site directed mutagenesis 
The human a-TTP gene flanked by SalI (5') and Not I (3') restriction sites from 
pET28b and subcloned into pGEX-4T -3 vector was created by Morley et al. [111]. With 
this fusion construct, only six additional amino acids were attached to the purified protein 
after the removal of GST tag by thrombin. This pGEX fusion construct was used as a 
template to create the following mutant constructs: F165A1D, F169A, l202A1D, 
V206A1D, M209A1D, F165D/M209D, l2021M209 and M264D. The double mutant 
constructs such as F165DIM209D and l202DIM209D were created by using primers 
encoding the F165D or l202D mutations for PCR with the a-hTTP M209D mutant DNA 
as a template. Turbo Pfu DNA polymerase was utilized to generate these mutations 
following the QuickChange Site-Directed mutagenesis protocol (Stratagene) with 10% 
DMSO in the reaction mixture. All primers (Table 9) were designed according to the 
guidelines suggested by the QuickChange protocol and were acquired from Sigma-
Genosys (Oakville, Ontario). 
The cycling parameters used for DNA amplification with turbo Pfu polymerase 
are listed in Table 10. The PCR products were then digested with Dpnl endonuclease for 
1 hour at 37°C prior to their transformation into XLI-Blue super competent cells. The 
transformed XLI-Blue cells were selected on agar plates containing 100 Jlg/mL 
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ampicillin and the cells were grown overnight at 37°C. Several ampicillin resistant 
colonies of each mutant construct were selected and amplified in 10 mL LB media. 
Table 10: Oligonucleotides primers used to create hydrophobic mutants of a-hTTP 
Primer Sequence TmeC) 
F165AF 5' CTTTGATCTGGAAGGTTGGCAGGCTTCTCATGCTTTTCAAATC 3' 82.4 
F165AR 5' GTGATTTGAAAAGCATGAGAAGCCTGCCAACCTTCCAGATCA 3' 83.4 
F165DF 5'CTTTGATCTGGAAGGTTGGCAGGATTCTCATGCTTTTCAAATCA 3' 82.4 
F165DR 5'AGTGATTTGAAAAGCATGAGAATCCTGCCAACCTTCCAGATCAA 3' 82.4 
F169DF 5'CAGTTTTCTCATGCTGATCAAATCACTCCATCC 3' 75.3 
F169DR 5' GGATGGAGTGATTTGATCAGCATGAGAAAACTG 3' 75.3 
1202AF 5' GATAAATGAACCAGTAGCTTTCCATGCTGTCTTTTCC 3' 74.9 
1202AR 5' GAAAAGACAGCATGGAAAGCTACTGGTTCATTTATC 3' 73.3 
1202DF 5' GATAAATGAACCAGTAGATTTCCATGCTGTCTTTTCC 3' 73.6 
1202DR 5' GGAAAAGACAGCATGGAAATCTACTGGTTCATTTATC 3' 73.6 
V206AF 5' CAGTAATTTTCCATGCTGCCTTTTCCATGATCAAACC 3' 78.2 
V206AR 5' GGTTTGATCATGGAAAAGGCAGCATGGAAAA TTACTG 3' 78.2 
V206DF 5' CAGTAATTTTCCATGCTGACTTTTCCATGATCAAACC 3' 76.0 
V206DR: 5' GGTTTGATCATGGAAAAGTCAGCATGGAAAA TTACTG 3' 76.0 
M209AF: 5'CCATGCTGTCTTTTCCGCGATCAAACCATTCCTGAC 3' 82.8 
M209AR: 5' CAGGAATGGTTTGATCGCGGAAAAGACAGCATGG 3' 82.1 
M209DF 5' CCAGTAATTTTCCATGCTGTCTTTTCCGATATCAAACCATTCCT 3' 79.5 
M209DR 5' AATTTTTTCAGTCAGGAATGGTTTGATATCGGAAAAGACAGCATG 3' 79.5 
M264DF 5' GGAATGGACAAATTTTATAGATAAGTCTGAAGATTATCTC 3' 68.8 
M264DR 5' CTGAGATAATCTTCAGACTTATCTATAAAATTTGTCCATTCCTGA 3' 72.6 
The Qiaprep Spin Miniprep kit was subsequently employed to purify plasmid 
DNA from each of the mutant TTP cultures. This kit utilizes an alkaline lysis based 
extraction method with improved DNA binding to the silica membrane. The targeted 
mutations were confirmed by sequencing by the Robarts Research Institute (London, ON) 
with a custom designed forward sense primer 5'-ATGGCAGAGGCGCGATCCCAGC-3' 
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Table 11: Cycling parameters utilizing turbo pfu polymerase in PCR amplification 
Segment Cycles Temp. Time Function 
1 1 95°C 30 s Denaturation 
2 95°C 30 s Denaturation 
18 55°C 1 min. Annealing 
68°C 6 min. Extension 
3 1 4°C 24hrs End 
During the initial stage of the mutagenesis study, the phusion hot start 
polymerase was used for DNA amplification of a-hTTP/pGEX-4T-3. With this 
polymerase, a greater number of amplification cycles were implemented as recommended 
by the supplier (Table 11). The reaction mixture contained: 10 JiL Phusion buffer 
(actual composition unknown), 1 JiL dNTP (200 JiM), 5 JiL each of forward and reverse 
primers (0.5 JiM), 10 ng DNA template, 2.5 ilL DMSO, 1.5 JiL Phusion polymerase and 
mQH20. 
Table 12: Cycling parameters utilizing Phusion hot start polymerase 
Segment Cycles Temp. Time Function 
1 1 98°C 30 s Denaturation 
98°C lOs Denaturation 
2 30 55°C 0.5 min. Annealing 
72°C 3.5 min. Extension 
1 72°C 10 min Final extension 
3 hold 4°C hold 
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Besides the greater number of amplification cycles might introduce some 
undesired off site mutations, hot start Pushion polymerase also requires phosphorylated 
primers and produces blunt end elongated DNA products which requires T4 DNA 
ligation. Due to the potential complication during T4 DNA ligation step, and the author's 
familiarity toward turbo Pfu polymerase based mutagenesis method, turbo Pfu 
polymerase facilitated PCR reaction was utilized to generate the targeted mutations listed 
in Table 9. 
5.4.2. Restriction enzyme digestion analysis of a-TTP mutant DNA samples 
Endonuclease digestion with NdeIlXhoI or NdeIlEcoRI was conducted at 37°C 
for 1 hr followed by enzyme inactivation at 65°C for 20 minutes. The reaction condition 
typically consisted of 10 JlL plasmid DNA (- 1 to 1.5 Jlg) , 1 JlL NdeI (20 U/Jll), 1 JlL 
XhoI (20 U/JlI) , 0.5 JlL BSA (lOOx) and 5 JlL NE buffer 4 (lOX) (final concentration 
consisted 50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate and 
1 mM dithiothreitol, pH 7.9 at 25°C). 
5.4.3. DNA concentration analysis 
In order to determine the DNA concentration of plasmid preparations and PCR 
products, purified samples were diluted in mQH20 and measured at 260 nm in a quartz 
cuvette. Since the absorbance of 1 unit at 260 nm corresponds to 50 Jlg plasmid DNA, 
the concentration of the plasmid DNA can be easily calculated using the following 
equation (Quantification of DNA, Qiagen): 
[DNA] = Abs260 * 50 Jlg/ml Eqn7 
5.5. Expression of a-hTTP in various expression vectors 
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The amount and identity of antibiotic added to the 10 mL pre-cultures varied 
depending on the expression vector. For a-hTTP/pET28b, the pre-culture was prepared 
to contain 30 Jlg/mL kanamycin and 50 Jlg/mL chloramphenicol, whereas 50 Jlg/mL 
ampicillin was used to select for a-hTTP/pET21b and a-hTTP/pGEX-4T-3 transformed 
E. coli cells. Wild-type a-hTTP and the mutant constructs were transformed into E. coli 
BL21 (DE3) competent cells for protein expression. The pre-cultures were grown 
overnight at 37°C. Five milliliters of overnight pre-culture was used to inoculate 500 m1 
LB media in 1 L baffled flasks for protein expression experiments. 
Typically, E. coli cultures were grown in baffled flasks at 3TC until reaching an 
OD at 600 nm between 0.4 and 0.6. Then the bacterial culture was cooled to room 
temperature before induction with 400 JlM IPTG. To improve the yield of soluble 
protein, the culture was grown at room temperature for 16 hours, except for I202A and 
V206D. Most of V206D remained in inclusion bodies when grown under these 
conditions, therefore the induction was carried out at 10°C and 100 JlM IPTG in an 
attempt to improve soluble protein production. I202A on the other hand, appeared to be 
soluble, yet could not be purified. Various expression and purification conditions were 
evaluated to overcome the purification issues for I202A and V206D, but all were futile, 
hence, these two mutants (especially I202A) were not included in most of tests. 
Following expression, the cells were harvested by centrifugation at 8000 rpm for 15 
minutes. Cell pellets were frozen, thawed twice and stored at -80°C until use. 
5.6. Purification of a-hTTP (6-His or GST tagged) 
Regardless of the purification methods, the purified protein was stored at 4°C and 
used within a few days after the purification. The purified protein was visualized on an 
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SDS-PAGE gel prior to use in assays. In general, D-hTTP ligand transfer activity 
remained intact within five days of purification. Purified protein samples were discarded 
if not used within the first five days. 
5.6.1. HiTrap IMAC Metal chelating affinity chromatography 
The thawed E. coli pellets were re-suspended in 10 m1 lysis buffer (25 mM 
phosphate, 0.5 M NaCI, 40 mM imidazole, pH 7.4) containing 4 mg lysozyme and 
incubated at room temperature for 45 minutes. The viscous cell lysate was clarified after 
3 x 15 seconds sonication with 15 seconds pulse on ice between the sonication. The 
sonicated lysate was centrifuged at 40,000xg for 30 minutes at 4°C. Purification of 6-
His-tag proteins was conducted using a pre-packed 1 mL HiTrap IMAC affinity column 
(GE Healthcare, Uppsala, Sweden) that had been rinsed with 5 mL of mQHzO to remove 
ethanol or storage buffer. A volume of 0.5 mL of NiS04·6HzO at 0.1 M was passed 
through the column, followed by a wash with 5 mL of mQHzO to remove excess 
unbound NiS04• The column was then equilibrated with 5 mL start buffer (25mM 
phosphate, 40 mM imidazole, 0.5M NaCI, pH 7.4). The lysate supernatant was applied to 
the column at a flow rate of about 1 mL/min. The column was washed with 5 ml of start 
buffer followed by wash with 100 mM imidazole in the start buffer. The non-specifically 
bound proteins were removed after a wash with 200 mM imidazole in the start buffer. 
Pure a-hTTP was eluted with elution buffer consisting of 25 mM phosphate, 0.5 M NaCl 
and 400 mM imidazole. The recovery of the pure a-hTTP was typically about 3 % of 
total protein from the cell lysate. 
5.6.2. Probond Metal chelating affinity chromatography 
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Alternatively, the Probond purification method was used in an attempt to resolve 
6-His a-hTTP from a 39 kDa unknown protein contaminant. In this case, E. coli pellets 
were resuspended in lO ml purification buffer (50 mM NaH2P04, 0.5 M NaCl, pH 8.0), 
lysozyme was added and the cell lysate was incubated on ice for 30 minutes. The lysate 
mixture was sonicated with 6 x lO second bursts, with lO-second cooling on ice between 
bursts. The viscosity of the sonicated lysate was reduced by passing the lysate through 
an l8-gauge syringe needle 5 to 6 times. The lysate was centrifuged at 40,000xg at 4°C 
for 30 minutes. The supernatant was then applied to the prewashed Probond column and 
allowed to bind to the column matrix for 30 minutes. The non-specific binding was 
removed by washing the column with 30 column volumes of 20 mM imidazole in 
purification buffer. Pure histidine tagged a-hTTP was eluted with purification buffer 
containing 250 mM imidazole. Unfortunately, this purity of a-hTTP was not improved 
by this purification method. 
5.6.3. Glutathione agarose affinity chromatography 
E. coli pellets were re-suspended in lO mL buffer A (150mM Tris pH 8.0, 150 
mM NaCl, 1 mM EDTA, lO% glycerol, 0.1 mM DTT and 0.1 mM PMSF). Lysozyme (4 
mg/ml) was added to the cell suspension, followed by 30 min incubation on ice. Nucleic 
acids were digested with the addition of lO mM MgCh, DNase I (500 units) and RNase 
(50 J..lg/mL) , followed by an additional 30 min incubation on ice. The cells were then 
sonicated for 3 x 15 seconds (with 15 seconds cooling on ice between the bursts) and 
centrifuged at 40,000xg for 30 min at 4°C. The supernatant was applied to a 1mL 
glutathione affinity column prepared in buffer A. Nonspecific binding proteins were 
removed by 15 column volumes wash each of buffer B (Buffer A plus 0.5 % Triton X 
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and 10 mM MgCh) and buffer C (50 mM Tris, pH 8,150 mM NaCl, 10 mM MgCh and 
0.1 mM DTT), respectively. On-column thrombin cleavage of GST -a-hTTP was 
completed after 2 hours of incubation at RT with 50 units of thrombin in phosphate 
buffered saline (20 mM NaH2POJNa2HP04 and 150 mM NaCl, pH 7.4) for every 1 to 
1.5 mL glutathione agarose. The O-hTTP was eluted in buffer C and a final concentration 
of 0.5 mM PMSF was added to prevent further secondary thrombin degradation. GST 
bound on the column was eluted with PBS containing 20 mM glutathione, and the 
column was regenerated with five column volumes each of cleaning buffer #1 (0.1 M 
H3B03, 0.5 M NaCl, pH 8.5) and cleaning buffer #2 (0.1 M CH3COONa, 0.5 M NaCl, 
pH 4.5), with mQH20 washes between the cleaning buffer washes. The regenerated 
column was stored in 2 M NaCl at 4°C for re-use about 15 times. 
5.7. Protein qualification and quantification methods 
5.7.1. Bradford protein concentration determination 
Protein concentrations were usually determined by the Bradford assay [222]. 
Briefly, ten microliters of purified protein diluted in 40 ~l PBS was mixed with 1 mL 
Bradford reagent, the absorbance of the protein samples at 595 nm was recorded. The 
protein concentration was extrapolated from a standard curve of BSA based on the Beer 
Lambert Law [223]. 
A= log 10 (IJI) = £ 1 c EqnS 
Where A = absorbance at 595 nm, 10 = intensity of the incident light, 1 = intensity of the 
transmitted beam, £ = extinction coefficient, c = concentration of protein sample, 1 = light 
path of 1 cm. 
5.7.2. NanoOrange protein quantification method 
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The NanoOrange quantification method was intended to improve the detection of 
the extremely diluted 6-his a-hTTP fractions obtained from fast performance liquid 
chromatography (FPLC) that were below the detection limit of the Bradford method. The 
kit was purchased from Molecular Probes and features increased sensitivity down to 10 
ng/rnL due to fluorescent detection of the NanoOrange dye:protein complexes (Eugene, 
Oregon). Ten microliter protein samples were diluted with 240 J11 of NanoOrange 
working solution as suggested by the manufacture's protocol in a 96-well microtiter 
plate. The plate was covered in aluminum foil. The mixture was incubated at 95°C for 
10 minutes and cooled to R T for 20 minutes before fluorescent measurement in a 
fluorescence-based microplate reader. The protein bound NanoOrange reagent illustrates 
strong emission fluorescence at 570 nm with excitation wavelength at 470 nm. Sample 
concentrations were determined using a standard curve of BSA. 
5.7.3. Sodium Dodecyl Sulfate-Polyacrylamine Gel Electrophoresis (SDS-PAGE) 
The homogeneity of a-hTTP was determined by SDS-PAGE performed 
according to Laemmli [224] using 3% and 12.5% polyacrylamide for stacking and 
resolving gels, respectively. Gels were subsequently incubated in fixing buffer (40% 
EtOH and 10% acetic acid) for 30 minutes, washed in dH20 for 5 minutes before 
subjecting the gels to overnight staining with 0.025% Coomassie staining solution (0.1 % 
Coomassie R-250, 25% MeOH and 10% acetic acid). The background staining was 
removed with de stain solution (10% MeOH and 10% acetic acid) for approximately three 
hours or until the complete removal of the background staining. For vesicle binding 
samples, the staining solution was freshly prepared by combining 1 part of ProtoBlue 
Safe Colloidal Coomassie G-250 Stain with 9 parts of absolute EtOH. Distilled water 
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was used to destain these gels. To preserve these gels for record keeping, films and gels 
were soaked in gel drying solution (40% MeOH, 10% glycerol, 7.5% acetic acid) for 
about 10 minutes, and then the gel - sandwiched with 2 preserving films - was assembled 
on the top of a clean glass. This assembly was allowed to air dry for at least 48 hours. 
For record keep, the dried gels were trimmed and taped to a notebook. 
5.7.4. Western blot analysis 
Following purification, protein samples were first separated by 15% SDS-PAGE, 
then transferred to PVDF membranes using a 200 rnA current for 2 hours. It is important 
to prevent gels from melting by keeping the transfer buffer cool with an ice block. The 
PVDF membrane was subsequently blocked with 3% BSA in Tris buffered saline (TBS), 
then incubated with a mouse antibody that recognizes the 6-His tag (Cell Signaling 
Technology, 1:2500 dilution in TBS) for 1.5 hrs, the washed using 6 x 5 min washes in 
TBS. Then the membrane was incubated with horse anti-mouse secondary antibody 
conjugated to alkaline phosphatase (Cell Signaling Technology, 1:2000 in TBS) for 1 hr. 
The blot was washed again with 6 x 5 min in TBS, and subsequently incubated with the 
ready to use 5-bromo-4-chloro-3-indoy1 phosphate/nitrob1ue tetrazo1iium (BCIPINBT) 
liquid substrate system (Sigma) for a few minutes or until the appearance of any purple 
bands. The alkaline phosphatase reaction was terminated by the replacement of 
BCIPINBT with mQH20. 
5.7.5. Intrinsic tryptophan fluorescence of a-hTTP 
Fluorescence measurements were performed on QuantaMaster-QM-2001-4 
fluorometer at RT. Spectra were recorded at a range of 300 - 400 nm with a fixed 
excitation wavelength set at 280 nm for tyrosine and 295 nm for tryptophan. The 
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fluorescence spectra of a -hTTP (10 JlM) in a 3 ml cuvette in the presence of either a-Toc 
or NBD-a-Toc in SET buffer were monitored. The effect of 2M NaCI on the protein 
conformation was also investigated. 
5.7.6. Acrylamide quenching of a-hTTP 
The intrinsic fluorescence of a-hTTP (2.5 JlM) was recorded before and after the 
addition of the soluble quencher acrylamide at concentrations ranging from 0.1 to 0.5 M. 
The quenching data was fitted to the Stern-Volmer equation: 
loll = 1 + Ksv [Q] Eqn9 
where 10 is the initial fluorescence, I is the fluorescence after addition of quencher , [Q] is 
the concentration of quencher and Ksv is the Stern-Volmer constant for dynamic 
quenching [225]. 
5.7.7. MAWI-TOF protein sequence analysis 
The detailed method was kindly provided by Amanda Rochon. The method is 
fairly similar to the protocol cited in Methods in Molecular Biology [226]. Purified 6-His 
a-hTTP with a contaminating 39 kDa protein was separated on a small 15% SDS-PAGE 
and the gel was fixed for 1 hour in fixing solution (7% glacial acetic acid and 40% (v/v) 
MeOH. The gel was stained in a staining solution (4 parts of Ix Colloidal Brilliant Blue 
G working solution and 1 part of MeOH) for 4 hours. Destaining the gel was achieved 
with 10% acetic acid in 25% (v/v) MeOH for 30 minutes on a shaker. The gel was rinsed 
with 25% MeOH, and de stained in 25% MeOH for overnight. The gel was scanned and 
stored in 25% (v/v) ammonium sulfate at RT until further processing. The 
microcentrifuge tubes (1.5 mL) to be used were rinsed twice with 50% acetonitrile 
(ACN) and 0.1 % trifluoroacetic acid solution. A clean razor blade was used to cut out 
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the 39 kDa and a-TTP bands along with a blank area as a negative control. These gel 
pieces were destained twice with 200 JlL of 100 mM NH4HC03/50% ACN for 45 
minutes each at 37°C. The gel slices were dehydrated in 100 JlL ACN for 5 to 10 
minutest at RT. ACN was subsequently removed in a high speed vaccum concentrator 
for 5 to 10 minutes at R T. Trypsin used for digestion was first reconstituted in 50 mM 
acetic acid and then diluted to 20 Jlg/mL in 40 mM N&HC03/1O% ACN. The ACN 
dried gel slices were rehydrated in 20 JlL trypsin at 20 Jlg/mL for I hour at R T. At the 
end of incubation, excess trypsin solution was removed. Gel slices were covered in 
digestion buffer (40 mM NH4HC03/1O% ACN) and incubated overnight at 37°C. One 
hundred fifty microliters of mQH20 was added and incubate for 10 minutes with frequent 
vortexing. The supernatant was transferred to a pre-rinsed microcentrifuge tube. The 
gel slices were mixed and extracted two more times with 50 JlL 50% ACN/5% TFA (v/v) 
for 60 minutes at RT. The extracts were combined and dried in a speed vac concentrator 
for 2 hrs at RT. The dried sample was resuspended in 10 JlL 2.5% TFA in mQH20. The 
peptides were subsequently purified and concentrated using a CI8 ZipTip (Millipore) 
following the manufacturer's protocols. Samples eluted in 50% MeOHlO.I % TFA were 
submitted to Mr. Tim Jones in the Chemistry department for MALDI-TOF mass 
spectroscopy analysis. 
5.7.S. Phospholipid extraction from purified 6-his a-TTP 
The Bligh and Dyer phospholipid extraction procedure [227] was used to extract 
any E. coli phospholipids that might have bound to a-hTTP during expression and 
purification. To each milliliter of purified protein sample, 3.75 mL of CHCh: MeOH 
solvent mixture (1:2, v/v) was added and the sample vortexed. Then 1.25 mL CHCh was 
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added with vigorous vortex mixing. Another 1.25 mL mQH20 was added and the sample 
was vortexed. The resulting mixture was centrifuged at 1000 rpm in an IEC table top 
centrifuge for 5 minutes at room temperature to generate both organic and aqueous 
phases. The bottom organic phase was recovered with a Pasteur pipette, and dried under 
N2. A few drops of CHCb: MeOH solvent mixture was added to dissolve the dried lipid. 
The extracted lipids were separated on a silica plate in an organic solvent mixture 
(CHCb: MeOH:NH40Hl60:35:8). 
5.7.9. Factor Xa digestion of 6-His tag a-hTTP 
Purified 6-His tag a-hTTP was diluted in and dialyzed against reaction buffer (20 
mM Tris·HCI, 100 mM NaCI, pH 8.2) for 45 minutes at 4°C. At the end of dialysis, the 
protein solution was centrifuged at 5000 rpm for 5 min. Dialyzed 6-His a-hTTP at 0.5 
mg/ mL concentration was digested by 6 JlL Factor Xa (1 mg/mL) in the presence of 1 
mM CaCh at room temperature for a time course of 0, 1 hr, 2 hrs, 3 hrs and 4 hrs. 
Alternatively, on-column digestion was performed following the routine metal affinity 
purification procedure with the exception that, following the wash with 200 mM 
imidazole, the matrix was washed with 5 column volumes of the above reaction buffer to 
remove imidazole. Pure a-hTTP that was bound to the column was digested with 20 Jlg 
of Factor Xa added to the column in reaction buffer for 2 hours with gentle rocking. 
The cleaved a-hTTP was first eluted with reaction buffer, then 400 mM imidazole was 
applied to remove the undigested a-hTTP and the 39 kDa protein contaminant that were 
still bound to the column. 
5.7.10. pH stability of a-hTTP 
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The stability of 6-His a-hTTP at 10 /-lM was tested in two buffer systems at 
neutral and acidic pH. Both Buffer 1 (20 mM sodium citrate, and 150 mM NaCI, pH 
7.08) and Buffer 2 (250 mM sucrose, 150 mM KCl, 50 mM sodium citrate, 1 mM EDTA, 
pH 7.40) tested were at neutral pH. SEA buffer (250 mM sucrose, 50 mM sodium 
acetate and 150 mM KCI, pH 5.0) was the acidic buffer tested. Ligand binding and 
transfer were also tested at low pH with SEA buffer. 
5.8. Preparation and analysis of phospholipids 
5.8.1. LUVs and SUVs preparation 
Acceptor lipid vesicles for ligand transfer assays contained 97 mol% PC and 3 
mol% quencher TRITC-DHPE, unless otherwise specified. For anionic lipid vesicles, 15 
mol% of the indicated anionic phospholipids was incorporated in vesicle preparations. 
For DPI and vesicle filtration methods, 90% DOPC and 10% DOPS phospholipid 
vesicles were utilized. 
Lipids dissolved in chloroform were evaporated under a stream of N2 and the 
residual solvent removed by continued evaporation under vacuum at 0.5 mmHg. Lipid 
mixtures were rehydrated in SET buffer (250 mM sucrose, 100 mM KCI, 50 mM Tris, 1 
mM EDTA, pH 7.4). The lipid suspensions were vortexed and incubated for 30 min at 
room temperature before liposome preparation. Large unilamellar vesicles (LUV s) were 
prepared with a Liposofast mini-extruder (Avestin, Inc). Briefly, lipid suspension was 
extruded through a polycarbonate membrane (100 nm membrane was used for standard 
LUV preparation) using 15 passages to produce uniformly sized LUVs. Small 
unilamellar vesicles (SUVs) were prepared, following the procedure described by 
Schroeder and Thompson [228] with minor modifications. Briefly, lipid suspensions 
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were sonicated using a titanium microprobe and a W-375 cell disruptor (Heat Systems-
Ultrasonic, Inc.). Lipid samples were sonicated on ice for 45 min with an output setting 
level of 2.5 and 35% duty cycle. The resulting liposomes were centrifuged at 110,000 x 
g for 2 hours at 4°C with a 40Ti rotor to remove large vesicles and titanium particles. 
Following centrifugation, the supernatant was collected and stored at 4°C until use. To 
compare the difference between probe and bath sonicated SUV s, SUV s were also 
prepared by sonication for 45 min with a Branson bath sonicator Model 2510 (Branson, 
USA). SUVs produced from both methods appeared to behave similarly for a-TTP 
mediated tocopherol transfer. Ideally, the phosphorous assay should be performed to 
determine the phospholipid concentration after each vesicle preparation, and this was 
attempted. However, due to the presence of high sucrose content in the SET buffer, lipid 
samples turned black during acidic digestion at 190°C, therefore phosphorus assays can 
not be used regularly to assess phospholipid concentration. 
To confirm there was no loss of phospholipid due to extrusion or sonication, the 
phosphorous assay was performed initially with SET buffer without sucrose. The result 
showed that the lipid concentration remains the same before and after the preparation. 
For the experiments that directly compared vesicles of different sizes, the same 
rehydrated lipid mixture (multilamillar vesicles or MLVs) was used to generate SUVs or 
LUVs of the same stock concentration. A rough estimation of vesicle concentration 
could be determined based on the emission spectrum of the quencher TRITC-DHPE at 
approximately 575nm. Lipid samples were prepared freshly for each experiment. 
5.8.2. Quantification of phospholipid with lipid phosphorous assay 
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The concentration of phospholipids was determined according to the method 
published by Rouser et al. [229]. Typically, lipid samples were oxidized in 150 ilL of 
70% perchloric acid (HCI04) at 180 to 190°C in test tubes covered in foil paper. The 
samples were allowed to cool to R T. The sides of the tubes were rinsed with 900 mL 
mQH20, and the contents were mixed by gentle vortexing. An equal volume of 167 ilL 
of 2.5% (v/v) ammonium molybdate and 10% ascorbic acid were added to the sample 
tubes followed by vortex mixing. All samples were incubated for 15 minutes at 50°C 
and then cooled to RT before measuring the optical density (O.D.) at 820 nm. The 
sample should appear from grey-green to blue. Duplicate measurements of 0-50 nmoles 
Na2HP04 standards were run at the same time as other phospholipid samples. 
5.8.3. Dynamic light scattering analysis of the sizes of the SUVs and LUVs 
The sizes of vesicles were determined at two institutions. Wyatt Technology 
Corportation (Sant Barbara, CA) analyzed SUVs samples with a Dynamic Titan dynamic 
light scattering instrument called DynaPro Nanostar with a detection radius ranging from 
0.5 to 10000 nm at a laser wavelength of 660 nm. Similarly, the measurement of various 
sizes of vesicles at McMaster University was performed using a fixed angle quasi-elastic 
light-scattering instrument (QELS) with kind assistance from Mr. Yuguo Cui. 
5.9. Characteristics of fluorescent ligand NBD-a-Toc 
5.9.1. Equilibrium titration of a-hTTPwildtypeandmutants with NBD-a-Toc 
200 nM of wild type a-hTTP or the mutants was titrated in a 3 mL cuvette with 
serial additions of 2 ilL aliquots of NBD-a-Toc from concentrated stocks in EtOH. The 
final EtOH was kept below 2% (v/v) of the total volume. The mixture was allowed to 
equilibrate for 10 min with end-over-end rotation after each addition of NBD-a-Toc. 
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The fluorescence emission between 525 nm and 535 nm was recorded until the maximum 
fluorescence was achieved. The excitation wavelength was set at 466 nm. For 
competition experiments, a-hTTP (200 nM) was pre-incubated with NBD-a-Toc (1 ~M) 
for 15 minutes. 100 ~M Triton X-lOO was included in the SET buffer for competition 
experiments to provide a more thermodynamically favorable aqueous environment for 
such competition [163] to occur. Competitor such as cholesterol or natural tocopherol 
was added in incremental concentrations up to 40 ~M. 
5.9.2. Partitioning of NBD-a-Toc between a-hTTPand PC lipid vesicles 
The partition coefficient of NBD-a-Toc was measured following literature 
procedures for fluorescent fatty acid transfer from albumins and F ABPs to lipid vesicles 
[138, 177]. The method enables determination of the partition coefficient of a-hTTP for 
lipid vesicles by incubating the protein with a range of mole ratios of lipids. Briefly, 
several solutions were prepared containing a 10: 1 ratio of a-hTTP:NBD-a-Toc that 
assured the absence of appreciable amounts of free NBD-a-Toc. The samples were 
incubated for 15 min with gentle rotation at RT. To each of these solutions amounts of 
LUVs or SUVs containing TRITC-DHPE (measured as ~M total phospholipid) were 
added so that the final lipid concentration ranged from 50 to 400 ~M. The final protein 
and ligand concentrations were 1.0 ~M a-hTTP and 0.1 ~M NBD-a-Toc in SET buffer 
at pH 7.4. The resulting mixture was incubated for 15 min to allow NBD-a-Toc to 
equilibrate between a-hTTP and acceptor SUVs or LUVs. The fluorescence spectrum of 
NBD-a-Toc from 475nm to 600nm was recorded, and the changes in the fluorescence at 
520 nm were applied to the following equation [177, 230] to calculate the partition 
coefficients: 
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lILlF = l/Kp(lI.<:l.Fmax)(mol a-hTTP/mol PC) + lILlFmax EqnlO 
where LlF is the difference between the initial fluorescence of NBD-a-Toc bound to a-
hTTP and the fluorescence at a given proteinlPC ratio, and LlFmax is the maximum 
fluorescence change [128]. A plot of lILlF versus (lI.<:l.Fmax)(mol a-hTTP/mol PC) gave a 
straight line whose slope was equal to lIKp. 
5.9.3. Spectroscopic measurement of NBD-a-Toc concentration 
The absorbance of the diluted NBD-a-Toc in 1 m1 EtOH was measured at 469 nm 
in a UV spectrometer (Spectronic Genesys 2). The concentration was calculated using 
Beer-Lambert's law with an extinction coefficient of 17,602 cm-I·M-I. 
5.9.4. Reduction of NBD-a-Toc by Sodium Dithionite (Na2S204) 
NBD-a-Toc was reduced in a 500 f..lL quartz cuvette, by first incubating 2 f..lM a-
hTTP with 0.2 f..lM NBD-a-Toc for 15 minutes or until the fluorescent curve reached its 
plateau. Several additions of 50 f..lL of 1M sodium dithionite were added to the mixture 
as the change in fluorescence after each addition was monitored at 526 nm with an 
excitation wavelength of 466 nm. Alternatively, sodium dithionite reduction of NBD-a-
Toc was also tested in the presence of 800 f..lM bovine liver PC alone or in combination 
with 2 f..lM a-hTTP. 
5.10. Fluorescence resonance energy transfer (FRET assay) 
Experiments were performed using a Photon Technologies, Inc. QuantaMaster-
QM-200l-4 fluorometer (Photon Technologies International, Inc.) equipped with a SPF-
17 stopped flow device in order to determine the kinetics of NBD-a-Toc transfer. The 
excitation and emission wavelengths used were 466 nm and 526 nm respectively. The 
emission spectrum of NBD-a-Toc overlaps with the excitation spectrum of TRITC-
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DHPE, thus, upon mixing ofNBD-a-Toc containing donor and TRITC-DHPE containing 
acceptor vesicles, the fluorescence intensity decreases with time. Alternatively, for the 
reversed transfer of NBD-a-Toc, the extraction of NBD-a-Toc from the quencher 
containing vesicles exhibited a time dependent increase in the fluorescence intensity. All 
samples were prepared in SET buffer, and mixing of an equal volume of the donor and 
the acceptor samples was achieved by the SPF-17 stopped-flow device. All experiments 
were performed at RT. 
5.10.1. Spontaneous transfer of NBD-a-Toc from donor vesicles to acceptor vesicles. 
To study the inter-vesicular transfer of NBD-a-Toc, 1 mol% of NBD-a-Toc was 
incorporated into PC LUVs, and the transfer of NBD-a-Toc from PC LUVs to PC LUVs 
or SUV s was monitored. In one occasion, C9-anthroyloxy-a-tocopherol (AO-a-Toc) 
was tested in the place of NBD-a-Toc to determine the kinetics of a-Toc transfer when it 
is conjugate to a more hydrophobic anthroylxy label. 
5.10.2. Transfer of NBD- a-Toc from a-hTTP to acceptor vesicles. 
Standard transfer experiments were performed by incubating 0.45 OM NBD-a-
Toc with 4 OM O-hTTP for 15 minutes at RT prior to mixing the sample with 200 OM 
acceptor vesicles using the SPF-17 stopped-flow device. The final concentrations after 
mixing were 0.225 ~ NBD-a-Toc, 2 JlM a-hTTP and 100 JlM vesicles. The ratio of a-
hTTP to NBD-a-Toc was kept at 9: 1 to ensure that there was no free ligand and that the 
fluorescence signal was solely contributed by protein-bound NBD-a-Toc. A 50-fold 
molar excess of acceptor vesicle to a-hTTP was used based on the partition coefficient of 
NBD-a-Toc between a-hTTP and vesicles. The fluorescence quenching was monitored 
over time and the fluorescence values were normalized to the starting fluorescent 
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intensity of NBD-a-Toc bound to O-hTTP as 100%. Under our assay conditions, the rate 
of NBD-a-Toc transfer was best fitted with a single exponential decay equation (Eqn 11) 
provided by Prism software (version 5, GraphPad Software, Inc., El Camino Real, San 
Diego, CA) as: 
y = (Yo-Yinj)*exp( -k*X)+Yinj Eqn11 
where Yo is the initial fluorescence when NBD-a-Toc bound to a-hTTP, k is the rate 
constant, x is the half time for transfer, and Yinf is the remaining fluorescence signal after 
NBD-a-Toc has been transferred to the acceptor vesicle which in our case is 
approximately 55% of the original fluorescence signal. 
5.10.3. Pick up of NBD-a-Tocfrom membrane vesicles by a-hTTP 
The donor vesicles in the optimized pick-up assay consisted of 0.25 /lM NBD-a-
Toc in 50 /lM bovine liver PC plus 1.5 /lM quencher TRITC-DHPE. In some 
experiments, other lipids such as PS, LBPA and CL were also included in the donor 
vesicles to be tested at 5%, 10% and 15% of the total 50 /lM respectively. The baseline 
fluorescence at 526 nm was obtained by recording the initial fluorescence of the donor 
vesicles. Subsequently, NBD-a-Toc in the donor vesicles was extracted by mixing the 
donor vesicles with 2.5 /lM a-hTTP. The rate of NBD-a-Toc transfer to a-hTTP was 
best fitted with a single exponential association equation (Eqn 12) provided by Prism 
software 
y = Y max*(1-exp( -k*X» Eqn12 
where Ymax is the final fluorescence when the maximum amount of NBD-a-Toc is 
bound to a-hTTP, k is the rate constant for ligand binding, X is the time when half of the 
maximum NBD-a-toc is bound to a-hTTP. 
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5.11. Assessment of a-hTTP binding to phospholipid membranes 
Binding of a-hTTP to lipid membranes was investigated using two different 
methods. A size exclusion filtration method was utilized to study the effect of membrane 
curvature on the binding of the protein to lipid membranes by testing protein binding to 
both SUVs and LUVs. In contrast, a Dual Polarization Interferometric (DPI) method was 
used primarily to measure the interaction between a-hTTP and a more planar lipid 
bilayer on the surface of the DPI sensor chip rather than vesicles. 
5.11.1. Size exclusion filtration method 
The binding of a-hTTP to lipid vesicles was performed similar to the previously 
published method by Huang et al. [207]. Wild type or mutant a-hTTP (31.5 f..lg) was 
incubated with increasing concentrations of SUVs or LUVs in a total of 200 f..lL SET 
buffer with gentle rocking for 30 minutes at room temperature. The samples were 
subsequently loaded onto pre-wet YM-100 microcon filters with the molecular weight 
cutoff at 100 kDa. These samples were then centrifuged at 10,000 x g in a bench top 
microcentrifuge for 20 minutes. The filters were washed once with 100 f..lL SET buffer, 
where the flow-through represents the free protein fraction that failed to bind to lipid 
vesicles. The microcon filters were inverted and washed three times with 100 f..ll SET 
buffer containing 150 f..lM Triton X-100 to collect the vesicle bound a-hTTP fractions . 
Each wash was completed by centrifugation at 3000 x g for 5 minutes. The samples were 
then separated on precast 10% SDS-PAGE mini gels and visualized after staining with 
Colloidal Coomassie G-250 overnight. After the gel destaining, the intensity of each 
protein band was quantified with Scion Image software (developed by Scion Corp.). The 
data analysis was completed with Prism software by plotting band intensities of each a-
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hTTP sample versus its concentration. A blank lane of the gel was taken as background 
control. 
5.11.2. Dual Polarization Interferometric assessment (DPI) 
The Analight Bio 200 dual polarization interferometer (Farfield Sensors Ltd, 
Manchester, UK) was used to study the association of a-hTTP to planar lipid bilayer 
containing 10% DOPS and 90% DOPC assembled on the DPI chip surface. DPI has been 
characterized in depth as a valuable quantitative tool to study protein conformation or 
protein and lipid interaction in vitro since DPI measures the changes in the mass, 
thickness and refractive index of the layer adsorbed on the chip's surface. Thus, when a 
protein is adsorbed on the surface of the sensor chip, the protein's behavior or 
interactions can be followed under different conditions [231, 232]. Due to the hyper-
sensitive detection in the changes on the sensor surface, all solutions were degassed for at 
least 30 minutes to remove any fine bubbles prior to use. Running buffer (10 mM 
potassium phosphate, 137 mM NaCl, pH 7.4) was used to dilute a-hTTP samples and 
prepare LUV s. All experiments were performed at 20°C. The instrument was first 
loaded with an unmodified silicon oxynitride sensor chip, then calibrated with 80% (v/v) 
ethanol and 20% (v/v) mQH20. Once a stable baseline was established, 100 nm 
DOPSIDOPC (1 :9) vesicles were passed over the sensor chip at a flow rate of 25 J.LL per 
minutes for 8 minutes. The vesicles ruptured and a stable bilayer was attained 
approximately 5 minutes after each injection. At the end of lipid injection, buffer was 
passed over the lipid bilayer for approximately 4 minutes at the rate of 50 J.LL per minute 
to remove any extra lipid that was deposited on the top of lipid bilayer. a-hTTP at the 
desired concentration was then injected over the lipid bilayer at a rate of 25 J.LL per 
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minute for 8 minutes. At the end of the injection, the protein layer was washed with 
buffer for a few minutes at 50 JlL per minute to remove nonspecific ally bound protein 
until a stable reading was obtained. To regenerate the sensor chip for another run of 
testing, existing lipid and protein layers were stripped with 150 JlL each of 2% SDS 
followed by 50% isopropyl alcohol. The procedure was repeated until the entire set of 
the data was collected. The data collected from the first 450 seconds of a-hTTP 
injection was resolved and fitted to a one site binding equation to calculate the maximum 
mass of protein (Bmax) deposited onto the lipid bilayer from a plot of the layer's mass 
versus time. Occasionally, the maximum binding data (Bmax) were plotted against 
protein concentrations to determine the binding affinity of the a-hTTP mutants to the 
lipid bilayer according to the one phase association equation. 
5.12. Software 
Deep View & PyMol 
Both software programs were used to visualize and create the crystal structure 
presentations of human a-hTTP. The coordinates for the crystal structures used in this 
study are: triton-XlOO bound a-hTTP (pdb: IOIP, IOIZ) and a-tocopherol bound holo-a-
hTTP (pdb: lR5L). 
Scion Image software 
This program was exploited to quantify the intensity of protein bands obtained 
from the size exclusion filtration vesicle binding experiments. 
Bioedit 
Bioedit was used mainly to analyze the presence of the targeted mutations by 
generating a sequence alignment of the mutants and wild type a-hTTP. It was also used 
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to generate the restriction map and to translate nucleotide sequences into protein 
sequences. 
Graphpad Prism version 5 
Prism software was utilized to characterize the kinetics of lipid binding and ligand 
transfer by a-hTTP using non-linear regression analysis (for a one site binding model). It 
was also occasionally used to perform T -tests to determine whether there was significant 
difference between two or more data sets. 
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7. APPENDIX I 
MALDI-TOF Spectrum Analysis Report 
Note: Individual ions scores> 48 indicate identity or extensive homology (p<0.05). 
1.) Analysis of (l-TTP control digest: 
Query Peptide Observed Mr(expt) Mr(calc) Score Rank 
R.EAGVPLAPLPLTDSFLLR.F 1908.9569 1907.9496 1908.0720 65 1 
Best match: S54352 Mass: 31844 Score: 72.09 human alpha-tocopherol transfer protein 
Matched peptide is underlined in Bold 
1 MAEARSQPSA GPQLNALPDH SPLLQPGLAA LRRRAREAGV PLAPLPLTDS FLLRFLRARD 
61 FDLDLAWRLL KNYYKWRAEC PEISADLHPR SIIGLLKAGY HGVLRSRDPT GSKVLIYRIA 
121 HWDPKVFTAY DVFRVSLITS ELIVQEVETQ RNGlKAIFDL EGWQFSHAFQ ITPSVAKKIA 
181 AVLTDSFPLK VRGIHLINEP VIFHAVFSMI KPFLTEKIKE RIHMHGNNYK QSLLQHFPDI 
241 LPLEYGGEEF SMEDICQEWT NFIMKSEDYL SSISESIQ 
Peak Mass Intensity 
1 112.280 4437.933 
3 175.328 20055.8lO 
9 258.301 6171.498 
11 282.377 12015.834 
12 288.369 2021.502 
16 329.347 3450.440 
19 357.336 4467.962 
26 454.342 1832.846 
31 539.433 905.425 
32 548.471 2536.627 
33 567.442 578.208 
34 6lO.337 436.940 
37 635 .515 19844.868 
38 638.449 1391.773 
45 750.553 2118.825 
49 851.563 748.172 
55 1061.708 1480.959 
62 1271.951 869.838 
64 1343.021 543.055 
65 1456.024 228.629 
66 1553.068 380.997 
68 1709.241 217.056 
70 1780.247 480 . 779 
75 1891.583 2288 . 227 
76 1908 . 948 9052 . 963 
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Calculated Masses for the peptide digest: EAGVPLAPLPLTDSFLLR 
N-Term Ion a b y C-Term Ion 
1 E 102.055 130.050 175.119 18 R 
2 A 173.092 201.087 288.203 17 L 
3 G 230.114 258.108 401.287 16 L 
4 V 329.182 357.1777 548.355 15 F 
5 P 426.235 454.230 635.388 14 S 
6 L 539.319 567.314 750.414 13 D 
7 A 610.356 638.351 851.462 12 T 
8 P 707.409 735.404 964.546 11 L 
9 L 820.493 848.488 1061.599 10 P 
10 P 917.545 945.540 1174.683 9 L 
11 L 1030.630 1058.624 1271.736 8 P 
12 T 1131.677 1159.672 1342.773 7 A 
13 D 1246.704 1274.699 1455.857 6 L 
14 S 1333.736 1361.731 1552.910 5 P 
15 F 1480.805 1508.800 1651.978 4 V 
16 L 1593.889 1621.884 1709.000 3 G 
17 L 1706.973 1734.968 1780.037 2 A 
18 R 1863.074 1891.069 1909.079 1 E 
2.) Analysis of 39 kD E. coli unknown digest: 
Best match: MMECF Mass: 39309 Score: 89 
outer membrane porin ompF precursor - Escherichia coli (strain K-12) 
Query Peptide Observed Mr(expt) Mr(calc) Score Rank 
K.YDANNIYLAANYGETR.N 1847.9950 1846.9877 1846.8485 89 1 
Matched pep tides are underlined in Bold 
1 MMKRNlLAVI VPALLVAGTA NAAEIYNKDG NKVDLYGKAV GLHYFSKGNG ENSYGGNGDM 
61 TYARLGFKGE TQINSDLTGY GQWEYNFQGN NSEGADAQTG NKTRLAFAGL KYADVGSFDY 
121 GRNYGVVYDA LGYTDMLPEF GGDTAYSDDF FVGRVGGVAT YRNSNFFGLV DGLNFAVQYL 
181 GKNERDTARR SNGDGVGGSI SYEYEGFGIV GAYGAADRTN LQEESSLGKG KKAEQWATGL 
241 KYDANNIYLA ANYGETRNAT PITNKFTNTS GFANKTQDVL LVAQYQFDFG LRPSIAYTKS 
301 KAKDVEGIGD VDLVNYFEVG ATYYFNKNMS TYVDYIINQI DSDNKLGVGS DDTVAVGIVY 
361 QF 
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Calculated Masses for the peptide digest: KYDANNIYLAANYGETRN 
N-Term Ion a b y C-Term Ion 
1 y 136.076 164.071 175.119 16 R 
2 D 251.103 279.098 276.167 15 T 
3 A 322.140 350.135 405.209 14 E 
4 N 436.183 464.178 462.231 13 G 
5 N 550.226 578.221 625.294 12 Y 
6 I 663.310 691.305 739.337 11 N 
7 Y 826.373 854.368 810.374 10 A 
8 L 939.457 967.452 881.411 9 A 
9 A 1010.494 1038.489 994.495 8 L 
10 A 1081.531 1109.526 1157.559 7 Y 
11 N 1195.574 1223.569 1270.643 6 I 
12 Y 1358.638 1386.632 1384.686 5 N 
13 G 1415.659 1443.654 1498.728 4 N 
14 E 1544.702 1572.695 1569.766 3 A 
15 T 1645.749 1673.744 1684.793 2 D 
16 R 1801.850 1829.845 1847.856 1 Y 
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7. APPENDIX II 
Nucleotide Sequence of Hydrophobic Mutants 
Note: Mutated nucleotides are the underlined bold fonts 
.... 1··· ·1 · ... I· ... I .... I· ... I .... I .... I . ... I · ... I 
10 20 30 40 50 
84-F165A CCNNN-----
----,..,----- ----NNNNNN N---------
----------
44-F165D C--------- --- .... ------
---------- ----------
--NNNNNNNN 
19-F169D NNNNN-----
----------
----NNNNNN NN--------
----------
86-1202A N---------
---------- ----------
----...,...,...,---
------NNNN 
67-1202D 
--------_ .... 
---------- ---------- ----------
---NNNNNNN 
91-V206A 
---------- ---------- ---------- ----------
--NN-NNNNN 
92-V206D C---------
---------- ---------- ----------
----NNNNNN 
87-M209A 
---------- ---------- ---------- ----------
----CNNNNN 
45-F165D/M C---------
---------- ---------- ----------
---NNNNNNN 
69-1202D/M NN--------
---------- ---------- ----------
----NNNNNN 
47-M264D 
---------- ---------- ---------- ----------
----CNNNNN 
hTTP D4948 gcagcagcgg cggcgggcat ggcagaggcg ega tee cage cctcggcggg 
.... I .... I 
· ... I···· I .... I .... I .... I··· . I .... I .... I 
60 70 80 90 100 
84-F165A 
-----NNNCN CACGCGCTAC CGGACCACTC TCCGTTGCTG CAGCCGGGCC 
44-F165D NNNNNNNNCN NNCGCGCTAC CGGACCACTC TCCGTTGCTG CAGCCGGGCC 
19-F169D 
---------N NACGCGCTAC CGGACCACTC TCCGTTGCTG CAGCCGGGCC 
86-1202A NNNNNNNNNN NNCGCGCTAC CGGACCACTC TCCGTTGCTG CAGCCGGGCC 
67-1202D NNNNNNNNCT NNCGCGCTAC CGGACCNCTC TCCGTTGCTG CAGCCGGGCC 
91-V206A NNNNNCNNCT CACGCGCTAC CGGACCACTC TCCGTTGCTG CAGCCGGGCC 
92-V206D NNNNNNNNCT NNCGCGCTAC CGGACCACTC TCCGTTGCTG CAGCCGGGCC 
87-M209A NNNNNCNNCT CACGCGCTAC CGGACCACTC TCCGTTGCTG CAGCCGGGCC 
45-F165D/M NNNNNCNNCT CACGCGCTAC CGGACCACTC TCCGTTGCTG CAGCCGGGCC 
69-1202D/M NNNNNNNNNT NNCGCGCTAC CGGACCACTC TCCGTTGCTG CAGCCGGGCC 
47-M264D NNNNNNNNCT NNCGCGCTAC CGGACCACTC TCCGTTGCTG CAGCCGGGCC 
hTTP D4948 gccgcagctc aacgcgctac cggaccactc tccgttgctg cagccgggcc 
.... I ... ·1 · ... I· ... I ... · 1· ... I .... I···· I .... I· . ··1 
110 120 130 140 150 
84-F165A TGGCGGCGCT GCGGCgccgg gcccgGGAAG CTGGCGTCCC GCTCGCGCCG 
44-F165D TGGCGGCGCT GCGGCGCCGG GCCCGGGAAG CTGGCGTCCC GCTCGCGCCG 
19-F169D TGGcGGCGCT GCGGCGCCGG GCCCGGGAAG CTGGCGTCCC GCTCGCGCCG 
86-1202A TGGCGGCGCT GCGGCGCCGG GCCCGGGAAG CTGGCGTCCC GCTCGCGCCG 
67-1202D TGGCGGCGCT GCGGCGCCGG GCCCGGGAAG CTGGCGTCCC GCTCGCGCCG 
91-V206A TGGCGGCGCT GCGGCGCCGG GCCCGGGAAG CTGGCGTCCC GCTCGCGCCG 
92-V206D TGGCGGCGCT GCGGCGCCGG GCCCGGGAAG CTGGCGTCCC GCTCGCGCCG 
87-M209A TGGCGGCGCT GCGGCGCCGG GCCCGGGAAG CTGGCGTCCC GCTCGCGCCG 
45-F165D/M TGGCGGCGCT GCGGCGCCGG GCCCGGGAAG CTGGCGTCCC GCTCGCGCCG 
69-1202D/M TGGCGGCGCT GCGGCGCCGG GCCCGGGAAG CTGGCGTCCC GCTCGCGCCG 
47-M264D TGGCGGCGCT GCGGCGCCGG GCCCGGGAAG CTGGCGTCCC GCTCGCGCCG 
hTTP D4948 tggcggcgct gcggcgccgg gcccgggaag ctggcgtccc gctcgcgccg 
.... I .. ··1 · ... I· ... I ... ·1·· ··1 .... I·· . ·1 .... I· . ··1 
160 170 180 190 200 
84-F165A CTGCCGCTCA cCgACTCCTT CCTGCTGCGG TTCCTGCGCG CCCGGGATTT 
44-F165D CTGCCGCTCA CCGACTCCTT CCTGCTGCGG TTCCTGCGCG CCCGGGATTT 
19-F169D CTGCCGCTCA CCGACTCCTT CCTGCTGCGG TTCCTGCGCG CCCGGGATTT 
86-1202A CTGCCGCTCA CCGACTCCTT CCTGCTGCGG TTCCTGCGCG CCCGGGATTT 
170 
67-1202D CTGCCGCTCA CCGACTCCTT CCTGCTGCGG TTCCTGCGCG CCCGGGATTT 
91-V206A CTGCCGCTCA CCGACTCCTT CCTGCTGCGG TTCCTGCGCG CCCGGGATTT 
92-V206D CTGCCGCTCA CCGACTCCTT CCTGCTGCGG TTCCTGCGCG CCCGGGATTT 
87-M209A CTGCCGCTCA CCGACTCCTT CCTGCTGCGG TTCCTGCGCG CCCGGGATTT 
45-F165D/M CTGCCGCTCA CCGACTCCTT CCTGCTGCGG TTCCTGCGCG CCCGGGATTT 
69-1202D/M CTGCCGCTCA CCGACTCCTT CCTGCTGCGG TTCCTGCGCG CCCGGGATTT 
47-M264D CTGCCGCTCA CCGACTCCTT CCTGCTGCGG TTCCTGCGCG CCCGGGATTT 
hTTP D4948 ctgccgctca ccgactcctt cctgctgcgg ttcctgcgcg cccgggattt 
. . .. 1 .... 1 ... · 1 .. . ·1 . . .. 1 ... · 1 . ... I ··· ·1 ... ·1· · · ·1 
210 220 230 240 250 
84-F165A CGATCTGGAC CTGGCCTGGC GGTTACTAAA AAACTATTAT AAGTGGAGAG 
44-F165D CGATCTGGAC CTGGCCTGGC GGTTACTAAA AAACTATTAT AAGTGGAGAG 
19-F169D CGATCTGGAC CTGGCCTGGC GGTTACTAAA AAACTATTAT AAGTGGAGAG 
86-1202A CGATCTGGAC CTGGCCTGGC GGTTACTAAA AAACTATTAT AAGTGGAGAG 
67 - 1202D CGATCTGGAC CTGGCCTGGC GGTTACTAAA AAACTATTAT AAGTGGAGAG 
91-V206A CGATCTGGAC CTGGCCTGGC GGTTACTAAA AAACTATTAT AAGTGGAGAG 
92-V206D CGATCTGGAC CTGGCCTGGC GGTTACTAAA AAACTATTAT AAGTGGAGAG 
87 - M209A CGATCTGGAC CTGGCCTGGC GGTTACTAAA AAACTATTAT AAGTGGAGAG 
45-F165D/M CGATCTGGAC CTGGCCTGGC GGTTACTAAA AAACTATTAT AAGTGGAGAG 
69-1202D/M CGATCTGGAC CTGGCCTGGC GGTTACTAAA AAACTATTAT AAGTGGAGAG 
47-M264D CGATCTGGAC CTGGCCTGGC GGTTACTAAA AAACTATTAT AAGTGGAGAG 
hTTP D4948 cgatctggac ctggcctggc ggttactaaa aaactattat aagtggagag 
.... 1 .... 1 .. . · 1 ... · 1 . ··· 1·· .. 1 ···· 1· .. · 1 · ... I · . ·· 1 
260 270 280 290 300 
84 - F165A CAGAATGTCC AGAAATAAGT GCAGATCTAC ACCCTAGAAG TATTATTGGC 
44-F165D CAGAATGTCC AGAAATAAGT GCAGATCTAC ACCCTAGAAG TATTATTGGC 
19-F169D CAGAATGTCC AGAAATAAGT GCAGATCTAC ACCCTAGAAG TATTATTGGC 
86-1202A CAGAATGTCC AGAAATAAGT GCAGATCTAC ACCCTAGAAG TATTATTGGC 
67 - 1202D CAGAATGTCC AGAAATAAGT GCAGATCTAC ACCCTAGAAG TATTATTGGC 
91-V206A CAGAATGTCC AGAAATAAGT GCAGATCTAC ACCCTAGAAG TATTATTGGC 
92-V206D CAGAATGTCC AGAAATAAGT GCAGATCTAC ACCCTAGAAG TATTATTGGC 
87-M209A CAGAATGTCC AGAAATAAGT GCAGATCTAC ACCCTAGAAG TATTATTGGC 
45-F165D/M CAGAATGTCC AGAAATAAGT GCAGATCTAC ACCCTAGAAG TATTATTGGC 
69-1202D/M CAGAATGTCC AGAAATAAGT GCAGATCTAC ACCCTAGAAG TATTATTGGC 
47-M264D CAGAATGTCC AGAAATAAGT GCAGATCTAC ACCCTAGAAG TATTATTGGC 
hTTP D4948 cagaatgtcc agaaataagt gcagatctac accctagaag tattattggc 
. . . . I· .. · 1 ... ·1 . ... 1 ... · 1· .. · 1 . . .. I · . . ·1 · ... I ·· ··1 
310 320 330 340 350 
84-F165A CTCCTAAAGG CTGGCTACCA TGGAGTCCTG AGATCCAGGG ATCCCACTGG 
44-F165D CTCCTAAAGG CTGGCTACCA TGGAGTCCTG AGATCCAGGG ATCCCACTGG 
19-F169D CTCCTAAAGG CTGGCTACCA TGGAGTCCTG AGATCCAGGG ATCCCACTGG 
86-1202A CTCCTAAAGG CTGGCTACCA TGGAGTCCTG AGATCCAGGG ATCCCACTGG 
67 - 1202D CTCCTAAAGG CTGGCTACCA TGGAGTCCTG AGATCCAGGG ATCCCACTGG 
91-V206A CTCCTAAAGG CTGGCTACCA TGGAGTCCTG AGATCCAGGG ATCCCACTGG 
92 - V206D CTCCTAAAGG CTGGCTACCA TGGAGTCCTG AGATCCAGGG ATCCCACTGG 
87-H209A CTCCTAAAGG CTGGCTACCA TGGAGTCCTG AGATCCAGGG ATCCCACTGG 
45-F165D/M CTCCTAAAGG CTGGCTACCA TGGAGTCCTG AGATCCAGGG ATCCCACTGG 
69 - 1202D/M CTCCTAAAGG CTGGCTACCA TGGAGTCCTG AGATCCAGGG ATCCCACTGG 
47-M264D CTCCTAAAGG CTGGCTACCA TGGAGTCCTG AGATCCAGGG ATCCCACTGG 
hTTP D4948 ctcctaaagg c t ggctacca tggagtcctg agatccaggg atcccactgg 
. . . · 1· .. · 1 ... ·1· · .. 1 .. .. I· ... 1 .. . ·1· .. ·1 · ... I · . · ·1 
360 370 380 390 400 
84 - F165A CAGCAAAGTT CTTATTTACA GAATCGCACA CTGGGACCCC AAAGTTTTTA 
171 
44-F165D CAGCAAAGTT CTTATTTACA GAATCGCACA CTGGGACCCC AAAGTTTTTA 
19-F169D CAGCAAAGTT CTTATTTACA GAATCGCACA CTGGGACCCC AAAGTTTTTA 
86-I202A CAGCAAAGTT CTTATTTACA GAATCGCACA CTGGGACCCC AAAGTTTTTA 
67-I202D CAGCAAAGTT CTTATTTACA GAATCGCACA ,CTGGGACCCC AAAGTTTTTA 
91-V206A CAGCAAAGTT CTTATTTACA GAATCGCACA CTGGGACCCC AAAGTTTTTA 
92-V206D CAGCAAAGTT CTTATTTACA GAATCGCACA CTGGGACCCC AAAGTTTTTA 
87-M209A CAGCAAAGTT CTTATTTACA GAATCGCACA CTGGGACCCC AAAGTTTTTA 
45-F165D/M CAGCAAAGTT CTTATTTACA GAATCGCACA CTGGGACCCC AAAGTTTTTA 
69-I202D/M CAGCAAAGTT CTTATTTACA GAATCGCACA CTGGGACCCC AAAGTTTTTA 
47-M264D CAGCAAAGTT CTTATTTACA GAATCGCACA CTGGGACCCC AAAGTTTTTA 
hTTP D4948 cagcaaagtt cttatttaca gaatcgcaca ctgggacccc aaagttttta 
.... I .... I 
.... 1···· 1 .... 1····1 .... 1····1 .... 1····1 
410 420 430 440 450 
84-F165A CAGCTTATGA CGTATTTCGA GTAAGTCTAA TCACATCCGA GCTTATTGTA 
44-F165D CAGCTTATGA CGTATTTCGA GTAAGTCTAA TCACATCCGA GCTTATTGTA 
19-F169D CAGCTTATGA CGTATTTCGA GTAAGTCTAA TCACATCCGA GCTTATTGTA 
86-I202A CAGCTTATGA CGTATTTCGA GTAAGTCTAA TCACATCCGA GCTTATTGTA 
67-I202D CAGCTTATGA CGTATTTCGA GTAAGTCTAA TCACATCCGA GCTTATTGTA 
91-V206A CAGCTTATGA CGTATTTCGA GTAAGTCTAA TCACATCCGA GCTTATTGTA 
92-V206D CAGCTTATGA CGTATTTCGA GTAAGTCTAA TCACATCCGA GCTTATTGTA 
87-M209A CAGCTTATGA CGTATTTCGA GTAAGTCTAA TCACATCCGA GCTTATTGTA 
45-F165D/M CAGCTTATGA CGTATTTCGA GTAAGTCTAA TCACATCCGA GCTTATTGTA 
69-I202D/M CAGCTTATGA CGTATTTCGA GTAAGTCTAA TCACATCCGA GCTTATTGTA 
47-M264D CAGCTTATGA CGTATTTCGA GTAAGTCTAA TCACATCCGA GCTTATTGTA 
hTTP D4948 cagcttatga cgtatttcga gtaagtctaa tcacatccga gcttattgta 
.. ··1····1 .... 1····1 .. ··1···· 1 .... 1····1 .... 1····1 
460 470 480 490 500 
84-F165A CAGGAGGTAG AAACTCAGCG GAATGGAATC AAGGCTATCT TTGATCTGGA 
44-F165D CAGGAGGTAG AAACTCAGCG GAATGGAATC AAGGCTATCT TTGATCTGGA 
19-F169D CAGGAGGTAG AAACTCAGCG GAATGGAATC AAGGCTATCT TTGATCTGGA 
86-I202A CAGGAGGTAG AAACTCAGCG GAATGGAATC AAGGCTATCT TTGATCTGGA 
67-I202D CAGGAGGTAG AAACTCAGCG GAATGGAATC AAGGCTATCT TTGATCTGGA 
91-V206A CAGGAGGTAG AAACTCAGCG GAATGGAATC AAGGCTATCT TTGATCTGGA 
92-V206D CAGGAGGTAG AAACTCAGCG GAATGGAATC AAGGCTATCT TTGATCTGGA 
87-M209A CAGGAGGTAG AAACTCAGCG GAATGGAATC AAGGCTATCT TTGATCTGGA 
45-F165D/M CAGGAGGTAG AAACTCAGCG GAATGGAATC AAGGCTATCT TTGATCTGGA 
69-I202D/M CAGGAGGTAG AAACTCAGCG GAATGGAATC AAGGCTATCT TTGATCTGGA 
47-M264D CAGGAGGTAG AAACTCAGCG GAATGGAATC AAGGCTATCT TTGATCTGGA 
hTTP D4948 caggaggtag aaactcagcg gaatggaatc aaggctatct ttgatctgga 
.... 1····1 .... 1····1 .... 1····1 .... 1····1 .... 1····1 
510 520 530 540 550 
84-F165A AGGTTGGCAG GCTTCTCATG CTTTTCAAAT CACTCCATCC GTAGCCAAGA 
44-F165D AGGTTGGCAG GATTCTCATG CTTTTCAAAT CACTCCATCC GTAGCCAAGA 
19-F169D AGGTTGGCAG TTTTCTCATG CTGATCAAAT CACTCCATCC GTAGCCAAGA 
86-I202A AGGTTGGCAG TTTTCTCATG CTTTTCAAAT CACTCCATCC GTAGCCAAGA 
67-I202D AGGTTGGCAG TTTTCTCATG CTTTTCAAAT CACTCCATCC GTAGCCAAGA 
91-V206A AGGTTGGCAG TTTTCTCATG CTTTTCAAAT CACTCCATCC GTAGCCAAGA 
92-V206D AGGTTGGCAG TTTTCTCATG CTTTTCAAAT CACTCCATCC GTAGCCAAGA 
87-M209A AGGTTGGCAG TTTTCTCATG CTTTTCAAAT CACTCCATCC GTAGCCAAGA 
45-F165D/M AGGTTGGCAG GATTCTCATG CTTTTCAAAT CACTCCATCC GTAGCCAAGA 
69-I202D/M AGGTTGGCAG TTTTCTCATG CTTTTCAAAT CACTCCATCC GTAGCCAAGA 
47-M264D AGGTTGGCAG TTTTCTCATG CTTTTCAAAT CACTCCATCC GTAGCCAAGA 
hTTP D4948 aggttggcag ttttctcatg cttttcaaat cactccatcc gtagccaaga 
172 
· .. · 1·· · ·1 .. .. 1· ··· 1 .. .. 1· ···1 .... 1· · · · 1 .... 1· ···1 
560 570 580 590 600 
84-F165A AGATTGCTGC TGTACTTACG GATTCATTTC , CATTGAAAGT TCGTGGCATC 
44-F165D AGATTGCTGC TGTACTTACG GATTCATTTC CATTGAAAGT TCGTGGCATC 
19-F169D AGATTGCTGC TGTACTTACG GATTCATTTC CATTGAAAGT TCGTGGCATC 
86-1202A AGATTGCTGC TGTACTTACG GATTCATTTC CATTGAAAGT TCGTGGCATC 
67-1202D AGATTGCTGC TGTACTTACG GATTCATTTC CATTGAAAGT TCGTGGCATC 
91-V206A AGATTGCTGC TGTACTTACG GATTCATTTC CATTGAAAGT TCGTGGCATC 
92 - V206D AGATTGCTGC TGTACTTACG GATTCATTTC CATTGAAAGT TCGTGGCATC 
87-M209A AGATTGCTGC TGTACTTACG GATTCATTTC CATTGAAAGT TCGTGGCATC 
45-F165D/M AGATTGCTGC TGTACTTACG GATTCATTTC CATTGAAAGT TCGTGGCATC 
69-1202D/M AGATTGCTGC TGTACTTACG GATTCATTTC CATTGAAAGT TCGTGGCATC 
47-M264D AGATTGCTGC TGTACTTACG GATTCATTTC CATTGAAAGT TCGTGGCATC 
hTTP D4948 agattgctgc tgtacttacg gattcatttc cattgaaagt tcgtggcatc 
.... 1· · · · 1 .... 1····1 .... 1·· · · 1 .. ··1· · · · 1 .. .. 1· · ·· 1 
610 620 630 640 650 
84-F165A CATTTGATAA ATGAACCAGT AATTTTCCAT GCTGTCTTTT CCATGATCAA 
44-F165D CATTTGATAA ATGAACCAGT AATTTTCCAT GCTGTCTTTT CCATGATCAA 
19 - F169D CATTTGATAA ATGAACCAGT AATTTTCCAT GCTGTCTTTT CCATGATCAA 
86-1202A CATTTGATAA ATGAACCAGT AGCTTTCCAT GCTGTCTTTT CCATGATCAA 
67-1202D CATTTGATAA ATGAACCAGT AGATTTCCAT GCTGTCTTTT CCATGATCAA 
91-V206A CATTTGATAA ATGAACCAGT AATTTTCCAT GCTGCCTTTT CCATGATCAA 
92-V206D CATTTGATAA ATGAACCAGT AATTTTCCAT GCTGACTTTT CCATGATCAA 
87-M209A CATTTGATAA ATGAACCAGT AATTTTCCAT GCTGTCTTTT CCGCGATCAA 
45-F165D/M CATTTGATAA ATGAACCAGT AATTTTCCAT GCTGTCTTTT CCGATATCAA 
69-1202D/M CATTTGATAA ATGAACCAGT AGATTTCCAT GCTGTCTTTT CCGATATCAA 
47-M264D CATTTGATAA ATGAACCAGT AATTTTCCAT GCTGTCTTTT CCATGATCAA 
hTTP D4948 catttgataa atgaaccagt aattttccat gctgtctttt ccatgatcaa 
.. .. 1··· · 1 .... 1·· · ·1 .... 1···· 1 .... 1· ··· 1 · .. · 1····1 
660 670 680 690 700 
84-F165A ACCATTCCTG ACTGAAAAAA TTAAGGAACG GATTCACATG CATGGGAACA 
44-F165D ACCATTCCTG ACTGAAAAAA TTAAGGAACG GATTCACATG CATGGGAACA 
19-F169D ACCATTCCTG ACTGAAAAAA TTAAGGAACG GATTCACATG CATGGGAACA 
86-1202A ACCATTCCTG ACTGAAAAAA TTAAGGAACG GATTCACATG CATGGGAACA 
67-1202D ACCATTCCTG ACTGAAAAAA TTAAGGAACG GATTCACATG CATGGGAACA 
91-V206A ACCATTCCTG ACTGAAAAAA TTAAGGAACG GATTCACATG CATGGGAACA 
92-V206D ACCATTCCTG ACTGAAAAAA TTAAGGAACG GATTCACATG CATGGGAACA 
87-M209A ACCATTCCTG ACTGAAAAAA TTAAGGAACG GATTCACATG CATGGGAACA 
45-F165D/M ACCATTCCTG ACTGAAAAAA TTAAGGAACG GATTCACATG CATGGGAACA 
69-1202D/M ACCATTCCTG ACTGAAAAAA TTAAGGAACG GATTCACATG CATGGGAACA 
47-M264D ACCATTCCTG ACTGAAAAAA TTAAGGAACG GATTCACATG CATGGGAACA 
hTTP D4948 accattcctg actgaaaaaa ttaaggaacg gattcacatg catgggaaca 
.... 1· ··· 1 .... 1· ·· · 1 .... 1··· ·1 .... 1· ·· · 1 · .. · 1·· · · 1 
710 720 730 740 750 
84-F165A ACTACAAACA AAGCTTGCTT CAGCATTTCC CAGACATTCT TCCTCTGGAA 
44-F165D ACTACAAACA AAGCTTGCTT CAGCATTTCC CAGACATTCT TCCTCTGGAA 
19-F169D ACTACAAACA AAGCTTGCTT CAGCATTTCC CAGACATTCT TCCTCTGGAA 
86-1202A ACTACAAACA AAGCTTGCTT CAGCATTTCC CAGACATTCT TCCTCTGGAA 
67-1202D ACTACAAACA AAGCTTGCTT CAGCATTTCC CAGACATTCT TCCTCTGGAA 
91-V206A ACTACAAACA AAGCTTGCTT CAGCATTTCC CAGACATTCT TCCTCTGGAA 
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92-V206D ACTACAAACA AAGCTTGCTT CAGCATTTCC CAGACATTCT TCCTCTGGAA 
87-M209A ACTACAAACA AAGCTTGCTT CAGCATTTCC CAGACATTCT TCCTCTGGAA 
45-F165D/M ACTACAAACA AAGCTTGCTT CAGCATTTCC CAGACATTCT TCCTCTGGAA 
69-1202D/M ACTACAAACA AAGCTTGCTT CAGCATTTCC CAGACATTCT TCCTCTGGAA 
47-M264D ACTACAAACA AAGCTTGCTT CAGCATTTCC CAGACATTCT TCCTCTGGAA 
hTTP D4948 actacaaaca aagcttgctt cagcatttcc cagacattct tcctctggaa 
... · 1· · .. 1 · ... I· ... 1 .. . ·1· ···1 .... 1 ... · 1 · .. ·1· . ··1 
760 770 780 790 800 
84-F165A TATGGTGGTG AAGAATTCTC CATGGAGGAC ATTTGTCAGG AATGGACAAA 
44-F165D TATGGTGGTG AAGAATTCTC CATGGAGGAC ATTTGTCAGG AATGGACAAA 
19-F169D TATGGTGGTG AAGAATTCTC CATGGAGGAC ATTTGTCAGG AATGGACAAA 
86-1202A TATGGTGGTG AAGAATTCTC CATGGAGGAC ATTTGTCAGG AATGGACAAA 
67-1202D TATGGTGGTG AAGAATTCTC CATGGAGGAC ATTTGTCAGG AATGGACAAA 
91-V206A TATGGTGGTG AAGAATTCTC CATGGAGGAC ATTTGTCAGG AATGGACAAA 
92-V206D TATGGTGGTG AAGAATTCTC CATGGAGGAC ATTTGTCAGG AATGGACAAA 
87-M209A TATGGTGGTG AAGAATTCTC CATGGAGGAC ATTTGTCAGG AATGGACAAA 
45-F165D/M TATGGTGGTG AAGAATTCTC CATGGAGGAC ATTTGTCAGG AATGGACAAA 
69-1202D/M TATGGTGGTG AAGAATTCTC CATGGAGGAC ATTTGTCAGG AATGGACAAA 
47-M264D TATGGTGGTG AAGAATTCTC CATGGAGGAC ATTTGTCAGG AATGGACAAA 
hTTP D4948 tatggtggtg aagaattctc catggaggac atttgtcagg aatggacaaa 
.... 1 .... 1 
· . ·· 1· ·· . 1 .... 1 ···· 1 .... 1 ... ·1 · ... I· . ··1 
810 820 830 840 850 
84-F165A TTTTATAATG AAGTCTGAAG ATTATCTCAG CAGCATTTCT GAGAGCATTC 
44-F165D TTTTATAATG AAGTCTGAAG ATTATCTCAG CAGCATTTCT GAGAGCATTC 
19 - F169D TTTTATAATG AAGTCTGAAG ATTATCTCAG CAGCATTTCT GAGAGCATTC 
86-1202A TTTTATAATG AAGTCTGAAG ATTATCTCAG CAGCATTTCT GAGAGCATTC 
67-1202D TTTTATAATG AAGTCTGAAG ATTATCTCAG CAGCATTTCT GAGAGCATTC 
91-V206A TTTTATAATG AAGTCTGAAG ATTATCTCAG CAGCATTTCT GAGAGCATTC 
92-V206D TTTTATAATG AAGTCTGAAG ATTATCTCAG CAGCATTTCT GAGAGCATTC 
87-M209A TTTTATAATG AAGTCTGAAG ATTATCTCAG CAGCATTTCT GAGAGCATTC 
45-F165D/M TTTTATAATG AAGTCTGAAG ATTATCTCAG CAGCATTTCT GAGAGCATTC 
69-1202D/M TTTTATAATG AAGTCTGAAG ATTATCTCAG CAGCATTTCT GAGAGCATTC 
47-M264D TTTTATAGAT AAGTCTGAAG ATTATCTCAG CAGCATTTCT GAGAGCATTC 
hTTP D4948 ttttataatg aagtctgaag attatctcag cagcatttct gagagcattc 
... ·1· .. · 1 · ... I··· ·1 ... ·1····1 ... ·1·· ··1 · ... I· . . · 1 
860 870 880 890 900 
84-F165A AATGATAGGC GGCCGCATCG TGACTGACTG ACGATCTGCC TCGCGCGTTT 
44-F165D AATGATAGGC GGCCGCATCG TGACTGACTG ACGATCTGCC TCGCGCGTTT 
19-F169D AATGATAGGC GGCCGCATCG TGACTGACTG ACGATCTGCC TCGCGCGTTT 
86-1202A AATGATAGGC GGCCGCATCG TGACTGACTG ACGATCTGCC TCGCGCGTTT 
67-1202D AATGATAGGC GGCCGCATCG TGACTGACTG ACGATCTGCC TCGCGCGTTT 
91-V206A AATGATAGGC GGCCGCATCG TGACTGACTG ACGATCTGCC TCGCGCGTTT 
92-V206D AATGATAGGC GGCCGCATCG TGACTGACTG ACGATCTGCC TCGCGCGTTT 
87-M209A AATGATAGGC GGCCGCATCG TGACTGACTG ACGATCTGCC TCGCGCGTTT 
45-F165D/M AATGATAGGC GGCCGCATCG TGACTGACTG ACGATCTGCC TCGCGCGTTT 
69-1202D/M AATGATAGGC GGCCGCATCG TGACTGACTG ACGATCTGCC TCGCGCGTTT 
47-M264D AATGATAGGC GGCCGCATCG TGACTGACTG ACGATCTGCC TCGCGCGTTT 
hTTP D4948 aatgagaagt tatgtcatgt gaatggcttc ctaactaaaa atacatgagt 
... . 1 .... 1 .... I·· .. 1 ····1····1 ... . 1·· ·· 1 ····1····1 
174 
910 920 930 940 950 
84-F165A CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GANACGGTCA 
44-F165D CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GANANGGTCA 
19-F169D CGGTGATGAC GGTGAAAACC TCTGACACNT . GCAGCTCCCG GAGACGGTCA 
86-1202A CGGTGATGAC GGTGAAAACC TCTGACNCNT GCN ....... . . . . . . . . . . 
67-1202D CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GANANGGTCA 
91-V206A CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA 
92-V206D CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GANANGGTCA 
87-M209A CGGTGANGAC GGTGAAAACC TCTGANACAT GCAGCTCCCG GANACGGTCA 
45-FI65D/M CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCNCG GANANNGTCA 
69-1202D/M CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGANGGTCA 
47-M264D CGGTGATGAC NGTGAAAACC TCTGACNCAT GCAGCTCNCG GANACGGTCA 
hTTP D49488 gatatccaac ctggttaaat gaatgaaaga aaaggagcaa atcttttaaa 
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Translation ofhTTP D49488 Nucleotide Sequence 
1 gea gea geg geg geg gge atg gea gag geg ega tee eag eee teg 45 
1 A A A A A G MAE A R S Q PSIS 
46 geg ggg eeg eag etc aae geg eta eeg gae cae tet eeg ttg etg 90 
16 A G P Q L N ALP 0 H S P L L 30 
91 eag eeg gge etg geg geg etg egg ege egg gee egg gaa get gge 135 
31 Q P G L A A L R R R ARE A G 45 
136 gte eeg etc geg eeg etg eeg etc ace gae tee tte etg etg egg 180 
46 V P LAP L P LTD S F L L R 60 
181 tte etg ege gee egg gat tte gat etg gae etg gee tgg egg tta 225 
61 F L R A R 0 F 0 L 0 LAW R L 75 
226 eta aaa aae tat tat aag tgg aga gea gaa tgt eea gaa ata agt 270 
76 L K N Y Y K W RAE C PEl S 90 
271 gea gat eta cae eet aga agt att att gge etc eta aag get gge 315 
91 A 0 L H P R S I I G L L K A G 105 
316 tae cat gga gte etg aga tee agg gat eee act gge age aaa gtt 360 
106 Y H G V L R S R 0 P T G S K V 120 
361 ett att tae aga ate gea cae tgg gae eee aaa gtt ttt aea get 405 
121 L I Y R I A H WOP K V F T A 135 
406 tat gae gta ttt ega gta agt eta ate aea tee gag ett att gta 450 
136 Y 0 V F R V S LIT S ELI V 150 
451 eag gag gta gaa act eag egg aat gga ate aag get ate ttt gat 495 
151 Q EVE T Q R N G I K A I F 0 165 
496 etg gaa ggt tgg eag ttt tet cat get ttt eaa ate act eea tee 540 
166 LEG W Q F S H A F Q I T P S 180 
541 gta gee aag aag att get get gta ett aeg gat tea ttt eea ttg 585 
181 V A K K I A A V LTD S F P L 195 
586 aaa gtt egt gge ate cat ttg ata aat gaa eea gta att tte cat 630 
196 K V R G I H LIN E P V I F H 210 
631 get gte ttt tee atg ate aaa eea tte etg act gaa aaa att aag 675 
211 A V F S M I K P F L T E K I K 225 
676 gaa egg att cae atg cat ggg aae aae tae aaa eaa age ttg ett 720 
226 E R I H M H G N N Y K Q S L L 240 
721 eag cat tte eea gae att ett eet etg gaa tat ggt ggt gaa gaa 765 
241 Q H F POI L P LEY G GEE 255 
766 tte tee atg gag gae att tgt eag gaa tgg aea aat ttt ata atg 810 
256 F S M E DIe Q E W T NFl M 270 
811 aag tet gaa gat tat etc age age att tet gag age att eaa tga 855 
271 K SED Y L S SIS E S I Q * 285 
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7. APPENDIX III 
Efficiency of Glutathion Agarose Affinity Purification 
Invitrogen G2879 SigmaG4510 
Protein Yield #of Protein #of 
(mg protein/g cells) trials Yield purifications 
(mg 
protein/g 
cells) 
WT 0.43 ± 0.16 >4 1.59 ± 0.19 >4 
F165A n1a 3.16 2 
F165D 0.49 2 2.17 ± 0.66 3 
F169D n1a 1.66 ± 0.53 3 
I202A n1a 0.06 2 
I202D 0.62 1 1.85 1 
V206A n1a 2.69 1 
V206D n1a 0.08 2 
M209A n1a 2.27 1 
M209D 0.43 1 0.67 1 
F165D M209D 0.25 2 1.86 2 
I202D M209D 0.48 1 1.81 2 
M264D n1a 2.15 1 
R192H n1a 2.55 2 
K211A n1a 1.25 2 
K217A n1a 1.36 3 
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